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Today, antibiotics have become a victim of their own success [1] 
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1. Bacterial resistance: do bacteria win the battle? 
 
1.1. Bacterial resistance: a global emerging threat 
Throughout history, infectious diseases have caused pandemic disasters decimating complete 
civilizations. Even today, infections remain a major cause of disease worldwide and 
respiratory infections, HIV/AIDS, and malaria are the main causes of death in low-income 
countries [2, 3]. Also in high-income countries infections remain an important cause of 
morbidity and mortality. For instance, up to 10% of hospitalized patients will suffer from a 
nosocomial infection [4]. Mainly elderly, patients with underlying diseases (like cystic 
fibrosis), or patients undergoing medical treatments and surgery (like immunosuppression, 
chemotherapy, transplantations, or implantation of foreign bodies) are vulnerable to infections 
by opportunistic pathogens.  
 
The discovery of penicillin was a milestone in the history of medical science [1, 5, 6]. Many 
more antibiotics were developed during the golden era of antimicrobial drug discovery, and 
they revolutionized medicine in many respects [1, 5, 6]. Antibiotics made incurable diseases 
like tuberculosis and pneumonia treatable [1]. Also, antibiotics enabled the development of 
modern medicine because they have successfully treated or prevented infections in patients 
who are receiving immunosuppressing cancer chemotherapy or who have had organ 
transplants or joint replacements, among others [7, 8]. Perioperative antimicrobial prophylaxis 
has contributed to a decrease in the incidence of surgical site infections [8, 9]. However, 
bacteria develop resistance against antibacterial agents, sometimes shortly after their 
introduction to the market (Figure 1) [5].  
 
 
Figure 1. Resistance development against antibiotics happens within 8 years on average. Bars mark the number 
of years between introduction to the market and the first report of clinical resistance (red: resistance occurred in 
less than 8 years, blue: resistance development took longer than the average 8 years) [10]. 
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Mis- and overuse of antibiotics, both in humans and animals [11], global trade, and migration 
contributed to the spread of resistant micro-organisms [12]. The prevalence of multidrug-
resistant (MDR) pathogens is increasing and infections that are untreatable with last resort 
antibiotics have been reported [13]. The World Health Organization recognized antimicrobial 
resistance (AMR) as one of the top three threats to human health [14]. Yearly, 50,000 people 
die in the USA and Europe from infections caused by resistant pathogens, and this number is 
estimated to be over 700,000 deaths globally [15]. If we do not take action to tackle AMR 
now, by 2050 10 million people are estimated to die every year from drug-resistant infections 
which are more deaths than caused by cancer [16].  
 
In addition, predictive macroeconomic models have estimated that the world will produce 
around 8 trillion USD less yearly by 2050 when AMR is not addressed [15]. This huge 
number is based only on the effects of lost economic output resulting from increased rates of 
death and illness [15]. It does not take into account the rise in healthcare costs associated with 
drug-resistant infections, or the problems that will arise in other medical areas. Indeed, AMR 
also threatens the safety and efficacy of common surgeries, like hip replacements or caesarian 
sections, and of immunosuppressing chemotherapy, among others [8, 15, 16].  
 
Most nosocomial infections are caused by a small group of pathogens, referred to as the 
ESKAPE bugs (i.e. Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) [17]. The 
prevalence of these ESKAPE pathogens in our hospitals is increasing and they effectively 
“escape” the effects of antibacterial drugs [17, 18]. The Centers for Disease Control and 
Prevention (CDC) assessed the threats of AMR based on several factors, including clinical 
and economic impact, incidence and 10-year projection of incidence, or the availability of 
effective antibiotics. Based on these assessments, CDC classified the threat level by important 
pathogens as urgent, serious, and concerning (Table 1) [7]. The rise of AMR and the lack of 
novel antibiotics might lead us towards a ‘post-antibiotic era’ [19].  
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Table 1. CDC assessment of antibacterial resistance threats [7]. 
Urgent threats Clostridium difficile 
 Carbapenem-resistant Enterobacteriaceae 
 Drug-resistant Neisseria gonorrhoeae 
Serious threats Multidrug-resistant Acinetobacter 
 Drug-resistant Campylobacter 
 Fluconazole-resistant Candida 
 ESBLs producing Enterobacteriaceae 
 Vancomycin-resistant Enterococci 
 Multidrug-resistant Pseudomonas aeruginosa 
 Drug-resistant nontyphoidal Salmonella 
 Drug-resistant Salmonella Typhimurium 
 Drug-resistant Shigella 
 Methicillin-resistant Staphylococcus aureus 
 Drug-resistant Streptococcus pneumoniae 
 Drug-resistant tuberculosis 
Concerning threats Vancomycin-resistant Staphylococcus aureus 
 Erythromycin-resistant Group A Streptococcus 
 Clindamycin-resistant Group B Streptococcus 
 
1.2. Intrinsic, acquired, and adaptive resistance 
Intrinsic, acquired and adaptive resistance are three main resistance types that can be 
distinguished in bacteria [20]. Intrinsic resistance originates from innate properties, applies to 
all strains of a species and limits the activity of all antibiotics of a certain class [5, 11, 20]. For 
instance, differences in cell wall structure between Gram-negative and Gram-positive bacteria 
contribute to distinct susceptibilities towards antibiotics. Gram-negative bacteria possess a 
thin peptidoglycan cell wall surrounded by a poorly permeable outer membrane containing 
lipopolysaccharides. This outer membrane is responsible for the intrinsic resistantance 
towards glycopeptide antibiotics, among others [11, 21]. In contrast, Gram-positive bacteria 
possess thick layers of peptidoglycan and teichoic acids threading through, but lack the outer 
membrane [21].  
 
Acquired resistance usually occurs when susceptible bacteria obtain new genetic material with 
resistance genes (e.g. plasmids and transposons) from resistant micro-organisms. The transfer 
of new genetic material might take place by conjugation, transformation or transduction, and 
can result in the expression of efflux pumps or antibiotic degrading enzymes, or in a bypass of 
the antibacterial target [5, 11]. Plasmids might contain genes that cause resistance towards 
important classes of antibiotics, but also genes encoding virulence determinants [11]. In 
addition, acquired resistance might also arise after spontaneous mutations in the chromosomes 
of susceptible strains conferring resistance to structurally similar compounds [11].  
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Finally, adaptive resistance is a reversible and temporary phenomenon enabling bacteria to 
survive antibacterial treatment. It is observed in several bacterial species upon exposure to 
nonlethal or consecutive incremental amounts of antibiotics, or in other stress conditions [20, 
22]. When the trigger is removed from the environment, bacteria quickly return to the non-
resistant phenotype. Adaptive resistance originates from changes in protein expression, for 
instance, a downregulation of porins or an upregulation of efflux pumps [20, 22]. Adaptive 
resistance is not transferred vertically as is the case in innate and acquired resistance [20, 22].   
 
Horizontal gene transfer (HGT) and the increased expression of genes encoding efflux pumps, 
resulted in the emergence of MDR pathogens. HGT leads to the acquisition and accumulation 
of genes originating from resistance plasmids or transposons causing resistance towards 
several classes of antibiotics. A single resistance plasmid can contain several resistances 
genes and once acquired by a bacterium, resistance plasmids are stably maintained and 
transferred efficiently to other cells [23, 24]. Some main resistance mechanisms towards 
important antibacterial drug classes will be summarized in the subsequent paragraphs based 
on examples in three bacterial species: Staphylococcus aureus, representing Gram-positive 
micro-organisms, and Pseudomonas aeruginosa and Burkholderia cenocepacia, representing 
Gram-negative micro-organisms. 
 
1.3. Resistance in Staphylococcus aureus 
S. aureus is a Gram-positive coccus that colonizes the human skin and nose as a commensal. 
However, S. aureus is also responsible for a plethora of infections, ranging from skin and soft 
tissue infections to life threatening endocarditis, pneumonia, and sepsis [25]. Over time, S. 
aureus developed resistance towards several antibiotics, making treatment challenging.  
 
1.3.1. Beta-lactam resistance  
Resistance towards penicillin was observed in 1942, almost simultaneously with its 
introduction in the early 1940s [26]. Certain S. aureus strains produced penicillinases that 
hydrolyze the β-lactam ring in the penicillin molecule [11]. Twenty years later, 80% of S. 
aureus strains were resistant towards penicillin [26]. Methicillin and oxacillin are 
penicillinase-resistant, however, resistance occurred shortly after their introduction due to 
acquisition of the mecA resistance gene. This gene is located on the mobile genetic element 
SCCmec, and encodes an alternative penicillin-binding protein, PBP2a [5, 11]. This PBP2a 
has a similar activity as the original PBP, but shows lower affinity for β-lactam antibiotics, 
resulting in resistance towards all β-lactam antibiotics [27]. Methicillin resistant S. aureus 
(MRSA) infections occurred mainly in healthcare environments (healthcare associated 
MRSA, HA-MRSA) affecting older patients with comorbid conditions, often resulting in 
pneumonia and bacteremia [28]. More recently, MRSA infections in a healthy younger 
population unrelated to the healthcare environment (community associated MRSA, CA-
MRSA) emerged [28]. In contrast to HA-MRSA, clinical syndromes are mainly skin and soft 
tissue infections, but infections with CA-MRSA might also result in severe sepsis. In addition, 
CA-MRSA often carries genes for the Panton-Valentine leukocidin, explaining the increased 
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virulence [28]. Both HA-MRSA and CA-MRSA carry the SCCmec containing the mecA 
gene, although the SCCmec in HA-MRSA strains is larger [28].  
 
1.3.2. Vancomycin resistance 
Vancomycin is the drug of choice to treat MRSA infections [29]. However, an MRSA isolate 
with reduced susceptibility towards vancomycin (vancomycin intermediate-resistant S. 
aureus, VISA) was for the first time reported in 1997 [30]. The reduced susceptibility of 
VISA is mainly caused by a thickened cell wall that sequesters vancomycin and limits its 
action [5, 31]. In 2002, a vancomycin resistant S. aureus (VRSA, MIC>256µg/ml) was 
isolated in a diabetes patient’s infected chronic foot ulcer [5]. The VRSA possessed the vanA 
resistance gene, probably acquired from the vancomycin resistant Enterococcus faecalis that 
co-infected the wound [5]. Acquisition and expression of vanA changes the vancomycin 
binding site D-ala D-ala into D-ala D-lactate, reducing the affinity for vancomycin a 1000 
times [5].  
 
1.3.3. Resistance to other antibacterial agents 
MRSA possesses several efflux pumps belonging to the major facilitator superfamily (MFS), 
e.g. TetK, expelling tetracyclines, and NorA, expelling fluoroquinolones and several 
disinfectants [25, 32]. In addition, resistance towards fluoroquinolones is also mediated by 
mutations in grlA/grlB and gyrA/gyrB, resulting in a lower affinity for their targets 
topoisomerase IV and DNA gyrase [27]. Resistance towards aminoglycosides originates 
mainly in the activity of aminoglycoside modifying enzymes (AME). These enzymes 
inactivate the aminoglycoside molecule by acetylation, adenylation or phosphorylation, 
preventing binding of the aminoglycosides to their target, the 30S ribosomal subunit [11, 33]. 
Against last resort antibiotics, like linezolid, resistance is described as well and originates 
from mutations in the 23S rRNA gene [34, 35]. 
 
1.4. Resistance in Pseudomonas aeruginosa 
P. aeruginosa is a Gram-negative micro-organism ubiquitous in nature (e.g. soil, water, 
plants) and persisting in hospital settings [36]. Although P. aeruginosa is rarely part of the 
normal human microbiome, hospitalized patients are frequently (50%) colonized [36]. P. 
aeruginosa is an important causative agent of nosocomial infections [37]. Treatment of these 
infections is challenging because P. aeruginosa possesses several intrinsic and acquired 
resistance mechanisms [5, 37, 38].  
 
1.4.1. Resistance towards β-lactams 
The expression of AmpC, a chromosomally encoded serine β-lactamase, is induced upon the 
exposure to ampicillin and narrow-spectrum cephalosporins. This results in the deactivation 
of these β-lactams [39-41]. Although ureidopenicillins (e.g., piperacillin) and extended-
spectrum cephalosporins (e.g., ceftazidime) are hydrolyzed by AmpC too, they are weak 
AmpC inducers and thus effective in treating P. aeruginosa infections. However, an increased 
AmpC production (derepressed production of AmpC), due to mutations in regulatory genes, 
renders these  ureidopenicillins and extended-spectrum cephalosporins ineffective. In this 
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case, treatment with carbapenems is an option as they are not hydrolyzed by AmpC [36, 40, 
41]. Several other β-lactamases have been identified in P. aeruginosa isolates, among them 
four carbenicillin hydrolyzing β-lactamases (PSE-1, PSE-4, CARB -3, and CARB-4), class A 
extended spectrum β-lactamases (ESBL, hydrolyzing carboxypenicillins, ureidopenicillins, 
extended-spectrum cephalosporins and aztreonam), classical and extended-spectrum 
oxacillinases and carbapenemases or metallo β-lactamases (MBLs) [37, 42].   
 
In addition, also the activity of efflux pumps belonging to the resistance nodulation division 
(RND) family contributes to β-lactam resistance. RND efflux pumps are three-component 
systems consisting out of an energy dependent pump in the cytoplasmic membrane, an outer 
membrane protein and a linker protein in the periplasmic space [5, 37, 43]. MexAB-OprM, 
MexCD-OprJ, MexEF-OprN, and MexXY-OprM are clinically important RND efflux pumps 
in P. aeruginosa [37]. Especially MexAB-OprM contributes to the resistance towards β-
lactams, only imipenem is not expelled [11, 37, 40]. Resistance towards imipenem is due to a 
downregulation of the outer membrane protein OprD [37].  
 
1.4.2. Resistance towards fluoroquinolones 
Fluoroquinolones are substrates for MexAB-OprM, MexCD-OprJ, MexEF-OprN, and 
MexXY-OprM [37]. Mutations in their regulatory genes (e.g. nalB for MexAB-OprM) causes 
efflux pump overexpression resulting in MDR phenotypes [37, 44]. Secondly, structural 
changes in the fluoroquinolone target enzymes DNA gyrase and topoisomerase IV result in 
lower binding affinity for fluoroquinolones [37]. These alterations originate in point 
mutations in quinolone-resistance determining regions of gyrA/gyrB or parC/parE [37, 45, 
46]. 
 
1.4.3. Resistance towards polymyxin 
In susceptible Gram-negative organisms, the cationic polymyxins and other antimicrobial 
peptides (AMPs) bind the negatively charged lipopolysaccharides (LPS) located in the outer 
membrane. This results in membrane destabilization and permeabilization, leading to self-
promoted uptake [47, 48]. Next, they disrupt the cytoplasmic membrane and interfere with 
several intracellular processes [47]. P. aeruginosa is not inherently resistant towards 
polymyxin as the positively charged 4-amino-4-deoxy-L-arabinose (aminoarabinose, Ara4N) 
that is responsible for polymyxin resistance in Burkholderia species (see below) is not 
constitutively present in P. aeruginosa LPS.	   Presence of Ara4N reduces the net negative 
charge and subsequently the binding affinity of AMPs and polymyxin. However, several P. 
aeruginosa strain have mutations in the pmrA/pmrB and phoP/phoQ two-component systems 
(TCS) (as well as in other TCS) resulting in their activation and leading to upregulation of the 
genes responsible for the synthesis and transport of Ara4N to the LPS [49]. 
 
1.4.4. Resistance towards aminoglycosides 
Impermeability due to a decreased uptake (by changes in LPS) [40, 50-53], and the activity of 
AMEs [52] are major aminoglycoside resistance mechanisms. P. aeruginosa can carry up to 
five different AMEs resulting in broad-spectrum aminoglycoside resistance [50]. Increased 
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efflux (by upregulation of MexXY) is a relatively rare resistance mechanism [37]. In 2003, 
another aminoglycoside resistance mechanism was reported in a clinical isolate from a 
Japanese patient [37]. This aminoglycoside-resistant P. aeruginosa clinical isolate possessed a 
16S rRNA methylase (RmtA) responsible for 16S rRNA target modification resulting in high-
level resistance to various aminoglycosides, including amikacin, tobramycin and gentamicin	  
[37].  
 
1.5. Resistance in Burkholderia cenocepacia 
B. cenocepacia is a Gram-negative opportunistic pathogen grouped together with 19 other 
phenotypically similar species in the Burkholderia cepacia complex (Bcc) [54]. B. 
cenocepacia possesses a large genome (over 8Mbp in the case of B. cenocepacia J2315) 
compared to other Gram-negative bacteria and is known for its versatility (e.g., Bcc cause 
onion rot but also promote plant growth, or degrade pollutants in soil and groundwater) [55, 
56]. Moreover, their original habitat, the rhizosphere soil, contains plenty other micro-
organisms producing antibiotics, generating a selective pressure resulting in a species with 
innate resistance to a great part of our antibiotic drug arsenal (including β-lactams, 
aminoglycosides, and fluoroquinolones) [55-58]. The extreme resistance is shown by the 
ability of Bcc species to use penicillin as a carbon source and to survive in chlorhexidine 
solutions [47]. B. cenocepacia possesses Ara4N as a constitutive part of the lipid A and inner 
core of the LPS and is thus resistant towards polymyxin B and antimicrobial peptides, 
antibiotics that are considered to be the last-resort treatment of MDR Gram-negative bacteria 
[49]. In addition, many other mechanisms conferring resistance towards polymyxins and 
AMPs are described, including the efflux pump NorM [49]. Similarly, aminoglycoside self-
promoted uptake is disturbed in B. cenocepacia, explaining their resistance [59]. Other 
resistance mechanisms, like β-lactamases and efflux pumps expelling aminoglycosides, 
chloramphenicol, fluoroquinolones, and tetracyclines are present in B. cenocepacia as well 
[60, 61].  
 
 
 
	  	   13 
 
 
 
 
 
 
 
United we stand, divided we fall [62] 
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2. Biofilms: what, where and why? 
 
Since Van Leeuwenhoek, Koch and Pasteur described their observations, centuries of research 
followed unraveling prokaryotic life. Now, more than ever before we know how bacteria 
behave, cause infections and persist. The term ‘biofilms’ was first introduced by Costerton et 
al. in 1978 [63], and since then the awareness grew that this mode of bacterial growth 
contributes to the inability to cure certain infections, as one of their characteristics is a 
reduced susceptibility towards antimicrobial agents. 
 
2.1. Biofilms: some important characteristics  
Although bacteria are single-celled organisms, they can organize themselves in complex 
sessile multicellular consortia, known as biofilms [64, 65]. Biofilms are formed everywhere: 
in industrial settings, in natural environments, and in the human body [66]. Bacterial cells 
residing in biofilms are attached to each other or to a surface and they are embedded in a 
matrix of extracellular polymeric substances [65]. The biofilm cells are phenotypically 
different from their planktonic counterparts because growth rate and gene transcription is 
altered [65].  
 
2.2. Biofilm formation 
Biofilm formation is a complex developmental process [67]. Adhesion, proliferation, and 
detachment are the three mayor steps in biofilm formation [68]. The process is dynamic and 
starts with planktonic bacteria that attach reversibly to a surface (Figure 2). Pili, flagella, 
receptors, or other adhesive surface appendages make contact with biotic or abiotic surfaces 
[69]. Adhesion is followed by the secretion of extracellular polymeric substances resulting in 
an irreversible attachment [69]. Subsequently, cells proliferate resulting in the formation of 
micro-colonies. The biofilm grows and cells differentiate, resulting in a mature biofilm with 
multilayered cell clusters [65, 69]. Quorum sensing (QS), or cell-to-cell signaling, plays an 
important role in the development of the biofilm [65]. Finally, cells disperse from the biofilm 
and form biofilms elsewhere [70]. This dispersion happens passively by external forces like 
hydrodynamic shear stress [67] or actively initiated by the bacteria themselves. This active 
detachment is under the control of several sensory systems, e.g. QS [68] and c-di-GMP [67] 
and involves surfactant-like molecules [68]. 
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Figure 2. Simplified representation of the different steps in biofilm formation. After attachment of planktonic 
cells to a surface, they produce an extracellular polymeric matrix (EPM) and form micro-colonies, resulting in a 
mature biofilm. Finally, cells disperse and the process can start again [70]. 
 
2.3. Biofilm structure and organization 
A biofilm is built up out of microbial cells and their self-produced extracellular matrix, 
holding the cells together and accounting for approx. 90% of the biofilm biomass [67]. The 
matrix contains proteins, exopolysaccharides and extracellular DNA (eDNA) [71] and 
provides the cells with water and nutrients. The composition of the matrix is species 
dependent, e.g. the matrix of P. aeruginosa biofilms might contain the exopolysaccharides 
alginate, Pel, and Psl [72], while the matrix of S. aureus strains possessing the ica-operon is 
composed of polysaccharide intercellular adhesin (PIA), which is a polymer of N-
acetylglucosamine (PNAG) [73, 74], and teichoic acids [68]. Moreover, major differences in 
exopolysaccharide composition are observed within a bacterial species as well. For instance, 
mucoid strains of P. aeruginosa, as encountered in lungs of cystic fibrosis (CF) patients, 
produce alginate while other P. aeruginosa strains do not produce alginate [75]. Besides being 
strain-dependent, the matrix composition is also determined by environmental conditions like 
medium, substrate, and the age of the biofilm [73, 75]. Young P. aeruginosa biofilms were 
dispersed upon DNase treatment, suggesting eDNA is an important matrix component. In 
contrast, no dispersion was induced in mature biofilms, as other extracellular polymeric 
substances formed the biofilm matrix [75]. The shape of the biofilms is dependent on several 
conditions, for instance, if glucose is available as a carbon source, mushroom-shaped biofilms 
will be formed in flow-chambers, while flat biofilms are formed if citrate is the only available 
carbon source [75]. Cell clusters within the biofilm structure can grow to considerable sizes 
(up to a few millimeters) and water channels provide transport of metabolic waste products 
and nutrients [76]. These water channels are maintained by rhamnolipids in P. aeruginosa 
biofilms [75]. Biofilms shield cells from the activity of chemical disinfection or antimicrobial 
therapy, and from host immune defenses like phagocytosis and opsonisation [69, 71]. This 
contributes to their recalcitrant nature. 
 
2.4. Recalcitrance of biofilms 
Biofilms show a reduced susceptibility to antimicrobial agents compared to planktonic cells. 
Both resistance and tolerance mechanisms contribute to this recalcitrance [65, 77]. Resistant 
bacteria grow in the presence of antibiotics, and the mechanisms enabling them to do so are 
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described above. In contrast, tolerant bacteria survive a transient exposure to otherwise 
bactericidal antibiotics because they grow slowly and have a reduced metabolism [78]. Some 
relevant examples of resistance, tolerance and other mechanisms contributing to the 
recalcitrance of biofilms will be given in the following paragraphs. 
 
2.4.1. Reduced growth rate and metabolic activity 
Bacteria residing in the deeper biofilm areas have a reduced growth rate and metabolic 
activity due to oxygen and nutritional limitations and the accumulation of toxic waste 
products. Moreover, beside nutrient limitations, a general stress response is responsible for 
slow growth in cells residing in biofilms [79]. For instance, the expression of sigma factor 
rpoS was increased in biofilms [80]. RpoS mediates the expression of many genes involved in 
stress and starvation processes (e.g. RpoS controls the regulation of 10% of the Escherichia 
coli genome) [81]. Although it was thought that RpoS was only expressed during stationary 
phase, it is recognized now that RpoS expression is induced at high cell densities, thus also in 
biofilms. RpoS mRNA was identified in sputum of cystic fibrosis patients chronically 
infected with P. aeruginosa [79].  
 
The slow-growing cell subpopulations have an increased tolerance to antibiotics that target 
processes active in dividing or metabolically active bacteria [65, 67, 69, 75]. For instance, 
inactive subpopulations are tolerant to ciprofloxacin, tetracycline, or tobramycin, while active 
subpopulations are sensitive [65]. However, this decreased susceptibility of inactive 
subpopulations does not apply to all antibiotics: colistin kills the slow growing subpopulation, 
while the metabolically active subpopulation survives by inducing the expression of MDR 
efflux pumps and by modifying the LPS with aminoarabinose	  [75, 82]. 
 
2.4.2. A specific phenotype 
The gene expression between planktonic and biofilm cells is altered which partially 
contributes to the difference in resistance observed. Various genes are expressed only in 
biofilms, e.g. ndvB gene in P. aeruginosa PA14 strain [75]. In these biofilms, ndvB gene 
products produce periplasmic glucans that sequester tobramycin [75]. Another gene, tolA, was 
upregulated in P. aeruginosa biofilms compared to planktonic cells  [83]. TolA changes the 
LPS structure resulting in a decreased binding affinity for aminoglycosides and other 
polycations [83].   
 
Several studies report increased activity of efflux pumps in biofilms [65, 84]. E.g., PA1874-
1877, an efflux pump in P. aeruginosa, was more expressed in biofilms than in planktonic 
cells, conferring biofilm resistance towards several fluoroquinolones and aminoglycosides 
[65]. Also, as biofilms consist out of several phenotypic subpopulations, the expression of 
efflux pumps is dependent on the location in the biofilm, for instance, a higher expression of 
MexAB-OprM in cells populating the substratum was observed in P. aeruginosa biofilms [65, 
85].  
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2.4.3. Reduced antibiotic penetration: sequestration and deactivation 
In general, diffusion of most antibiotics through the biofilm is not hampered [76, 86], 
however, positively charged antibiotics like aminoglycosides poorly penetrate the biofilm as 
they are sequestered by the EPM [86, 87]. Addition of alginate lyase and DNase to mucoid P. 
aeruginosa biofilms increases the diffusion of these antibiotics through the biofilm [75, 82]. 
In contrast, the inability of ampicillin to diffuse through a Klebsiella pneumoniae Kp1 biofilm 
is not due to sequestration, but to the activity of β-lactamases [80]. Also in P. aeruginosa 
biofilms, β-lactamases accumulate within the biofilm resulting in β-lactam neutralization 
while penetrating the biofilm [70, 82, 88].  
 
2.4.4. Horizontal gene transfer and mutators 
Horizontal gene transfer within the biofilm happens more frequently than in planktonic cells, 
[89] since biofilm bacteria typically reside closer to each other [82]. The efficient 
transmission of antimicrobial-resistance genes between bacteria of the same species or 
between different species can make the biofilm community more resistant and virulent [67, 
69, 70]. Also, P. aeruginosa biofilm cells are characterized by an increased mutability 
compared to planktonic cells, for example, a hypermutable subpopulation (‘mutators’) is 
present in the lungs of CF patients [82]. Mutators, deficient in the DNA mismatch repair 
system, exhibit high frequencies of point mutations, and hence develop rapidly antimicrobial 
resistance [34, 90]. 
 
2.4.5. Persister cells  
Persisters are a small subpopulation of drug-tolerant dormant cells. They are not mutants as 
re-inoculation of persister cells gives rise to a population with both persisters and non-
persisters. Persisters are present both in biofilms and planktonic cultures, but those in biofilms 
are problematic as the matrix protects them from host immune defenses [77]. When an 
antibiotic therapy is stopped, the remaining persister cells act as a reservoir and are 
responsible for repopulating the biofilm (Figure 3) [67, 89, 91]. More and more it is accepted 
that persister cells are an important cause of recalcitrance in biofilm infections [91].  
 
 
Figure 3. Representation of the killing of non-persisters (red dots) in the biofilm and in the planktonic culture. 
However, host immune factors and antibiotics are unable to kill surviving persisters (blue dots) in the biofilm, 
while planktonic persisters are efficiently removed [77]. 
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2.5. Biofilm infections 
Commensal biofilms are encountered in dental plaque and in the intestine [92], but biofilms 
are also estimated to be involved in 80% of all bacterial and fungal infections [70]. Biofilm-
related infections are a serious clinical problem as they are often very difficult to eradicate 
[65, 93]. Biofilms might arise on medical indwelling devices, such as endotracheal tubes, 
vascular or urinary catheters, prosthetic cardiac valves, implants and prosthetic joints. In 
addition, biofilms are formed in CF patients’ lungs, and in chronic wounds, and  they are 
involved in infections like otitis media, chronic sinusitis and vaginosis [93].  
 
The bacteria used in the experiments in this dissertation are important pathogens involved in 
respiratory tract infections in CF patients and in chronically infected wounds. For this reason I 
will focus on these two clinical conditions in the following paragraphs. 
 
2.5.1. Biofilm infections in cystic fibrosis patients 
2.5.1.1. Cystic fibrosis 
CF is the most common lethal autosomal recessive genetic disorder in the Caucasian 
population, affecting one in 2500 [94]. Although life expectancy has increased drastically, 
many CF patients still die in young adulthood [95]. CF originates in mutations in the cystic 
fibrosis transmembrane conductance regulator gene (CFTR), coding for a chloride channel 
[96]. A defect in chloride secretion in the respiratory epithelium results in the production of 
viscous dehydrated mucus. Mucociliary clearance is impaired in removing this thick mucus 
layer, which subsequently forms an ideal environment for bacterial colonization and infection 
[96].  
 
2.5.1.2. Bacteria causing lung infections in CF patients  
The lower respiratory tract of young CF patients is colonized with S. aureus and Haemophilus 
influenzae [97]. However, from later infancy on P. aeruginosa predominates [97]. Other 
micro-organisms that might be involved in lung infection are Bcc species and 
Stenotrophomonas maltophilia, among others (Figure 4) [97].  
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Figure 4. The distribution and evolution of bacterial species colonizing the lung of CF patients in function of 
their age [98]. 
 
Chronic lung infection with P. aeruginosa and subsequent severe lung damage is the main 
cause of morbidity and mortality in CF patients [87, 95]. Initially, CF patients become 
infected with non-mucoid P. aeruginosa. However, the CF lung environment stimulates a 
switch towards a mucoid phenotype [99]. This switch occurs after a mutation in the anti-
sigma factor mucA [100]. In contrast to the non-mucoid phenotype, the mucoid phenotype 
overproduces alginate. Alginate activates a strong immune response that is harmful for the 
surrounding lung tissue [101]. Moreover, alginate causes an increased resistance towards 
antibiotics and the activity of host immune factors as this mucoid matrix protects the micro-
colonies [67, 99].  
 
Also Bcc species form biofilms in the lungs of CF patients [58]. Up to 8% of CF patients are 
infected with Bcc [102], of which B. cenocepacia and B. multivorans are the most prevalent 
(85-97% of all Bcc infections) [103]. Bcc infection can result in the cepacia syndrome, which 
is an invasive and often fatal pneumonia with acute deterioration of the lung function and 
septicemia [56, 87].  
 
2.5.1.3. Antimicrobial treatments in CF patients 
The treatment of pulmonary infections in CF patients has improved greatly due to the 
introduction of inhaled antibiotics (tobramycin, amikacin, colistin, aztreonam, and 
levofloxacin) [95, 104]. Advantages of inhalation therapy are the relatively quick and simple 
administration and a targeted drug delivery [104]. This targeted delivery allows high 
intrapulmonary drug concentrations, while systemic toxicity is limited [104].  
 
Preventing the establishment of chronic P. aeruginosa infection is the focus of current 
therapy; patients are isolated from those with a chronic infection, and an aggressive 
eradication therapy is initiated when colonization is identified [82]. This therapy consists out 
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of nebulized tobramycin as monotherapy or oral ciprofloxacin in combination with nebulized 
colistin for 3 weeks to 3 months [82]. Additionally, long-term daily nebulization of DNase 
helps to prevent infection with P. aeruginosa, reducing the need for antibiotics and enhancing 
the lung function [82, 105]. This approach has changed the epidemiology of chronic P. 
aeruginosa lung infections in CF patients: chronic lung infections with P. aeruginosa that 
were common in children, now mainly occur in older patients [82]. Chronically infected 
patients require a life-long antibiotic treatment to suppress the infection [82], which consists 
out of at least one nebulized antibiotic: tobramycin, colistin, or aztreonam [104]. Inhaled 
tobramycin has the most impact in improving the lung function, as well as in reducing the 
bacterial load and the number of exacerbations [104]. In addition, this chronic suppressive 
therapy is supplemented every 3 months with other antipseudomonal antibiotics during 2 
weeks [82]. CF patients facing exacerbations of P. aeruginosa infection are treated with two 
anti-pseudomonal antibiotics with distinct mode of action: a β-lactam (ceftazidime, cefepime, 
piperacilline/tazobactam, meropenem, or aztreonam [106]) combined with an aminoglycoside 
or ciprofloxacin [107]. Effective chronic suppressive therapies are lacking in case of Bcc 
infections [58] and no standardized regimens to treat Bcc have been developed [108].  
 
In addition, different antibiotic adjuvants are currently investigated. These adjuvants might 
improve the efficacy of antibiotic treatments by increasing the susceptibility of the 
bacteria/biofilms towards the antibiotics or the host immune system, or they might cause a 
reduction in bacterial virulence [95]. For example, the alginate oligosaccharide OligoG 
increases the activity of macrolides, tetracyclines and β-lactams towards formed biofilms of 
P. aeruginosa and Bcc and is currently investigated to treat CF patients in a clinical trial phase 
II [95]. Garlic extracts (allicine and ajoene) have anti-biofilm properties as well [95] and 
interfere with QS [109]. Garlic-treated biofilms of P. aeruginosa were more susceptible 
towards tobramycin than the control and this was also proven in a mice pulmonary infection 
model. However, a clinical trial in 26 CF patients could not demonstrate a significant 
difference compared to placebo [95]. Gallium formulated with gentamicin in liposomes 
increased the activity of gentamicin against P. aeruginosa CF clinical isolates in vitro [110] 
and gallium nitrate was active towards P. aeruginosa biofilms in vitro and in animal models 
[111]. The latter is currently in phase II clinical trial for CF patients [112]. 
 
2.5.2. Chronic wounds 
Chronic wounds, including pressure sores, venous ulcers, and diabetic foot ulcers, are a major 
cause of morbidity and 1-2% of the population in developed countries will face a chronic 
wound in their lifetime [113, 114]. The incidence is increasing with increasing life 
expectancy, and an increase in life style diseases such as diabetes, obesity, and vascular 
diseases. Many factors contribute to the emergence and persistence of chronic wounds, 
including patient’s factors like an uncontrolled immune response, but also the microbial load 
and type of bacterial species determines if a wound becomes (chronically) infected [115].  
 
2.5.2.1. The wound healing process, biofilms, and the uncontrolled immune response 
The normal wound healing processes, i.e. coagulation, inflammation, cell proliferation and re-
epithelialization, are disturbed in chronic wounds [113, 116]. Although the role of biofilms is 
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not completely understood, it is assumed that biofilms arising after wound colonization are 
responsible for a delay in healing and development into a chronic state as they induce chronic 
inflammation [76, 117, 118]. This hypothesis is supported by the fact that biofilms were 
present in only 6% of acute wound specimens, compared to 90% in specimens of chronic 
wounds [76, 119]. In normal wound healing, bacteria and debris are removed in the 
inflammatory phase and this prevents infection [120]. In chronic wounds, however, the 
inflammatory phase is prolonged because polymorphonuclear neutrophils (PMNs) that 
migrated to the tissue around the wound to kill the invading bacteria, are ineffective in 
clearing the biofilm cells [76]. PMNs release toxic compounds, for instance reactive oxygen 
species (ROS) and elastase, that contribute to severe surrounding tissue damage and non-
healing of the wound [76]. Beside toxic compounds released by immune cells, also bacteria 
release toxins enabling them to invade deeper into the tissue, contributing to the host damage 
[121]. 
 
2.5.2.2. Four situations depending on the bacterial load present in wounds 
The term contamination is used to describe the condition in which non-replicating bacteria are 
temporarily present in wounds, while the term colonization refers to growing bacteria in 
wounds. In both conditions, there is no host damage and wound healing is not delayed [113]. 
In contrast, higher numbers of bacteria prevent wounds from healing. The transition between 
colonization and non-healing is thought to take place when over 105 colony forming 
units/gram tissue are present [122]. Local infection or critical colonization is the condition 
between colonization and infection. In this situation, bacteria do cause a delay in wound 
healing [113]. This situation is often observed in elderly patients with an impaired immune 
response [121], or when bacteria form biofilms [123]. Critical colonization is characterized by 
non-healing wounds that clinically not look infected [120]. Critical colonization can finally 
result in an infection with host injury, clinical signs like redness, pain, and warmth, or 
septicemia [123]. However, these classic signals are not always displayed in chronic wounds. 
Foul odor, wound breakdown and discoloration of granulation tissue are other signs pointing 
towards infection [122].  
 
2.5.2.3. A diverse microbial flora in chronic wounds 
In most cases, the microbiota in a wound is composed out of two to five different bacterial 
species [76]. Initially, skin commensals such as S. aureus and β-hemolytic streptococci are 
found in wounds [29]. For example, S. aureus was isolated from 43% of infected and 88% of 
clinically non-infected leg ulcers [122]. In a later stage, Gram-negative bacteria, especially 
coliforms, and anaerobes are encountered as well [29].  
 
2.5.2.4. Antimicrobial treatment of chronic wounds 
Treatment of chronic wounds is a multistep approach, starting with debridement in which 
necrotic tissue, senescent cells, bacteria, or foreign material are removed [69, 119]. There is 
sufficient evidence that frequent (weekly) debridement increases the healing rates of chronic 
wounds [119]. Debridement cannot remove the biofilm completely, but it forces the biofilm to 
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reattach and reform. During this time (2-3 days), the biofilm is more susceptible to antibiotics 
and host immune defenses [119].  
 
Antibiotic therapy should be fine-tuned upon the identification of the causing pathogens, their 
antibiotic susceptibility and the patient’s clinical response [124]. Wounds with clinical signs 
of infection are often treated with systemic antibiotics [125]. Topical antibiotics, like fusidic 
acid, mupirocin, polymyxin, or metronidazole are also used in low-grade infections [125-
127]. However, clinical signs of infection are not always clearly present in chronic wounds. It 
is often difficult for clinicians to determine if the micro-organisms present are responsible for 
the non-healing and if subsequently antibiotic therapy is appropriate and justifiable [29]. 
Generally, clinically non-infected wounds should not be treated with systemic antimicrobial 
therapy [128]. Moreover, sufficient evidence for the effectiveness of antibiotics in treatment 
of chronic wounds is lacking [29, 122]. Lipsky et al. recommend a topical antiseptic for a 
short time in chronic wounds with no clear clinical signs of infection [125]. However, also the 
use of antiseptics in treatment of chronic wounds is a subject of debate [129]. Antiseptics are 
cytotoxic to cells involved in the wound healing process, although this cytotoxicity is mainly 
observed solely in vitro [129]. Moreover, the cytotoxicity depends on the  concentration of the 
antiseptic [129] and it is not observed when applying ointments, gels, or dressings with a 
more sustained release, in contrast to solutions [125]. An example to illustrate the complexity 
is povidone iodine; in vitro data suggest cytotoxicity at 10%, while this is not observed 
clinically, and a 3% povidone iodine hydrogel has shown to contribute positively to wound 
healing [126]. In addition, iodine is active towards S. aureus and P. aeruginosa biofilms 
[126], justifying its use in chronic wound treatment. Moreover, antiseptics are preferred over 
topical antibiotics, as antibiotics are more prone to resistance development [125, 129]. In 
addition, the topically used antibiotics neomycin and bacitracin cause contact sensitization in 
10% of patients [127, 129].  
 
Beside debridement and subsequent topical or systemic antibacterial treatment, other 
measures like wound hydration are indispensable [130], together with tackling the underlying 
diseases that are the primary cause of chronic wounds [122].  
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It is perhaps ironic that the current challenges are in part the result of the past success [131]
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3. From golden era to discovery void 
 
Almost all antibiotic classes currently in use were discovered between the 1930s and 1980s 
(Figure 5). Consequently, this era is referred to as the golden era in antibacterial drug 
discovery. In 1967, the US Surgeon General declared “that we had essentially defeated 
infectious diseases and could close the book on them” [91, 132]. Pharmaceutical industry 
focused more on treatments for cancer and chronic diseases. However, due to the emergence 
of MDR bacteria, new antibiotics are urgently needed.  
 
 
Figure 5. Time-line representing the discovery of new antibiotic classes. Most antibiotics were discovered 
between 1930 and 1980. In the following years, referred to as the discovery void, very few new antibiotics were 
discovered [133]. 
 
3.1. The golden era: 1930s to 1980s 
The discovery of sulfonamides and penicillin in the 1930s was the start of a golden era that 
lasted more than 40 years [19, 132]. Aminoglycosides, and later tetracyclines, cephalosporins, 
macrolides, glycopeptides, quinolones, and carbapenems were developed [132, 134, 135].  
Most of these drug classes were discovered by empirical screening of natural products [132, 
136]. The basic chemotypes of these classes were used as scaffolds to develop new analogues 
using medicinal chemistry. This synthetic tailoring resulted in drugs with a broader spectrum, 
an increased potency, a better safety profile and/or a new possible route of administration 
[132, 136]. This is exemplified by the fact that from 12 antibacterial scaffolds over 200 
antibacterial analogs were developed and approved, especially β-lactams, tetracyclines, 
quinolones, and macrolides [132]. Although these derivatives are likely to more rapidly lead 
to resistance by existing mechanisms [135], optimization of antibiotics was and is still 
important in antibacterial drugs discovery [137].  
 
However, between 1970 and 1999, mupirocin was the only drug marketed with a new mode 
of action. All other antibiotic drugs developed in this period were modifications of existing 
drugs [19, 137].  
 
3.2. A new millennium, a new hope? 
Several initiatives were launched to stimulate the investigation for new antibiotics, e.g. the US 
Generating Antibiotic Incentives act, the 10x’20 act from the Infectious Diseases Society of 
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America, and the Innovative Medicines Initiative New Drugs for Bad Bugs, the Urgent Need, 
Antibiotic Action initiative and the Antibiotic Resistance (ReAct) in Europe [19, 135]. From 
2000 on, twenty-six new antibacterial drugs and two new β-lactam/β-lactamase inhibitor 
combinations were approved by the Food and Drug Administration (FDA) [19, 138-143]. 
These new drugs are mainly derivatives of existing scaffolds, i.e. nine quinolones, three 
glycopeptides, a macrolide, four carbapenems, two cephalosporines, and a tetracycline [19]. 
Nevertheless, six of the newly approved drugs belong to five new classes, which is a 
considerable improvement over earlier years (Table 2) [19]. However, despite being new 
marketed classes of antibiotics, these antibiotics are based on old discoveries as the 
oxazolidinones, the lipopeptides, and pleuromutilines were patented already in 1978, 1987, 
and 1952, respectively [144, 145]. Moreover, none of these first-in-class drugs is active 
against Gram-negative micro-organisms [19]. 
  
Table 2. The first-in-class antibiotics launched since 2000. Based on information from [19]. C. = Clostridium, M. 
= Mycobacterium.  
Year of approval Name Class Spectrum Mode of action 
2000 linezolid oxazolidinone Gram-positive protein synthesis 
inhibitor 
2003 daptomycin lipopeptide Gram-positive formation of cell 
membrane pores 
2007 retapamulin pleuromutilin Gram-positive protein synthesis 
inhibitor 
2010 fidaxomicin tiacumicin C. difficile binds RNA 
polymerase 
2012 bedaquiline diarylquinoline M. tuberculosis ATP synthase 
inhibitor 
 
3.3. The low commercial potential of antibiotics 
In 1990, research and development (R&D) for antibacterial drugs was operating in 18 big 
pharmaceutical companies [19]. By now, only AstraZeneca, Novartis [146], GSK, Sanofi-
Aventis [19], and Merck [6] remain [147] and many R&D is done in small biotechnological 
companies. For instance, in 2005, 7 antibacterials were in clinical development in large 
pharmaceutical companies, while 12 in biotech companies [132]. One of the strategies used 
by small biotech companies is the purchase of niche products from big pharma that quit their 
development [132]. For instance, Abbott Laboratories discovered and patented tiacumicins in 
1986. However, only 26 years later, the small pharmaceutical company Optimer 
Pharmaceuticals launched tiacumicin B or fidaxomicin (Dificid), a first-in-class drug to treat 
diarrhea caused by C. difficile [19]. Nevertheless, Optimer Pharmaceuticals had to close down 
their business as the revenue for Dificid was disappointing due to the availability of cheap 
generics [148]. Niche products, addressing only a small segment of the market, are not 
commercially interesting as no broad or empirical use is possible [132]. Only if diagnostic 
methods improve, these niche antibacterial drugs will become interesting for big pharma. Till 
then, pharmaceutical companies will focus on broad-spectrum agents [132, 147].  
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The exodus of pharmaceutical industry from antibacterial R&D two decades ago [149] was 
due to (i) scientific, (ii) economic and (iii) regulatory challenges [147].  
 
First of all, the identification of new antibiotic classes is extremely difficult. Efforts to 
identify new antibiotics by screening large existing libraries of small molecules failed [133]. 
For instance, GSK performed 70 high-throughput screens between 1995 and 2001 but 
identified only in 7% of the screens lead compounds [147] of which none made it into clinical 
trials [135]. Screenings in other therapeutic areas have a success rate that is 10 times more in 
this phase [147]. A main obstacle is the bacterial impermeability [133].  
 
Secondly, investment in R&D of new antibacterial agents is economically unattractive 
compared to other classes of drugs. Although costs of R&D have been rising last years for all 
classes of drugs, this is especially problematic for antibiotics as the return on investment is 
lower and the risk higher [15]. The return on investment in a traditional business model 
depends on the price of the new drug multiplied by the volume of sales, and both are low for 
new antibiotics for several reasons [147]. Antibiotics are mainly used in curative short-term 
therapies, while drugs used to treat chronic diseases are taken for a long period on a pill-a-day 
basis [132, 144]. Drugs in other therapeutic areas with similar short periods of treatment have 
been commercially lucrative thanks to high prices [15]. However, antibiotics are generally 
low in price because cheap generics prevail the antibiotic market and the price of new 
antibiotics is benchmarked against the prices of these generics [147]. In addition, new 
antibiotics will often be reserved for a small group of patients to prevent resistance 
development, limiting their use and subsequently the revenue [136, 147, 150]. Moreover, 
resistance will develop inevitably when the new drug is used, resulting in its devaluation 
[151]. However, resistance development is unpredictable, contributing to the economic 
uncertainty regarding return on investment of antibiotics over time [7]. These factors 
contribute to a limited (or even negative) and unpredictable return on investment and a new 
business model that de-links the volume of sales from the revenues is thus necessary [147, 
151].  
 
The regulatory requirements imposed by the FDA are a third barrier for development of new 
antibiotics as clinical trials have become more expensive and time consuming, while risk of 
failing increased [151]. A reformation in regulatory requirements is necessary, improving the 
feasibility and clinical relevance of clinical trials [151]. One of the ideas proposed is the 
Limited Population Antibacterial Drug regulatory approval pathway, in which trials focus on 
MDR pathogens [7, 151]. Drugs approved after such trials will receive a narrow indication 
label [7, 151]. These trials will be smaller and thus less expensive and shorter in time [7, 151]. 
Several initiatives were recently launched to attract the pharmaceutical industry back to 
antibiotic development and to fill the pipeline again. However, it is questionable if these 
initiatives are sufficient and if this eventually will result in the discovery of a sufficient 
amount of new antibiotics. The pharmaceutical industry is currently not able to meet the needs 
necessary to fight AMR, so it is important that academia remain dedicated into AMR research 
and development of new treatment strategies.  
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Natural products, an unsurpassed source of evolved chemical diversity [152] 
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4. Platforms used for antibiotic drug discovery 
 
Most of the antibiotics currently in use were discovered by empirical whole-cell screening of 
natural products (NP). However, the systematic screening of the same pool of NP resulted in 
re-identifying similar classes of already known antibiotics [153]. This caused a switch 
towards a target-based approach and the application of new techniques based on genomics, 
high-throughput screening (HTS), structure based drug design (SBDD), and combinatorial 
chemistry [153].  
 
4.1. Phenotypic whole-cell screening of natural products 
NP are secondary metabolites produced by bacteria, fungi, and plants displaying antibacterial 
activity to protect themselves [132]. Particularly soil actinomycetes provided many NP that 
were a tremendous source for new antibiotics [132, 136]. Over 23,000 NP are characterized 
and they are complex and diverse chemical compounds with several stereo-specific carbon 
centers and sizes ranging from small (100 Da) to large molecules (> 1000 Da) [153].  
 
NP were screened in a low-throughput manner, a method that did not change for several 
decades [144, 153]. Soil samples were collected all over the world, from which bacteria and 
fungi were isolated [153]. NP were extracted from culture broths and their effect on growth 
inhibition of test organisms was analyzed in whole-cell screens [145, 153]. A pharmaceutical 
company like Eli Lilly was able to test 35,000 strains annually applying this approach [153]. 
NP that exhibited antibacterial activity were included in subsequent assays. Toxicity tests in 
animals were conducted to evaluate the selectivity [145] and medicinal chemistry changed 
features of active NP resulting in antibiotics with more drug-like properties and less toxicity 
[132, 154]. Also, the mode of action was determined, although this was often not elucidated 
until years after the introduction to the market.  
 
Gradually, a more target-based approach gained interest over empirical screenings [145]. For 
example, it was appreciated that, among others, the cell wall synthesis machinery had proven 
to be a successful and selective target. For this reason, Merck used another endpoint than 
growth inhibition in their phenotypic screens, namely the formation of spheroplasts [145, 
155]. This screen resulted in the discovery of fosfomycin and thienamycin [145, 155].  
 
However, interest in NP screening decreased as no new classes of antibiotics were discovered 
anymore. In 30 years, only one new class of antibiotics was discovered, represented by 
daptomycin [153]. Similar NP are abundant and these are consequently rediscovered when 
screening fermentation broths. These NP mask the presence of other (low-abundant) 
antibiotics [154], making it increasingly difficult to discover new classes [144]. An example 
of this is streptomycin, which is produced by approx. 1% of all actinomycetes, whereas 
daptomycin is produced by only 0.000001% of all actinomycetes [153, 154]. In order to 
overcome this background noise, ‘dereplication’ methods were introduced to separate known 
compounds from new compounds in NP extracts [145]. Anyway, in the 1990s, the platform 
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was largely abandoned, as alternative promising methods had become available to discover 
new antibacterial drugs [132, 156].  
4.2. Genomics 
In 1995, the first whole genome sequence of a bacterial pathogen (H. influenzae) became 
available and this was the start of the genomic era for antibacterial drug discovery [144]. 
Bacterial genomes were enormous sources of information, among others, revealing new 
targets for antibiotic drug discovery [132].  
 
4.2.1. Target discovery 
Genomes of relevant pathogenic bacteria were analyzed and compared using bioinformatics 
for conserved genes that were absent or do not share sequence similarity in humans [136], 
leading to the identification of 150-350 (number depends on the span of the bacterial 
spectrum) potential targets [137]. 
 
However, there are several reasons why a single target-based screening turned out not to be 
suitable for antibacterial drug development. First of all, whether a gene is essential or not can 
strongly differ among bacterial species, even between strains [136]. This might be due to 
additional analogous enzymes or the activity of alternative biochemical routes [156]. E.g. 
methionyl tRNA synthetase was thought to be a valid target as it showed a high sequence 
homology between several pathogens, among them S. pneumoniae. However, 30% of the 
clinical isolates of S. pneumoniae were not susceptible to potent inhibitors of methionyl tRNA 
synthetase as they possessed an unrelated methionyl tRNA synthetase [136]. Furthermore, 
essential genes in vitro might become non-essential during disease [157] as nutrients are 
readily available in the human body and might provide reaction products making the inhibited 
enzyme not necessary for survival [137]. In addition, the target has to be ‘druggable’, which 
means that it should possess binding sites for drug-like molecules and that binding of such a 
molecule results in a biological effect [145]. It is accepted now that many of the promising 
targets are ‘undruggable’ [157].  
 
4.2.2. Finding an inhibitor for the selected target: HTS, SBDD, and synthetic compounds 
After finding a potentially suitable target, inhibitors for this target can be identified using HTS 
of large chemical libraries [135-137]. An alternative to HTS is SBDD, an in silico method 
where ligands are designed based on the crystallographic structure of the drug target [135]. 
Although inhibitors with activity against the purified targets were identified in HTS or 
designed in SBDD, they often failed to have antibacterial activity due to inefficient 
intracellular penetration [135-137, 145, 154].  
 
Between 1995 and 2001, GSK screened a synthetic compound library (consisting of 500,000 
compounds) against 67 isolated targets from S. pneumoniae. The hit rate was low: leads were 
identified against 5 targets only, and none of them made it to clinical trials [135]. The major 
cause for failure in the GSK screening programs, and in HTS in other pharmaceutical 
companies, was the low molecular diversity in their library [145]. Indeed, the early 
combinatorial compound collections turned out to be worthless in antibacterial drug discovery 
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[158]. Traditional combinatorial chemistry creates from few chemical scaffolds many unique 
molecules, assembled in ‘combi-chem’ libraries [153, 158]. These compounds are 
stereochemical diverse and distinct in the appendages around the scaffold, but miss the so 
called ‘skeletal diversity’ [158]. The combi-chem libraries were used in combination with 
historical chemical product libraries [154] that were developed for screening programs in 
other therapeutic areas [136]. These libraries were not solely developed against enzymes, but 
also against G-protein coupled receptors or ion channels. These targets show little similarity 
with the bacterial targets, and consequently, the library compounds showed low affinity for 
the bacterial enzymes [145], adding to the low hit rate. Furthermore, most antibacterial drugs 
possess different characteristics compared to non-antibacterial drugs, for instance, they do not 
meet Lipinsky’s rule of 5, they are larger, more complex and less lipophilic (Figure 6)  [136, 
154, 159]. Compounds that meet Lipinksy’s rule of 5 tend to lack the potential to penetrate 
bacterial cells [135]. 
 
 
Figure 6. Antimicrobial drugs differ both in size (molecular weight, Mw) and lipophilicity (ClogD) from other 
drugs (CMC: 4623 compounds from the commercially available Comprehensive Medicinal Chemistry database) 
[137]. 
 
4.3. The post-genomic era 
It is clear that the lack of success in the 1990s was not due to lack of innovation [145], but to 
the selection of a single target and its insufficient validation, the suboptimal in vitro screening 
process and screening huge random synthetic libraries with limited quality, complexity, and 
diversity [135, 137, 145, 159]. These important pitfalls from the genomic era have been 
comprehensively evaluated and helped to improve the current drug discovery methods. 
Genomics provided meaningful knowledge about important pathogens, as well as enabling 
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technologies, now applied in more sophisticated whole-cell screens [157]. Also, these 
techniques facilitate target identification and subsequently lead optimization [146, 160]. 
Moreover, there is again increased interest in NP, a proven source for antibiotic drug 
discovery [132, 154], now further explored by applying genome derived methods. Also the 
necessity of developing libraries focused on antibacterial research is recognized [137, 144, 
161]. In addition, the use of AMPs as such or as lead molecules is currently further 
investigated, and several AMPs are in clinical trials. The naturally occuring AMPs are 
cationic amphipatic molecules with diverse structures (α-helical peptides, disulfide bound β-
sheet peptides, loop structured peptides, or extended peptides) and sizes (ranging from 12 to 
100 aminoacids) [162]. Hence, AMP represent a unique and large area of chemical space. 
 
4.3.1. Revival of whole-cell screens 
4.3.1.1. Classical empiric whole-cell screens 
Recently conducted high-throughput whole-cells screens resulted in interesting hits, leads, 
and even marketed new drugs. The automation, miniaturization and techniques available for 
subsequent target identification, made whole-cell screenings attractive again [160].  
 
Andries et al. screened a commercially available library against the rapidly-growing non-
pathogenic surrogate Mycobacterium smegmatis [144, 160], and found compounds active 
against Mycobacterium tuberculosis, including a series of diarylquinolones that, after 
chemical optimization, led to the development of bedaquiline [160]. The mode of action was 
elucidated by whole-genome sequencing of cells that became resistant upon bedaquiline 
exposure [160]. Bedaquiline is the first antibacterial drug marketed that was discovered 
applying HTS [144].  
 
A disadvantage of empirical whole-cell screenings for growth inhibition is the oft-recurring 
identification of compounds that disrupt the bacterial membrane in a non-specific way 
(detergent activity, alkylation, energy poisoning) [135, 145]. This is often an indication of 
cytotoxicity towards mammalian cells and hence these hits are useless [135]. 
 
4.3.1.2. Target-based whole-cell screens  
Many hits identified in target-based cell-free screenings were useless as they lacked 
antibacterial activity. Now, target-based and whole-cell screenings are combined and this has 
resulted in the discovery of promising compounds [137, 157, 163, 164]. For instance, the NP 
platensimycin was discovered after screening 250,000 NP extracts in an ‘agar diffusion two-
plate differential sensitivity assay’ [137, 163, 165]. In such screenings, the sensitivity of a 
target depleted mutant for the library compounds is compared to the sensitivity of the wild 
type strain [137].  
 
Another method is the construction of reporter cells or biosensors [137]. A promoter that is 
selectively and strongly induced upon the inhibition or depletion of a selected target is fused 
with a reporter (e.g. luxCDABE operon of Photorhabdus luminescens) [159]. An inhibitor of 
the target will cause an up-regulation of the responsive promoter and hence also the reporter, 
resulting in the generation and emission of, in the case of the luxCDABE operon, 
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bioluminescence [159]. Reporter assays have been described for several bacteria, including 
Bacillus subtilis [135] and P. aeruginosa [159]. 
 
4.3.1.3. Whole-cell screens in the presence of mammalian cells 
High content screening uses cells, e.g. macrophages, that are intracellularly infected with a 
pathogen, e.g. Mycobacterium [157]. This resembles more the in vivo situation, so hits found 
in these screenings are expected to demonstrate higher in vivo activity [157]. An additional 
asset in this approach is that cytotoxic compounds are immediately eliminated [157]. A 
phenotypic screen in which 57,000 compounds were tested against a GFP-labeled 
Mycobacterium tuberculosis H37Rv in Raw264.7 macrophages is described that resulted in 
several groups of active molecules [160, 166]. 
 
4.3.1.4. In vivo screens 
Prontosil was discovered in 1932 by screening dyes in mice, and although it is impossible to 
screen the current libraries in mice, in vivo screening has several advantages over in vitro 
screening [144]. In vitro screenings might miss several promising compounds [144]. Some 
drugs require activation (also prontosil) by e.g. gut bacteria, and some bacterial targets are 
only expressed during infections [144]. A good alternative for mice is screening in the 
nematode Caenorhabditis elegans [144]. Furthermore, when screening in C. elegans, toxic 
compounds can be identified, and compounds with properties that would prevent them from 
being druggable (e.g. high protein binding), would not be identified as hits while they would 
bind to a target in in vitro screens [144]. More recently, other screening platforms for 
Mycobacterium species are described, in which the screening is performed in zebrafish larvae 
and amoeba [160]. However, the feasibility and asset of such platforms still has to be 
confirmed by screening large libraries [160]. 
 
4.3.2. Revival of NP discovery: back to the future 
There are new NP waiting to be discovered, but it is thought that they are produced at an even 
lower rate as is the case for daptomycin, so in theory tens of millions of actinomycetes would 
have to be tested on an annual base. Off course, this is impossible applying the methods used 
decades ago, which allows testing only tens of thousands actinomyces annually [154]. 
However, Cubist Pharmaceuticals developed a high-throughput miniaturized fermentation and 
screening, enabling them to screen 107  actinomycetes annually [154].  
 
Also, new sources can be invoked, e.g. marine actinomycetes [154], yielding new NP and thus 
potential new antibacterial drug scaffolds [132]. Furthermore, it is estimated that 99% of all 
bacteria on earth do not grow under laboratory conditions [144]. These uncultured bacteria are 
an untapped source of new NP and novel techniques to grow these are being developed [137, 
144, 167]. An innovative approach to grow uncultured bacteria in a high-throughput manner 
is their in situ cultivation using the isolation chip or ‘iChip’ (Figure 7) [144, 168]. Ling et al. 
used this device to isolate and grow 10,000 uncultured bacteria, and tested subsequently the 
antimicrobial activity of their NP extracts against S. aureus NCTC8325-4. This resulted in the 
identification of teixobactin, a depsipeptide representing the first member of a new class of 
antibiotics [169]. An alternative for trying to culture uncultured bacteria is analyzing soil for 
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their DNA. Based on metagenomics, several companies were able to produce antibiotics from 
soil DNA (Figure 8) [144]. 
 
 
Figure 7. Representation of the iChip device. The iChip consists of hundreds diffusion chambers (wholes are 1 
mm in diameter). A. The iChip is dipped in a diluted soil sample containing agar. B. Each whole captures a 
single cell C. Semi-permeable membranes prevent cell migration but allow diffusion of nutrients and growth 
factors, when the device is put back into the soil [168]. 
 
 
Figure 8. Simplified illustration of the metagenomic process applied to identify DNA of uncultivable bacteria in 
soil and producing NP from this isolated DNA, without necessitating to culture the uncultivable bacteria [170]. 
DNA isolated from soil samples is ligated in a Bacterial Artificial Chromosome (BAC). BAC is used as a vector 
and as it is based on F-plasmid DNA, it is passed through to the daughtercells when transformed into E. coli. 
Each colony of E. coli contains BAC with a different soil DNA fragment, resulting in a metagenomic library 
[171].  
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In addition, it is known now that the genomes of bacteria and yeast possess several gene 
clusters coding for enzymes producing secondary metabolites that are not expressed under 
conventional laboratory conditions. These cryptic pathways can be activated by several 
genetic methods, like overexpression of positive regulators, or by adapting the fermentation 
conditions [153]. As it is estimated that less than 10% of NP are produced by actinomycetes 
in fermentation broths, the other 90% cryptic gene clusters provide a source of new NP in 
known species [153, 154]. However, both the metagenomics approach with uncultured 
bacteria, as mining cryptic pathways, are very time-consuming and for this reason generally 
abandoned [144].  
 
Mutational biosynthesis, precursor-directed biosynthesis, and combinatorial biosynthesis are 
molecular methods in which NP intermediates, precursors, or metabolic pathways are adapted 
resulting in new analogs of NP [153], while ‘diverted total synthesis’, ‘function-oriented 
synthesis’, and ‘biology-oriented synthesis’ are some examples of chemical approaches to 
synthesize analogues of NP [172].  
 
It is clear that it is more difficult than sixty years ago, when new classes of antibiotics were 
well accessible as screening soil bacteria was enough. However, we have many tools now to 
find new antibiotics in sources that were thought empty before [154] or, like Baltz says: ‘We 
are in the early stages of a Renaissance in antibiotic discovery for actinomycetes’[154]. 
 
Nevertheless, NP might have severe limitations concerning stability, toxicity, 
pharmacokinetic, and their production, making the development into marketed drugs 
sometimes very difficult [137]. Thus beside NP research, other strategies should be followed 
as well. 
 
4.3.3. The position of synthetic compounds in the post-genomic era 
Beside the HTS of pure NP [152], NP extracts or fermentation broths [163], there is definitely 
a future for synthetic libraries and SBDD as well.  
 
4.3.3.1. Chemical space and Diversity-Oriented Synthesis  
Classic combinatorial chemistry generated libraries of insufficient skeleton-diversity, and thus 
covered only a concise part of the chemical space (Figure 9) [158]. However, the greater the 
chemical space occupied by a library, the greater the chance to find a compound that has 
affinity for a biological target [158]. Obviously, it is impossible to cover the entire chemical 
space in a single library, and the question remains as to what is the biologically relevant 
chemical space that has to be addressed in a library. It is unknown whether we should look in 
the region where NP and known drugs reside or whether completely new drugs can be found 
in ‘un-tapped areas of chemical space’ [158].  
 
Diversity-Oriented Synthesis (DOS) of compound libraries leads to smaller libraries than with 
combinatorial chemistry, but the compounds are more complex, stereochemically more 
diverse, and most importantly, the compounds differ greatly in their core structure [158]. The 
purpose of DOS is to design more suitable small molecule libraries that cover a considerable  
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part of the chemical space, including known bioactive areas of chemical space as well as 
unknown and unexplored regions [158]. 
 
Figure 9. Comparison between target-oriented synthesis, traditional combinatorial chemistry and DOS. The 
chemical space occupied by DOS is more diffuse compared to traditional combinatorial chemistry [173]. 
 
4.3.3.2. Establishment of rules for intracellular penetration to build new libraries 
It is clear that both more diverse and biological relevant compound libraries have to be 
designed. Antibiotics possess distinctive physicochemical properties compared to other drugs 
and these characteristics should be taken into account when designing new drugs. So far, 
general ‘rules’ for good antibiotic penetration into cells, especially into Gram-negative 
organisms are lacking, as the factors that determine uptake and efflux are only partially 
understood and each barrier is different [137, 147]. However, some features or rules of 
penetrations have been proposed [144, 145] and these can be used in guiding the development 
of synthetic compound libraries specific for antibacterial screenings and SBDD [144, 147].  
 
The rules for penetration should be established based on characteristics of compounds that do 
penetrate into bacteria, however, the number of compounds that do so is limited [144]. Some 
deductions were made already that can be implemented when new libraries are made [144]. 
Good permeability is expected for fairly hydrophilic compounds smaller than 600 Da, as these 
compounds are able to be transported through porins [137, 145]. Also zwitterionic compounds 
are more likely to penetrate Gram-negative bacteria [137] and anions are poor efflux pump 
substrates [144]. In contrast, hydrophobic cations will penetrate poorly as they are preferred 
substrates for MDR efflux pumps [144]. Interestingly, it has been observed that synthetic 
compounds containing fluorine and boron, which are not often encountered in NP, are 
favorable for penetration [144]. The successful synthetic fluoroquinolones confirm this. 
Considering these characteristics in screenings for and design of new antibacterial compounds 
proved to be a valuable approach, as exemplified by the activity of Anacor Pharmaceuticals. 
This company used their boron chemistry platform in antibacterial drug discovery [144, 145, 
174]. They found that ABX, a first-in-class compound that inhibits bacterial leucyl tRNA 
synthetase, showed both in vitro and in vivo activity towards several Gram-negative 
pathogens [145]. A related compound, AN3365, of which the structure is not disclosed yet, 
successfully passed clinical phase I trials [145, 174]. 
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Remember two benefits from failure. First, if you do fail, you learn what isn’t working and 
second, the failure provides you the possibility to try a new approach.  Roger Von Oech [131]
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5. Repurposing: old drugs, new hope?  
 
5.1. A shortcut to finding ‘new’ drugs 
Drug repurposing (or repositioning) is a term used to describe the use of drugs (either drug 
candidates, abandoned drugs, approved drugs, or withdrawn drugs) to treat a disease for 
which they were initially not developed for [175, 176]. The term drug repositioning was 
introduced in 2004 by Ashburn and Thor [177], and the number of publications using this and 
similar terms increased drastically in recent years [175]. However, the idea is not new and 
several drugs have been repurposed earlier. One of the most famous examples is sildenafil, 
which was in development for angina pectoris but was eventually marketed for erectile 
dysfunction, a side effect that appeared in the clinical trials [178, 179]. Indeed, in the past, 
repurposing was mainly based on serendipitous clinical observations [178], while in the last 
decade, small repurposing startup companies were founded and units were created in big 
pharmaceutical companies focusing on drug repurposing [179].  
 
The main advantages of drug repurposing over de novo drug development are reduced time 
and costs in the R&D process, as knowledge concerning safety and pharmacology are 
available for the repurposing candidates [180]. However, clinical trials are required to prove 
efficacy for the new indication [181]. In addition, if higher doses of the repurposing candidate 
are required for the new indication and these fall outside the approved therapeutic window, 
additional phase I clinical trials have to be performed [181].  
 
Drug libraries suitable for laboratory-based HTS were developed and are commercially 
available (e.g. John Hopkins Clinical Compound Collection, the NIH Chemical Genomics 
Center Pharmaceutical Collection, NIH Clinical Collection (NIHCC) [181], the Prestwick 
Chemical Library [182], the Library of Pharmaceutically Active Compounds (LOPAC) [160, 
183], and the Screen-Well FDA-approved drug library V2 [184]). For example, the Prestwick 
Chemical Library consists out of 1280 approved off-patent drugs and has a high chemical and 
pharmacological heterogeneity [182].  
 
5.2. Repurposing in the field of infectious diseases 
5.2.1. Non-antibiotic approved drugs with antibacterial activity 
For lack of a better name, drugs in use for non-bacteriological indications but with 
antibacterial activity are in literature often called ‘non-antibiotic drugs’ or ‘non-antibiotics’ 
[185]. These compounds might possess a direct antibacterial activity and/or enhance the 
activity of existing antibiotics by increasing the susceptibility of the bacteria towards the 
antibiotics, e.g. by controlling efflux pumps. In addition, they might also affect the 
pathogenicity of bacteria [186] or act by interference with the host resulting in an improved 
pathogen clearance [184, 187].  
 
Several drug classes (e.g. antihistamines, local anesthetics, antihypertensive drugs, 
tranquilizers, anti-inflammatory drugs) are known to possess antibacterial activity, although 
they were not developed to treat bacterial infections [14, 186, 188]. The antimicrobial 
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properties of some of these compounds are known for decades [179, 186, 189]. For instance, a 
study dating from 1977 describes the antibacterial activity of tetracaine against P. aeruginosa 
[188]. Increased cell wall permeability and interference with the cell membrane, resulting in 
leakage of intracellular compounds followed by cell lysis was postulated as the mode of 
action [188]. Similarly, for several decades, studies have attributed bacteriostatic and 
bactericidal activities to the antifungal imidazoles. Sud and Feingold described in 1982 the 
distinct mode of action of miconazole and ketoconazole towards S. aureus [190]. In addition, 
several recent screening programs revealed promising repurposing candidates, as described 
below.  
 
5.2.2. Screening repurposing libraries reveals new drug candidates 
5.2.2.1. Screening for antibacterial activity 
Harbut et al. screened the LOPAC library against M. tuberculosis in nutrient-deprivation 
conditions with the aim to identify bactericidal compounds [183]. Auranofin, clinically used 
to treat rheumatoid arthritis was identified in this screen and activity towards several other 
Gram-positive pathogenic bacteria was observed [160, 183]. The target of auranofin was 
identified as the bacterial thioredoxin reductase [183]. Interestingly, this screening resulted 
not only in the discovery of a promising repurposing drug candidate, but also in the 
identification of a valuable target essential in many Gram-positive bacteria [160]. 
 
In a screening campaign using the NIHCC 1&2, Younis and colleagues identified 24 non-
antibiotic drugs, among them ebselen and 5-fluoro-2’-deoxyuridine [189]. These two 
compounds killed MRSA and VRSA at clinically achievable concentrations and the in vitro 
activity was confirmed in vivo in a mouse model for septicemic MRSA-infection [189]. The 
libraries used in the study of Younis et al. were also used in the present dissertation. These 
libraries contain 727 compounds that all passed human safety assessment and many of them 
are FDA approved drugs. 
 
5.2.2.2. Screening for anti-virulence activity 
The use of anti-virulence drugs as alternative for novel antibiotics is a new strategy to meet 
the demand for new therapies [180, 191, 192]. Anti-virulence drugs ‘disarm’ bacteria by 
inhibiting the production of disease-causing virulence factors rather than inhibiting bacterial 
growth or killing bacteria [192]. Anti-virulence drugs can be used both in prophylaxis or as 
helper compound of antibiotics in combination therapy during infection [192]. 
 
The Prestwick Chemical Library was screened against a P. aeruginosa biosensor for 
pyoverdine inhibitors [191]. Pyoverdine is an important virulence factor, and might thus be a 
valuable target [191]. Flucytocine, an antimycotic drug, was found to reduce the pyoverdine 
production at low iron levels, without affecting growth [191]. The effect was confirmed in a 
mouse model for pulmonary infection, where it protected mice from death [191]. The same 
research group performed a screen with the same library for QS-inhibitors in P. aeruginosa 
and identified the anthelmintic drug niclosamide as a potent QS inhibitor, protecting Galleria 
mellonella larvae from death after challenge with P. aeruginosa [180]. Another research 
group performed an in silico screen and found that raloxifene, a selective estrogen receptor 
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modulator, binds PhzB2, which is involved in pyocyanin production [193]. This resulted in a 
decreased pyocyanin production in vitro and an attenuation in P. aeruginosa virulence in 
infected C. elegans [193]. 
 
The NSAID diflunisal was identified to bind the phosphoryl-binding pocket of the 
transcription factor AgrA after in silico screening of the National Cancer Institute Library 
(90,000 compounds) [192]. AgrA is involved in the expression of several important S. aureus 
virulence factors, among them α-hemolysin (hla) and phenol soluble modulin type α (PSM)  
[192]. Incubation of MRSA in the presence of diflunisal resulted in a decreased hla  
expression by a factor 1,000 and a significant reduction of psm α expression [192]. Because 
the virulence factor PSM contributes to bone destruction during an S. aureus osteomyelitis 
infection, the protective effect of diflunisal towards PSM-induced osteoblast cell death was 
investigated [194]. Diflunisal potently inhibited killing by S. aureus of murine and human 
osteoblasts, without affecting the growth of S. aureus. In addition, a foam loaded with 
diflunisal was developed and the ability to inhibit pathogen-induced bone destruction was 
evaluated in mice with S. aureus osteomyelitis infection. Diflunisal did not cause a decrease 
in bacterial burden in the infected femurs, however, it reduced the bone destruction with 36% 
[194].   
 
5.2.2.3. Screening in the presence of antibiotics to identify potentiators  
The combination of antibiotics with non-antibiotic drugs as potentiators is a potentially 
valuable approach to overcome the problem of antibacterial drug resistance [195-197]. 
Several non-antibiotic drugs are described for additive or synergistic interactions with 
common antibiotics, restoring antimicrobial activity [187]. For instance, phenothiazines acted 
synergistically with aminoglycosides and macrolides against Burkholderia pseudomallei 
presumably by interaction with BpeAB-OprB and AmrAB-OprB efflux pumps [187]. A 
screening with 1059 previously approved drugs performed by Ejim and colleagues against P. 
aeruginosa PAO1, E. coli BW25113 and S. aureus ATCC 29213 in the presence of 
minocycline resulted in the identification of 6, 41, and 35 hits, respectively. These hits were 
non-antibiotic drugs that synergized with minocycline although they have never been used 
clinically to treat bacterial infections [198]. Disulfiram was one of the hits against S. aureus: 
alone, disulfiram has only weak antibacterial activity but it improved the activity of 
minocycline in a synergistic way against several MRSA strains, including MRSA USA300. 
Loperamide was a hit for P. aeruginosa: it has no antibacterial activity when used alone, 
however, it showed synergistic interaction with minocycline. The synergistic interaction was 
confirmed against several clinical strains of P. aeruginosa, and against Salmonella enterica 
Typhimurium. The efficacy of this combination was evaluated in a mouse model of infectious 
colitis caused by S. enterica Typhimurium. Treatment with the compounds alone had no 
impact on the infection, while the combination treatment reduced the microbial load in the 
cecum significantly [198].  
 
5.2.2.4. Screening for compounds with activity towards the host 
The Screen-Well FDA-approved drug library V2 (780 compounds) was screened against 
murine macrophages infected with Yersinia pestis CO92 [184]. This resulted in the 
identification of three hits (trifluoperazine, doxapram and amoxapine) that were able to 
Chapter I: Introduction   Repurposing: old drugs, new hope? 
	  
	  
	  
40 
increase the survival of mice in a murine model of pneumonic plague [184]. Those 
compounds exhibited no bacteriostatic or bactericidal activity, nor did they affect bacterial 
virulence (no influence on type III secretion system or protease activity), leading to the 
conclusion that trifluoperazine, doxapram and amoxapine target host cell pathways resulting 
in a decreased pathogenesis [184].    
 
In addition, ‘inverse genomic signature’ is a new in silico approach to rapidly identify 
antimicrobial treatments acting on host cells [199].  In brief, transcriptome profiles of human 
cells after treatment with an approved drug (available in public databases) are compared to 
profiles of cells after infection (or any disease state). Drugs causing an ‘inverse similarity’ in 
gene expression can further be examined as potential repurposing candidates in in vitro and in 
vivo experiments [199].  
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Biofilms are consortia of bacterial and/or fungal cells embedded in an extracellular matrix 
[200]. Bacteria can form biofilms in patient tissues, on body surfaces and on implanted 
medical devices [201]. The cells within these biofilms are phenotypically different from their 
planktonic counterparts [200] and they are more resistant and tolerant towards antibacterial 
treatments. Treating biofilm-related infections is challenging because it is difficult, or often 
impossible, to eradicate them with antibiotic therapy alone [201, 202]. In addition, the biofilm 
matrix protects the cells from host immune defenses [201] making biofilms reservoirs of 
persisting infections [70].  
 
Biofilms are a considerable problem in health care settings and it is estimated that 65-80% of 
infections is biofilm-related [200, 201]. Pathogens like S. aureus and P. aeruginosa are 
leading causes of biofilm infections, and also B. cenocepacia is thought to form biofilms in 
the lungs of CF patients [201, 203]. The main aim of this dissertation was investigating the 
use of approved and off-patent drugs as potentiators of antibiotics against biofilms of these 
three important pathogens.  
 
The first goal was the optimization of a quantification method based on the dye Cell Titer 
Blue (CTB). CTB is a non-fluorescent dye that is reduced by metabolically active cells into a 
fluorescent reaction product. The amount of fluorescence generated is related to the number 
of viable cells present. An existing protocol for CTB staining can be used in a high throughput 
way for quantification of the effect against biofilms of B. cenocepacia and S. aureus, but the 
signals generated by P. aeruginosa biofilms are too low and too variable. For this reason, we 
aimed to develop an alternative protocol using CTB, which enabled us using CTB for the 
rapid quantification of the effect of the treatments against P. aeruginosa biofilms as well 
(chapter III paper I).  
 
Secondly, we aimed to identify drugs that enhanced the activity of antibiotics against 
biofilms. In order to identify these potentiators, we screened a library of approved and off-
patent drugs in combination with tobramycin, against biofilms of P. aeruginosa and B. 
cenocepacia, and in combination with vancomycin against biofilms of S. aureus (chapter III 
paper II and III). Mature biofilms were formed in 96-well MTPs, which is a general in vitro 
biofilm model system allowing HTS. The biofilms were treated for 24 h with the combination 
antibiotic/library compound, and the effect was evaluated with CTB. For S. aureus and B. 
cenocepacia, the CTB method as described by Peeters et al. [200] was used, while for the 
screening against P. aeruginosa we used the new protocol described in paper I. Promising 
repurposing candidates were selected out of the hits resulting from these screening campaigns. 
Next, the activity of these selected hits was evaluated in lower concentrations and in 
combination with other antibiotics in the same in vitro biofilm model system. The effect was 
quantified by plate counts instead of CTB. 
 
The final goal of this dissertation was to confirm the in vitro effect of our selected 
combinations in models that mimic the in vivo situation more closely. Efficacy of a treatment 
in these model systems is a better predictor for the therapeutic value of the combinations. The 
models used in these experiments were both in vitro models (a chronic wound biofilm model 
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and a three-dimensional organotypic cell culture model) and in vivo models (Galleria 
mellonella and a mouse lung infection model). In contrast to the screening against S. aureus 
and B. cenocepacia, only a very limited number of hits were identified in the screening 
against P. aeruginosa, and the activity of none of these hits was evalutated in other model 
systems. Hence, the results of this screening were not included in the Chapter III but the 
results of this screening are briefly summarized in Chapter IV.  
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ABSTRACT 
 
The resazurin-based viability staining is often used to quantify viable biofilm cells grown in 
microtiter plates (MTP). The non-fluorescent resazurin is reduced by metabolically active 
cells to resorufin which is fluorescent. The amount of fluorescence generated is related to the 
number of viable cells present. Unfortunately, the linear range of the method is restricted and 
the lower limit of quantification is approximately 106 colony forming units (CFU) per biofilm.  
 
The goal of the present study was to optimize this method to broaden its applicability. We 
added fresh growth medium and resazurin to mature Staphylococcus aureus, Pseudomonas 
aeruginosa, Burkholderia cenocepacia and Candida albicans biofilms formed in MTP. 
Subsequently, the increase in resazurin-based fluorescence was followed over time and we 
determined the time needed to reach a specific value of fluorescence as well as the time to 
reach the maximum fluorescence. These time points correlate with the number of viable cells 
that were initially present and results were compared to plate counts.  
 
Using these alternative read-outs, we were able to extend the linear range from 106–108 to 
103–108 CFU per biofilm, meaning that lower numbers of viable cells can be measured and 
the effect of anti-biofilm treatments can be quantified more accurately. Moreover, this 
approach is less expensive and less laborious than conventional plating techniques. 
 
INTRODUCTION 
 
Conventionally used antibiotics are active against planktonic cells that cause acute infection, 
but often fail to completely eradicate biofilms leading to persistent infections [66, 111]. 
Biofilms are cell communities embedded in a highly hydrated self-produced extracellular 
matrix and are attached to biotic or abiotic surfaces. They show inherent tolerance and higher 
resistance to antibiotic treatment than their planktonic counterparts [80, 82, 111]. Therefore, 
there is an urgent need to develop novel anti-biofilm agents and to do so, good model systems 
and quantification methods are indispensable. 
 
Several direct and indirect methods are used to quantify biofilms in the static microtiter plate 
(MTP) model system [64], each with its own advantages and disadvantages. Plating is a 
common quantification method that allows the determination of the number of culturable 
cells. Selective conditions can be used and isolates are available for further research. 
Furthermore, absolute cell numbers are obtained, and both very low and very high numbers of 
micro-organisms can be accurately quantified [204]. However, plating requires detachment 
and dispersal of the biofilm cells to obtain a homogenous cell suspension and scraping, 
vortexing and/or sonication is used for this purpose [205]. The number of cells will be 
underestimated if the dispersing is not done accurately. Moreover, cells will not grow and 
form visible colonies if they are in a state of starvation or under stress [206, 207]. In addition, 
since plating is time-consuming and labor-intensive, it is not suitable for HTS. The number of 
microorganisms can also be estimated indirectly using several staining methods, for example 
with fluorescein diacetate, tetrazolium salts or resazurin [200]. Resazurin (7-hydroxy-3H-
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phenoxazin-3 one 10-oxide), also referred to as CellTiter-Blue (CTB) or AlamarBlue, is often 
preferred over other stains as it is easy to use, stable and non-toxic. Metabolically active cells 
reduce the blue and non-fluorescent resazurin to the pink fluorescent reaction product 
resorufin. This reduction is proportional to the number of metabolically active cells present. 
The fluorescence generated can be measured using plate readers [205, 208, 209]. 
Quantification with resazurin is fast, inexpensive and suitable for high-throughput estimation 
of the number of metabolically active cells. However, the results have to be interpreted 
carefully since only relative values are obtained and the resazurin method as conventionally 
used has a lower limit of quantification of approximately 106 colony forming units (CFU) per 
biofilm [200]. The present study evaluates an alternative approach of using resazurin to 
quantify the number of viable cells in bacterial and fungal biofilms. 
 
MATERIAL & METHODS 
 
Strains and culture conditions 
Staphylococcus aureus Mu50, Pseudomonas aeruginosa PAO1 and Burkholderia 
cenocepacia LMG 16656 were cultured on Mueller Hinton agar plates (MH, Lab M, 
Lancashire, UK) and Candida albicans SC5314 on yeast-peptone-dextrose agar plates (YPD, 
BD, Franklin Lakes, NJ). From these pure cultures, overnight suspensions were made by 
inoculating 40 ml MH broth for the bacteria and 40 ml YPD broth for C. albicans with a 
loopful of microorganisms. All strains were grown aerobically at 37 °C. 
 
Antibiotics and antiseptics  
The following antibiotics and antiseptics were used: tobramycin (TOB, TCI, Tokyo, Japan), 
ciprofloxacin (CIP, Sigma, Bornem, Belgium), vancomycin hydrochloride hydrate (VAN, 
Sigma), amphotericin B (AMF, Sigma), miconazol (MICO, Certa, Waregem, Belgium), 
chlorhexidin digluconate (CHX, Fagron, Waregem, Belgium), cedium (CED, 1mg/ml 
benzalkonium chloride, NaEDTA, Na2HPO4 2H2O, NaH2PO4 2H2O, NaCl, Qualiphar, 
Bornem, Belgium), clindamycin (CLIN, Certa) and ozonated olive oil (O3, Labo Althea, 
Kapelle Op Den Bos, Belgium). All compounds were dissolved in physiological saline (PS, 
0.9% (w/v) NaCl), except for CHX which was dissolved in water of standard hardness (WSH) 
and MICO which was dissolved in dimethylsulfoxide (DMSO, Sigma); and subsequently 
diluted in PS. Where necessary, solutions were filter sterilized (0.22 µm, Whatman, Dassel, 
Germany) prior to use. Treatment with ozonated olive oil was performed as described in 
[210]. 
 
Biofilm formation in 96-well microtiter plates 
Overnight suspensions were adjusted with MH broth for the bacteria and YPD broth for C. 
albicans to an optical density (595 nm) of 0.05 for B. cenocepacia, 0.2 for P. aeruginosa and 
S. aureus and 0.5 for C. albicans. These optical densities correspond to approximately 
5 × 107 cells/ml. A hundred microliters of the diluted cell suspensions were transferred to the 
wells of a polystyrene round-bottomed 96-well microtiter plate (MTP, SPL Lifescience, 
Korea) and then incubated at 37 °C. Ten wells filled with sterile medium served as blank 
control. Medium was removed after 4 h and biofilms were rinsed with PS to remove non-
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adhered cells. Fresh medium was subsequently added to the wells and plates were further 
incubated for 20 h. 
 
Set-up of calibration curves  
To investigate the relation between the number of metabolically active cells in the biofilm and 
the resazurin-based fluorescence signal obtained, biofilms were formed as described above. 
After 24 h of biofilm formation, medium was removed, biofilms were rinsed and 100 µl fresh 
PS was added to the wells. The plates were vortexed (5 min) and sonicated (5 min) (Branson 
3510; Branson Ultrasonics Corp., Danbury, CT) and the entire content of the wells was 
collected. This process was repeated twice in order to harvest all biofilm cells. Serial 10-fold 
dilutions of this suspension were made in PS and 50 µl of each dilution was added to the wells 
of a round-bottomed sterile 96-well MTP together with 50 µl double concentrated MH 
medium (5 wells per dilution). Subsequently, 20 µl CellTiter-Blue was added to the wells and 
the fluorescence (λex 535 nm/λem 590 nm) was measured every 5 min for 20 h using a 
multilabel microtiter plate reader (Envision; Perkin–Elmer LAS, Waltham, MA). Plates were 
incubated in the dark at 37 °C between the measurements and fluorescence measured in the 
blank control was used to correct for background signal. Simultaneously, the number of CFU 
per biofilm in each dilution was quantified using conventional plating techniques. The time to 
reach an absolute fluorescence value of 100,000 and the time to reach the maximum 
fluorescence was determined for each dilution. These time points and the number of CFU 
present in every dilution were then used to set up the calibration curves. The experiments 
were performed in triplicate for each strain. 
 
C. albicans is usually grown in media containing relatively high concentrations of glucose 
because this fermentable carbohydrate enhances fungal growth. However, our preliminary 
results showed that the use of this medium leads to high background levels of fluorescence, 
indicating that the medium influences the measurement (Figure S1). In order to avoid this, we 
decided to grow C. albicans biofilms in YPD, but carried out the resazurin assay in MH. 
 
Biofilm treatment and quantification  
Biofilms formed as described above were treated with 100 µl of various antibiotics and 
antiseptics for 24 h at 37 °C. Contact time for CHX however ranged from 1 to 30 min and 
reaction was stopped using Dey Engley neutralizing broth (DENB, Lab M, 7 g/l lecithin, 6 g/l 
sodium thiosulphate, 5 g/l tween 80, 5 g/l tryptone, 2.5 g/l sodium bisulphite, 1 g/l sodium 
thioglycollate, 0.02 g/l bromocresol purple, 2.5 g/l yeast extract). The supernatants were 
removed subsequently and the biofilms were rinsed with PS. Conventional plating and 
resazurin staining were then used to determine the number of culturable and viable biofilm 
cells, respectively (designed as CFUplating and CFUCTB). 
 
To determine CFUplating, 100 µl PS was added to the wells containing the treated biofilms and 
the MTP was sonicated and vortexed twice (same procedure as described above). The 
detached cells were quantified by conventional plating. To determine CFUCTB, 100 µl MH 
was added to the wells and the MTP was sonicated and vortexed twice. Subsequently, 20 µl 
resazurin was added and the MTP was incubated for 20 h at 37 °C. The fluorescence 
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generated by the reduction of resazurin was measured every 5 min and the time to reach the 
fluorescence signal of 100,000 and the maximum fluorescence signal were determined. The 
previous derived calibration curves were then used to calculate the CFUCTB. Finally, CFUplating 
and CFUCTB were compared for each condition. Statistical analysis was performed with SPSS 
software using independent sample t-tests. P values < 0.01 were considered to be statistically 
significantly different. 
 
RESULTS AND DISCUSSION 
 
Bacteria growing in biofilms cause persistent infections which are often not cleared with 
conventional antibiotic treatment alone. New anti-biofilm agents are urgently needed and to 
this end, good model systems and quantification methods are essential. The non-fluorescent 
dye resazurin is used to quantify metabolically active cells. In the conventionally used assay, 
resazurin is diluted in PS and added to biofilms formed and treated in MTP. The fluorescence 
generated by the reduction of resazurin to its fluorescent reaction product by metabolically 
active cells is typically measured after 30–120 min. However, the linear range is restricted 
and the lower limit of quantification is approximately 106 CFU per biofilm, which means that 
the assay cannot discriminate between cell numbers lower than 106 CFU per biofilm [200]. 
In the present study, we optimized this resazurin-based quantification method. Mature S. 
aureus, P. aeruginosa, B. cenocepacia and C. albicans biofilms were formed in MTP. 
Subsequently, these biofilms were disrupted, detached and collected. Serial dilutions were 
made and wells of a sterile MTP were filled with these diluted cell suspensions together with 
fresh MH growth medium and resazurin. The fluorescence generated by the reduction of 
resazurin was followed over time. The time to reach an absolute fluorescence value of 
100,000 and the time to reach the maximum fluorescence were determined for every dilution. 
The time to reach these fluorescence signals was plotted against the number of CFU present in 
every dilution, obtained by conventional plating, leading to the calibration curves shown in 
Figure 1. The linear range increased from 106–108 CFU per biofilm as described in [200] to 
approximately 103–108 CFU per biofilm. This results in a substantially decreased lower limit 
of quantification, making screenings for anti-biofilm agents more precise. Moreover, by 
measuring the fluorescence over an extended time, high fluorescence signals were generated 
for all species tested. This is interesting especially for micro-organisms that reduce resazurin 
slowly, like P. aeruginosa. 
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Figure 1. Calibration curves showing the relation between the time needed to reach an absolute fluorescence 
value of 100,000 (left) and maximum fluorescence value (right) and the number of CFU per biofilm determined 
by plating. A) S. aureus, B) P. aeruginosa, C) B. cenocepacia, D) C. albicans. 
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In order to validate our approach, mature biofilms of S. aureus, P. aeruginosa, B. cenocepacia 
and C. albicans were grown in MTP and treated with several anti-infective agents in various 
concentrations and/or contact times. Conventional plating was used to determine the 
CFUplating, and resazurin staining was used to determine CFUCTB. The CFUplating and CFUCTB 
obtained were then compared for each treatment. As shown in Figure 2, the results obtained 
with both quantification methods were very similar and confirm that this method can be 
implemented in screenings to assess the number of viable cells. 
 
Figure 2. The number of CFU per biofilm as determined by plating (CFUplating) and as calculated using the 
previously determined calibration curves (CFUCTB). Error bars represent standard deviations. * Statistically 
significantly different (p < 0.01), (n≥5). 
 
Both the time to reach a signal of 100,000 and the time to reach the maximum fluorescence 
were determined for every strain and treatment evaluated in this study. However, 
microorganisms that rapidly reduce resazurin reach the signal of 100,000 in a few minutes, 
consequently, the time to reach the maximum can be established more precisely and is 
therefore preferred. S. aureus rapidly reduces resazurin while the other organisms tested in the 
present study reduced resazurin more slowly. Hence, we calculated the CFUCTB for S. aureus 
using the time needed to reach the maximum fluorescence, and for the other strains using the 
time needed to reach a fluorescence value of 100,000. 
 
For some treatments, CFUplating and CFUCTB are statistically significantly different (Figure 2). 
However, these differences are minor and not biologically significant as they do not exceed 1 
log and will not influence the interpretation of the results obtained in screening assays. 
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CONCLUSION 
 
The resazurin assay is a simple method to quantify the number of viable cells in biofilms 
formed in MTP. By optimizing this assay, we were able to decrease the lower limit of 
quantification from 106 to 103 CFU per biofilm, meaning that substantially lower numbers of 
viable cells can be measured and the effect of anti-biofilm treatments can be quantified more 
accurately. Moreover, the assay described is faster and less labor intensive than conventional 
plating. 
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ABSTRACT 
 
Staphylococcus aureus biofilms are involved in a wide range of infections that are extremely 
difficult to cure with conventional antibiotic therapy.  
 
We aimed to identify potentiators of antibiotics against mature biofilms of S. aureus Mu50, a 
methicillin-resistant and vancomycin-intermediate strain. Over 700 off-patent drugs from a 
repurposing library were screened in combination with vancomycin in an MTP-based biofilm 
model system. This led to the identification of 25 hit compounds, including four 
phenothiazines among which thioridazine was the most potent. Their activity was evaluated in 
combination with other antibiotics against both planktonic as biofilm grown S. aureus cells. 
The most promising combinations were subsequently tested in an in vitro chronic wound 
biofilm infection model.  
 
Although no synergistic activity was observed against planktonic cells, thioridazine 
potentiated the activity of tobramycin, linezolid and flucloxacillin against S. aureus biofilm 
cells. However, this effect was only observed in a general 96-well MTP biofilm model and 
not in a chronic wound model of biofilm infection.  
 
We identified several drug compounds which potentiated the activity of suboptimal 
concentrations vancomycin against biofilms formed in an MTP-based biofilm model. A 
selected hit compound failed to potentiate the activity of three antibiotics tested in a model 
that mimics specific aspects of wound biofilms. This study provides a platform for 
discovering and evaluating potentiators against bacterial biofilms and highlights the necessity 
of using relevant in vitro biofilm model systems. 
 
INTRODUCTION 
 
Staphylococcus aureus is a notorious opportunistic pathogen that is involved in a wide range 
of infections, including chronic wounds, endocarditis, and infections associated with 
indwelling medical devices [202]. Treatment of these infections is challenging due to the 
frequent occurrence of antimicrobial resistant strains such as methicillin-resistant S. aureus 
(MRSA) [211]. In addition, S. aureus often reside within biofilms at the infection site [202]. 
Biofilms are cell communities embedded in a self-produced extracellular matrix in which the 
bacterial cells are protected from the host’s immune system and the activity of antimicrobial 
agents [202]. Biofilm-related infections often fail to respond to antibiotic therapy, leading to 
chronic infections for which more effective treatments are urgently needed [202].  
 
An approach to fill the antibiotic pipeline is screening repurposing libraries [212]. In drug 
repurposing or repositioning, drugs are used to treat diseases they were initially not developed 
for [176]. This approach has several advantages over de novo drug development, e.g. long 
term toxicity and metabolic properties are already known [176]. This reduces the risk, time 
and costs to bring the repurposed drug to the market [213]. Although several non-antibiotic 
drugs have antimicrobial activity, [186] none of these are currently used in antibacterial 
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therapy since their bactericidal activity is often only observed at very high concentrations 
making them clinically less useful [189]. However, the combination of antibiotics with non-
antibiotics as potentiators (‘helper’ compounds) could result in a greater antimicrobial effect 
and less toxicity when lower concentrations of both can be used. For this reason, the search 
for antibacterial potentiators has recently gained interest [187].  
 
Many whole-cell screenings are conducted using general growth medium and measuring 
inhibition of bacterial growth as the endpoint [214]. However, growth conditions and 
endpoints used to measure antibacterial activity are important parameters and different hits 
can be identified depending on whether compounds are screened for activity against 
planktonic or biofilm cells [214, 215]. Investigating alternative endpoints, like the ability to 
inhibit biofilm formation or quorum sensing, can lead to interesting results [180, 216]. 
However, few screenings are performed against biofilms [217, 218] and few studies evaluated 
off-patent drugs for their possible potentiator activity towards antibiotics that could be used 
for topical treatment of biofilm-related infections (including chronic wound infections) [219]. 
In addition, few studies have investigated the activity of their hit compounds under conditions 
simulating the host environment. In the present study, we performed a repurposing screen in 
the presence of vancomycin against S. aureus biofilms, followed by validation of a selected 
hit in an in vitro chronic wound biofilm model. 
 
MATERIAL & METHODS 
 
Strains and culture conditions  
The methicillin-resistant and vancomycin-intermediate strain S. aureus Mu50 was used in this 
study. Pure cultures were maintained on tryptic soy agar (TSA, Lab M, Lancashire, UK) 
plates. Overnight broth cultures (ON culture) were obtained by inoculating Mueller Hinton 
broth (MH broth, Lab M) with several colonies and incubated for 18 h with shaking. All 
cultures were kept aerobically at 37°C.  
 
Drugs and antibiotics used  
The National Institutes of Health Clinical Collection 1 and 2 (NIHCC 1&2, Evotec, San 
Francisco, USA) are repurposing libraries containing respectively 446 and 281 components at 
a concentration of 10 mM, dissolved in 100% DMSO and stored at -20°C in 96-well 
microtiter plates (MTPs). Ciprofloxacin (CIP) was obtained from Fluka (Buchs, Swiss), 
tobramycin (TOB) from TCI Europe (Antwerp, Belgium), rifampicin (RIF), gentamicin 
(GEN), vancomycin hydrochloride hydrate (VAN), linezolid (LNZ), tetracycline 
hydrochloride (TET), fusidic acid sodium salt (FA), flucloxacillin sodium (FLU), 
fluphenazine dihydrochloride (FLUPH), perphenazine (PERPH), trifluoperazine 
dihydrochloride (TRI) and thioridazine hydrochloride (TZ) were purchased from Sigma 
Aldrich (Bornem, Belgium). Solutions were made in physiological saline (PS, 0.9% w/v 
NaCl) and ointments in 70% white vaseline  (Fagron, Waregem, Belgium) and 30% liquid 
paraffin (Fagron). Perphenazine was first dissolved in DMSO (Sigma Aldrich) and 
subsequently diluted in PS. For the MIC and checkerboard tests, drugs were dissolved in 
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ultrapure Milli-Q water (MQ, Millipore, MA, USA). All solutions were made fresh on the day 
of the experiment and filter sterilized (0.22 µm, Whatman, Germany). 
 
Screening of the NIHCC 1&2 against mature biofilms of S. aureus Mu50 grown in 96-
well MTPs   
Biofilms were formed as previously described [220]. In brief, round-bottomed 96-well MTPs 
were filled with 100 µl of a diluted overnight bacterial suspension (OD595 0.2, approx. 5x107 
CFU/ml) and incubated for 4 h at 37°C. Subsequently, wells were rinsed with PS to remove 
all planktonic cells and 100 µl fresh MH broth was added. Plates were incubated for an 
additional 20 h at 37°C. The 24 h old biofilms were rinsed with 100 µl PS. Subsequently, 49 
µl PS, 1 µl of compound (final concentration: 100 µM), and 50 µl of a 80 µg/ml vancomycin 
solution was added (final concentration: 40 µg/ml) in case of combination treatment. In case 
of experiments carried out in the absence of vancomycin, 1 µl compound was added to 99 µl 
PS. All experiments were carried out at least in triplicate. A blank, a growth control and a 
control for vancomycin treatment alone were included on every plate. After 24 h incubation at 
37°C, the supernatant was removed and biofilms were rinsed with 100 µl PS. The number of 
metabolically active cells was determined by resazurin staining (Cell Titer Blue, CTB, 
Promega, Leiden, The Netherlands) using a multilabel MTP-reader (λex 535 nm/λem 590 nm, 
Envision, Perkin Elmer LAS, Waltham, MA) as previously described [200]. The blank 
corrected fluorescence signals generated by S. aureus biofilms treated with the combination of 
component and vancomycin were compared to the fluorescence signal generated after 
treatment with vancomycin alone. Successful hits were defined as combinations yielding a 
decrease in fluorescence signal of at least 90% compared to fluorescence generated by 
biofilms treated with vancomycin alone. 
 
Determination of the MIC and FIC  
MICs of thioridazine, fluphenazine, perphenazine and trifluoperazine against S. aureus Mu50 
were determined in triplicate using flat-bottom 96-well MTP (TPP, Trasadingen, Switzerland) 
as described earlier [221]. The inoculum was standardized to approx. 5x105 CFU/ml. The 
plates were incubated at 37°C for 24 h, and the optical density at 590 nm was measured using 
a multilabel MTP-reader (Envision). The MIC is the lowest concentration that generates a 
signal that is not significantly different from that of un-inoculated growth medium.  
 
Interaction between thioridazine (50-0.78 µM), fluphenazine (100-1.56 µM), perphenazine 
(100-1.56 µM), or trifluoperazine (50-0.78 µM), and tobramycin (1024-4 µg/ml), gentamicin 
(512-2 µg/ml), vancomycin (32-0.125 µg/ml), ciprofloxacin (256-1 µg/ml), linezolid (32-
0.125 µg/ml), tetracycline (256-2 µg/ml), fusidic acid (1-0.004 µg/ml), or flucloxacillin 
(1024-4 µg/ml) was determined by checkerboard assays and the fractional inhibitory 
concentration index (FICI) was calculated to determine whether the interaction was 
synergistic (FICI ≤ 0.5) or indifferent (FICI > 0.5). In order to do so, solutions of the 
antipsychotic phenothiazines were added to flat 96-well MTPs in a concentration gradient in 
one direction, and the antibiotic solutions were added in a concentration gradient in the other 
direction. A similar inoculum as in the MIC tests was subsequently added and the absorbance 
was measured after 24 h incubation. The FICI was calculated as follows: MICAB /MICA + 
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MICBA/MICB, where MICAB is the lowest concentration of the phenothiazine in the presence 
of the antibiotic where the absorbance does not differ from the absorbance of the uninoculated 
blank control, MICA is the lowest concentration of the phenothiazine that causes an 
absorbance that does not differ from that of the uninoculated blank control, MICBA is the 
lowest concentration of the antibiotic in the presence of a phenothiazine that causes an 
absorbance that does not differ from the absorbance of the blank control, while MICB is the 
lowest concentration of the antibiotics that causes an absorbance not different from that of the 
blank control. 
 
Biofilm eradication tests in 96-well MTPs  
The activity of the four phenothiazines against S. aureus biofilms was evaluated in a 96-well 
MTP biofilm model. Mature biofilms of S. aureus were grown as described above and 
subsequently treated with thioridazine, fluphenazine, perphenazine or trifluoroperazine (10, 
50, and 100 µM). The potentiating activity of thioridazine on antibiotics was investigated in 
the same model. Biofilms were treated with thioridazine (100 µM) in combination with 
tobramycin (1024 µg/ml), gentamicin (1024 µg/ml), flucloxacillin (1024 µg/ml), vancomycin 
(40 µg/ml), linezolid (20 µg/ml), tetracycline (128 µg/ml), ciprofloxacin (250 µg/ml), fusidic 
acid (1000 µg/ml) and rifampicin (512 µg/ml). After 24 h, the treatment solutions were 
removed and biofilms were rinsed with 100 µl PS. Cells were collected from the wells by 2 
cycles of shaking (5 min, 700 rpm, Titramax 1000) and sonicating (5 min, Branson 3570E-
MT, Branson Ultrasonic Corporation, Banbury, USA). The content of 5 wells was pooled in 
tubes containing 9 ml PS and the number of colony forming units per biofilm (CFU/BF) was 
determined by plating serial 10-fold dilutions on TSA plates. Experiments were performed in 
triplicate on at least 3 different days (n≥3). 
 
Validating the activity of tobramycin, linezolid, or flucloxacillin and thioridazine in an 
in vitro chronic wound biofilm model  
Preparation of the artificial dermis (AD) and biofilm formation were performed as described 
by Brackman et al. [222]. Briefly, an upper layer of the dermis was prepared by dissolving 
sodium hyaluronate (Lifecore Biomedical, MN, US) in PS, adjusting the pH to 3.5 followed 
by chemically crosslinking hyaluronate with ethylene glycol diglycidyl ether (EX810, Sigma). 
Freeze-drying containers were filled with this solution, stored overnight at 4°C, subsequently 
strored at -80°C, and freeze dried. Then, a second layer was prepared, containing hyaluronic 
acid and collagen. This was poured on the first layer. After freeze-drying, the dermis were 
removed from the freeze-drying vial, irradiated with a UV lamp to cross link the collagen, 
followed by sterilization in an oven (110°C, 1 h) [222]. The dermis were put in the wells of a 
24-well MTP and moistend with 1 ml bolton broth containing 50% (v/v) plasma (Sigma), and 
5% freeze-thawed horse blood. Ten µl of a diluted overnight S. aureus culture (104 CFU) was 
added to the dermis. After 24 h of biofilm formation at 37°C, the infected dermis was rinsed 
and subsequently solutions (100 µl) containing tobramycin (2048 µg/ml), linezolid (400 
µg/ml), or flucloxacillin (20.5 mg/ml) alone and with 100 µl thioridazin (100 µM) were 
added. Alternatively, the AD were covered with 250 mg ointment containing tobramycin (15 
mg/g), alone or combined with 0.25 mg/g thioridazine for 24 h. The AD were kept at 37°C 
during treatment. After treatment, AD were placed into tubes containing 10 ml PS, the sessile 
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cells were removed from the AD by three cycles of vortexing (30 s) and sonication (30 s) and 
the number of CFU/dermis was determined by plating the resulting suspensions. Every 
condition was tested in triplicate. 
 
Statistical analysis  
Statistical analysis were performed using SPSS version 23 software and data were analyzed 
with Kruskal-Wallis test. 
 
RESULTS AND DISCUSSION 
 
Hits resulting from screening NIHCC 1&2 against S. aureus biofilms  
Over 700 compounds from the NIHCC 1&2 repurposing libraries were screened for their 
ability to potentiate the antimicrobial activity of vancomycin against mature S. aureus 
biofilms formed in 96-well MTPs. The effect of the treatment was quantified using CTB, 
measuring the number of surviving metabolically active cells. Compounds that caused a 
decrease in fluorescence signal of ≥90% when combined with vancomycin compared to 
treatment with vancomycin alone (set to 100%) were retained for further analysis. Twenty-
five compounds (3.4%) met these requirements. This hit rate is much higher compared to the 
0.025% average hit rate usually seen in HTS [223] but comparable to screenings using similar 
repurposing libraries [189, 218]. Hits were classified according to their therapeutic indications 
and belonged to the following categories: anti-infective agents (n=6), antipsychotic drugs and 
antidepressants (n=5), antineoplastic and hormonal drugs (n=7), and a miscellaneous group 
(n=7) (Table 1).  
 
Subsequently, S. aureus biofilms were treated with the identified hits in absence of 
vancomycin. Six compounds (fluphenazine, trifluoperazine, sertraline, tamoxifen, 
oxymetholone, and amiodarone) did not cause a significant reduction in fluorescence signal 
compared to the growth control (Table 1). Hence, these compounds have no effect anti-
biofilm effect on their own measured by CTB staining. In contrast, the potentiating activity of 
the other hit compounds is at least partially due to their intrinsic anti-biofilm activity. 
 
Combining vancomycin with the antifungal imidazoles miconazole nitrate, oxiconazole 
nitrate or econazole nitrate resulted in a decrease in fluorescence signal of more than 90% 
compared to treatment with vancomycin alone. Interestingly, treatment with the imidazoles 
alone caused a significant decrease in fluorescence signal compared to the untreated control 
(p< 0.05) (Table 1). This indicates that these imidazoles substantially decrease the metabolic 
activity of S. aureus biofilms. For this reason, the effect of the combination cannot only be 
attributed to a direct potentiating effect. Activity of imidazoles against planktonic S. aureus 
has been known for decades [190]. Imidazoles cause a K+ leakage indicating membrane 
damage [190] and their interaction with bacterial flavohemoglobin results in an increased 
level of intracellular reactive oxygen species (ROS) [224].   
 
Sertraline, an antidepressant belonging to the selective serotonine reuptake inhibitors (SSRI), 
was identified as a potentiator in our screening. In absence of vancomycin, sertraline causes 
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no significant decrease in fluorescence signal meaning that it has no intrinsic activity against 
biofilms. Recently, Ayaz et al. showed that sertraline has both intrinsic and synergistic 
activity in combination with several antibiotics (among them moxifloxacin and levofloxacin) 
against planktonic S. aureus [225]. The authors suggest that efflux pump inhibition is the 
mode of action but this is not confirmed yet [225].  
 
The phenothiazines trifluoperazine HCl, perphenazine, fluphenazine dihydrochloride and 
thioridazine HCl, were all identified as hits in the current screening. Antibacterial properties 
of the first marketed antipsychotic drug belonging to this class, chlorpromazine, were known 
since its release 60 years ago. However, at that time chlorpromazine was not an interesting 
antibiotic agent or lead compound due to its severe side effects and relatively low 
antibacterial activity [226]. Today, as phenothiazines with less side effects (e.g. thioridazine) 
are available, and the need for new antibiotic therapies is high, these drugs are being 
investigated as potential repurposing drug candidates. Toxicity is acceptable for short-term 
treatments and their in vitro activity, either alone or as potentiators of antibiotics, especially 
beta-lactams, is promising [227]. Moreover, the mode of action has been investigated in 
detail. Phenothiazines inhibit the activity of efflux pumps, alter the cell wall structure, and 
interfere with other cellular processes [32, 226-230]. Interestingly, due to increased 
concentrations intracellularly, phenothiazines enhance killing of phagocytosed MRSA at 
clinically achievable concentrations [211]. However, conflicting results are obtained in in vivo 
models [228, 230, 231] and activity against biofilm cells has not been described in literature. 
Being valuable and potential repurposing drug candidates, we selected these four 
phenothiazines (thioridazine, fluphenazine, perphenazine and trifluoperazine) to investigate 
their activity against S. aureus biofilms in more detail. 
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Table 1. Hits identified in a screen of the NIHCC 1&2 against biofilms of S. aureus are classified according to 
their therapeutic indication. Compounds were tested at a concentration of 100 µM in the presence of vancomycin 
(VAN, 40 µg/ml) or in absence of vancomycin. Data shown are average percentages with standard deviation. 
*Significant reduction in fluorescence compared to growth control, p<0.05. SSRI: selective serotonin reuptake 
inhibitor, SERM: selective estrogen receptor modulator, NSAID: non-steroidal anti-inflammatory drugs 
 
COMPOUND 
 
 
 
DESCRIPTION 
 
 
 
Residual metabolic 
activity after 
treatment with 
compound and 
VAN compared to 
treatment with 
VAN alone ± SD 
Residual metabolic 
activity after 
treatment with 
compound compared 
to untreated control  
± SD 
 
Anti-infectives 
   Hexachlorophene Desinfectant 0 ±0   * 8   ±10  * 
Triclosan Desinfectant 0 ±0   * 2   ±3    * 
Miconazole Antifungal drug 9 ±10 * 33 ±22  * 
Econazole Antifungal drug 5 ±5   * 24 ±24  * 
Oxiconazole Antifungal drug 0 ±0   * 10 ±10  * 
Efavirenz Antiviral drug 0 ±1   * 5   ±8    * 
Antipsychotic drugs and antidepressants 
  Fluphenazine Antipsychotic 6 ±3   * 62 ±31 
Perphenazine Antipsychotic 9 ±3   * 48 ±24  * 
Thioridazine Antipsychotic 0 ±0   * 29 ±18  * 
Trifluoperazine Antipsychotic 0 ±0   * 67 ±36 
Sertraline Antidepressant 0 ±0   * 51 ±21   
Antineoplastic and/or hormonal drugs 
  Daunorubicin Antineoplastic 0 ±0   * 18 ±16  * 
Idarubicin Antineoplastic 0 ±0   * 15 ±27  * 
Toremifene SERM 0 ±0   * 9   ±7    * 
Tamoxifen SERM 0 ±0   * 67 ±10 
Clomifene citrate SERM 0 ±0   * 13 ±1    * 
Flutamide Anti-androgen 2 ±1   * 24 ±14  * 
Oxymetholone Anabolic steroid 0 ±0   * 88 ±47 
Miscellaneous group 
   Amiodarone Class III antiarrhythmic 6 ±9   * 68 ±6 
Carvedilol β blocker/α-1 blocker 8 ±6   * 41 ±6   *  
Honokiol Neolignal biphenol 0 ±0   * 0   ±0   * 
Sodium loxoprofen NSAID 3 ±1   * 42 ±29 * 
MK886 Lipoxygenase inhibitor 5 ±2   * 39 ±25 * 
5-Nonyloxytryptamine 5-HT1B receptor agonist 0 ±0   * 37 ±15 * 
Ethacrynic acid Diuretic 5 ±5   * 1   ±1   * 
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Activity of phenothiazines against planktonic S. aureus  
The MIC for planktonic cells was determined and thioridazine and trifluoperazine showed 
highest activity with MICs of 50 µM compared to 100 µM for fluphenazine and perphenazine. 
A possible interaction was evaluated in checkerboard assays measuring the growth inhibiting 
properties of varying concentrations of the phenothiazines and an antibiotic (vancomycin, 
tobramycin, ciprofloxacin, fusidic acid, gentamicin, tetracyclin or linezolid). FIC indices were 
> 0.5 for all combinations, indicating that there was no synergistic activity between 
phenothiazines and the antibiotics tested.  
 
Activity of phenothiazines against S. aureus biofilm cells   
We subsequently evaluated the biofilm eradicating effect of thioridazine, fluphenazine, 
trifluoperazine, and perphenazine in different concentrations (10-50-100 µM), using plate 
counts. Trifluoperazine and perphenazine did not result in a significant reduction in 
CFU/biofilm in contrast to thioridazine and fluphenazine (Figure 1). Thioridazine (50 µM or 
100 µM) caused a significant reduction of approx. 1 log10 in CFU/biofilm compared to the 
untreated control. However, thioridazine has no biofilm eradicating effect at lower 
concentrations. Fluphenazine (100 µM) caused a significant reduction of 0.5 log10 while lower 
concentrations were inactive. 
  
Figure 1. Treatment of mature S. aureus biofilms for 24 h with 100 µl PS (untreated control, CTRL), thioridazine 
(TZ, 10, 50, or 100 µM), fluphenazine (FLUPH, 100 µM), perphenazine (PERPH, 100 µM), or trifluoperazine 
(TRI, 100 µM). *Significantly different number of colony forming units/biofilm (CFU/BF) compared to CTRL 
(n>3; p<0.05, error bars indicate standard deviation) 
 
Being the most potent compound, thioridazine was evaluated for its capacity to potentiate the 
activity of other antibiotics. Biofilms were treated with thioridazine (100 µM) in combination 
with vancomycin (40 µg/ml, MIC=8 µg/ml), ciprofloxacin (250 µg/ml, MIC=62.5 µg/ml), 
linezolid (20 µg/ml, MIC=2 µg/ml), fusidic acid (1000 µg/ml, MIC=2 µg/ml), tetracycline 
(128 µg/ml, MIC=64 µg/ml), tobramycin (1024 µg/ml, MIC=512 µg/ml), flucloxacillin (1024 
µg/ml, MIC >512 µg/ml), gentamicin (1024 µg/ml, MIC=256 µg/ml) and rifampicin (512 
µg/ml, MIC>512 µg/ml) and the effect was quantified using plate counts. Treatment with the 
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combination thioridazine and tobramycin resulted in a clear additional anti-biofilm effect, 
reducing the CFU/BF to approx. 5 log10 (Figure 2). Although similar results were observed 
for 50 µM thioridazine, lower concentrations (10 µM) failed to potentiate the activity of 
tobramycin. So far, it is unclear what the mechanism is behind the potentiating effect. Also 
treatment with thioridazin and linezolid or flucloxacillin resulted in a significant reduction in 
log CFU/BF compared to treatment with the respective antibiotics alone. Linezolid is a 
putative substrate for the LmrS efflux pump [232] so thioridazine might interfere with this 
multidrug efflux pump. Potentiating activity towards beta-lactams is described in planktonic 
cells and is due to alterations in the cell wall biosynthesis and a decrease in expression of 
mecA and blaZ [227]. Combined treatment with thioridazine and gentamicin, vancomycin, 
ciprofloxacin, tetracycline, rifampicin or fusidic acid did not result in a significant decrease in 
CFU/BF compared to treatment with the respective antibiotic alone (Figure 2). Although 
ciprofloxacin, tetracycline, and fusidic acid are substrates for NorA, NorB, TET38, and MdeA 
efflux pumps [27], no additional effect is observed when these antibiotics are combined with 
thioridazine. Finally, the failure of thioridazine to potentiate the activity of fusidic acid might 
be due to ion-ion interactions as we observed precipitation when both drugs are in contact. 
 Figure 2. Treatment of mature S. aureus biofilms for 24 h with 100 µl PS (untreated control, CTRL), 
vancomycin (VAN, 40 µg/ml), ciprofloxacin (CIP, 250 µg/ml), linezolid (LNZ 20 µg/ml), fusidic acid (FA, 
1000 µg/ml), tetracycline (TET, 128 µg/ml), tobramycin (TOB, 1024 µg/ml), flucloxacillin (FLU, 1024 µg/ml), 
gentamicin (GEN, 1024 µg/ml), and rifampicin (RIF, 512 µg/ml) alone or in combination with thioridazine (TZ, 
100 µM). Antimicrobial activity was determined using plate counts. *Significantly different number of CFU/BF 
compared to CTRL (p<0.05), **Significantly different number of CFU/BF compared to treatment  with the 
respective antibiotics alone (p<0.05). P-value TZ vs TOB and TZ was 0.055. Data shown are the average (n≥3), 
error bars indicate standard deviation. 
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Activity against S. aureus biofilms grown in an in vitro chronic wound biofilm model  
As thioridazine causes a significant additional reduction in the number of CFU/BF in 
combination with tobramycin, linezolid, or flucloxacillin, compared to treatment with the 
antibiotic alone in a 96-well MTP biofilm model system, the activity of these combinations 
was evaluated in an in vitro chronic wound biofilm model [222].  
 
Biofilms of S. aureus formed in this model were treated with PS containing thioridazine 
and/or tobramycin, linezolid or flucloxacillin. Additionally, biofilms were treated with an 
ointment containing tobramycin and thioridazine. However, none of these treatments resulted 
in a decrease in the number of CFU (Figure 3), even though higher concentrations were 
applied. For example, we tested an ointment containing tobramycin concentrations 5 times 
higher compared to the ones present in the ophthalmic ointment TobrexR. 
 
Figure 3. Evaluation of the activity of formulated solutions and ointments in the chronic wound biofilm model. 
Dermis were treated 24 h p.i. with 100 µl physiological saline (untreated control, CTRL), tobramycin (TOB, 
2048 µg/ml), linezolid (LZD, 400 µg/ml), flucloxacillin (FLU, 20.5 mg/ml), alone or in combination with 
thioridazin (TZ, 100 µM), and with 250 mg ointment without compounds (CTRL) or including tobramycin (15 
mg/g) alone or in combination with thioridazine (0.25 mg/g corresponding to 15 times the amount used in the 
solutions). Data shown are the average (n≥3), error bars indicate standard deviation. 
 
The loss of antibiotic activity of the tested antibiotics is in accordance with the observation of 
Hill et al., who formed biofilms of S. aureus in a chronic wound biofilm constant depth film 
fermenter. These biofilms did not respond to treatment with high concentrations of 
flucloxacillin [233]. Also thioridazine was unable to cause a reduction in CFU/dermis, nor did 
it potentiate the activity of tobramycin, linezolid, or flucloxacllin. The high protein binding 
(99%) of thioridazine [234] might explain its deactivation in the chronic wound biofilm model 
since the medium used to moisten the artificial dermis contains 50% (v/v) plasma and 5% 
(v/v) horse blood. This hypothesis was evaluated in an experiment in which planktonic S. 
aureus Mu50 cells were treated with thioridazine (100 µM) in a plasma gradient. At 3% (v/v) 
plasma or less, thioridazine inhibits growth, whereas at 12% (v/v) plasma, S. aureus grows 
equally as the control without treatment. This means that thioridazine is deactivated at these 
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higher plasma concentrations (Figure S2). Loss of antibacterial activity of thioridazine due to 
protein binding was earlier postulated in in vivo tests [228, 230]. 
 
Other repurposing candidates in the NIHCC 1&2 library 
Beside the antifungal imidazoles, sertraline and the phenothiazines described above, other 
anti-infectives, antineoplastic and hormonal drugs were identified. These drugs displayed an 
antimicrobial activity when used alone, except for tamoxifen which has no activity alone but 
does potentiate the activity of vancomycin (Table 1). However, these compounds are toxic 
and this limits their potential as repurposing candidate. Nevertheless, promising results were 
generated for chemotherapeutic drugs in other repurposing studies [189]. As the need is high 
for active compounds against biofilms, these drugs might find an application in catheter lock 
therapy and impregnation or coating of biomaterials [218].  
 
Honokiol, MK-886 and 5-nonyloxytryptamine potentiated the activity of vancomycin and had 
antimicrobial activity on their own against biofilms of S. aureus Mu50. Honokiol has 
previous been described as being antimicrobial [235] and MK-886 and 5-nonyloxytryptamine 
were identified in another screen against planktonic MRSA [189]. Amiodarone and 
oxymetholone are potentiators of vancomycin and have no anti-biofilm effect on their own, in 
contrast to carvedilol and ethacrynic acid that cause a significant reduction in fluorescence 
signal compared to growth control when used alone. To our knowledge, these four drugs have 
not yet been identified as having antimicrobial activity or as antibacterial potentiators.  
 
Several compounds were not withheld as hit in the present study although they were 
previously discovered as hits with antibacterial activity in other screening projects. 
Benzbromaron in combination with vancomycin reduced the fluorescence signal with 87% 
compared to treatment with vancomycin alone (Table S1). This drug was identified in a 
screening as interfering with the S. aureus quorum sensing system [236] and also shows anti 
Candida albicans biofilm activity [218]. In the presence of vancomycin, loperamide reduces 
the fluorescence signal with 88% compared to treatment with vancomycin alone (Table S1). 
Loperamide permeabilizes the outer cell membrane of Gram-negative bacteria and was 
identified in a screen in the presence of minocycline to be active against Escherichia coli and 
Pseudomonas aeruginosa, but not against S. aureus [198]. Although both benzbromaron and 
loperamide displayed activity in our screen, they were not withheld as hits due to the strict 
cut-offs applied in this study (residual activity of 10% or less compared to vancomycin alone). 
 
In contrast, azelastine was not found to potentiate the activity of vancomycin in the present 
study, although it was previously identified as a potentiator of beta-lactams, macrolides, 
fluoroquinolones, aminoglycosides and tetracyclines against several Gram-positive bacteria 
(including S. aureus) [197]. Similarly, several NSAIDs [237], statins [238], and anesthetics 
[239], have been described to display antimicrobial activity but were not identified in the 
present screening, with the exception of loxoprofen. Several explanations can be given for this 
discrepancy. First of all, different strains are used in the different studies. Secondly, different 
concentrations are used among the studies. Thirdly, different media are used which can 
account for differences in the activity of these compounds (e.g. some statins need to be 
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activated by lactonases before they display antibacterial activity). Finally, most screening 
studies are targeting planktonic cells, while in the present study we specifically looked for 
potentiating activity against biofilm cells.  
 
CONCLUSION 
 
The aim of the present study was to identify compounds that increase the activity of 
antibiotics against established biofilms in a 96-well MTP model and subsequently investigate 
these combinations in a more relevant model system. Using this approach, we were able to 
identify 25 hits out of 727 off-patent drugs. Among these hits were four phenothiazines, of 
which thioridazine showed highest activity against both planktonic and biofilm cells. This 
compound was further evaluated in combination with several antibiotics in a 96-well MTP 
model. Combination with tobramycin, linezolid and flucloxacillin showed the highest activity. 
Evaluation in a recently described model for chronic wounds made it possible to estimate the 
value of these combinations in a model that mimics specific aspects of wound biofilms. 
Despite activity in the 96-well MTP biofilm model, no activity was observed in the chronic 
wound biofilm model. The present study provides a platform for discovering and evaluating 
potentiators against bacterial biofilms and highlights the necessity of using relevant in vitro 
biofilm model systems. 
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SUPPLEMENTARY DATA 
 
Table S1. The NIH Clinical Collection 1&2 were screened at a concentration of 100 µM in the presence of 40 
µg/ml vancomycin for potentiators against biofilms of S. aureus Mu50. Hits were subsequently tested in absence 
of vancomycin. Effect was evaluated using CTB staining. The values shown in the left column represent the 
mean residual metabolic activity of the compound in the presence of vancomycin compared to treatment with 
vancomycin  alone, and the standard deviation (SD). The values in the right column represent the mean residual 
metabolic activity of the compound compared to untreated control, and the standard deviation.  
 
PUBCHEM 
CODE 
COMPOUND NAME 
 
 MEAN 
(%) 
SD 
 
 MEAN 
(%) 
SD 
 
CPD000449281 Nalbuphine 81 20 
  CPD000449275 Raclopride 92 13 
  CPD000449271 Zacopride 104 17 
  CPD000449276 SKF 83566 D1 R agonist 101 18 
  CPD000449316 3'-deoxydenosine 118 40 
  CPD000449274 AM 404 N-arachidonoylaminofenol 67 17 
  CPD000059053 Pilocarpine 122 37 
  CPD000058291 Nifedipine 144 58 
  CPD000042823 Flurbiprofen 74 12 
  CPD000059136 Deferiprone 115 26 
  CPD000058470 Loxapine 117 29 
  CPD000326694 D-3-MEO-N-methylmorphinan 131 7 
  CPD000449282 Duloxetine 79 13 
  CPD000449320 Glycine 88 10 
  CPD000449318 Benzene acetic acid 116 24 
  CPD000058345 S-progesterone 117 7 
  CPD000058961 Famotine 122 25 
  CPD000449299 5-HTR-3 agonist 123 11 
  CPD000466270 Pancuronium 162 21 
  CPD000058175 Metronidazole 178 27 
  CPD000449327 Benzeneacetic acid 114 6 
  CPD000449323 Benzeneacetonitrile 110 18 
  CPD000449328 Selegiline HCl 178 23 
  CPD000449294 Zucapsaicin 111 33 
  CPD000058513 Salbutamol 134 17 
  CPD000057879 Vesamicol 129 48 
  CPD000469289 Picrotin 144 26 
  CPD000449268 Terazosin 161 44 
  CPD000449319 Diphenylcyclopropenone 85 7 
  CPD000449326 Thiazolidinecarboxylic acid 75 23 
  CPD000466274 Mesoridazine 123 13 
  CPD000449313 Pyridazinone difluoromethoxy 107 16 
  CPD000466275 Phenothiazine 72 17 
  CPD000449322 Cyclopentaquinolin 113 25 
  CPD000058306 Clotrimazole 57 13 
  CPD000058255 Loratadine 123 18 
  CPD000058500 Phenelzine 76 7 
  CPD000449311 Riluzole 134 23 
  CPD000449312 Naltrindole 206 21 
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CPD000449277 Nornicotine 134 12 
  CPD000449269 Bifemelane 104 17 
  CPD000449284 CGS antagonist  122 19 
  CPD000449287 Cinanserin 70 13 
  CPD000449272 Cisapride 68 32 
  CPD000449273 Indatrline 16 14 
  CPD000058520 Trazodone 45 10 
  CPD000449301 Prazosin 64 7 
  CPD000058525 Urapidil 83 27 
  CPD000449278 Cotinine 73 12 
  CPD000058313 Cycloserine 83 7 
  CPD000466268 Fluvoxamine 70 8 
  CPD000449270 Doxepin 82 9 
  CPD000059133 Trifluoperazine HCl 0 0 72 23 
CPD000058908 Hydroxy methylmorphinan 93 14 
  CPD000449329 Ornithine 86 7 
  CPD000148117 Maprotiline 72 33 
  CPD000466272 Pizotyline 80 17 
  CPD000059126 Beta-estradiol 135 13 
  CPD000059046 Diacetyl diaminohexane 158 40 
  CPD000058353 Diphengydramine 91 27 
  CPD000449267 Galanthamine 115 15 
  CPD000449296 Ifenprodil 157 26 
  CPD000059171 Tetraethylthiuram 188 43 
  CPD000449302 Piribedil 166 28 
  CPD000058460 Ketoconazole 143 21 
  CPD000058623 Tripelennamine 114 22 
  CPD000449325 Pryazinecarboxamide 139 22 
  CPD000059105 Amino tetrahydroacridine 290 152 
  CPD000058319 Ethynylestradiol 161 54 
  CPD000449317 Pyrimidinone arabinofu 218 46 
  CPD000449324 L-glutaminic acid 147 31 
  CPD000449305 Trifluoromethylphenylpiperazine  111 66 
  CPD000449298 Pramipexole 230 55 
  CPD000058189 Lidocaine 235 55 
  CPD000449290 Indometacine 179 49 
  CPD000058555 Tomelukast 78 50 
  CPD000466269 Paroxetine 107 10 
  CPD000449288 Epigallocatechin 83 26 
  CPD000145728 Amino hydroxy benzoic 208 59 
  CPD000449321 Oxiranecarboxylic acid 194 77 
  CPD000338536 Cephalexine 85 1 
  CPD000466390 Pidotimod 79 9 
  CPD000466386 Ramipril 95 75 
  CPD000469284 Fenpiverinium 31 5 
  CPD000058610 Nortestosterone 54 2 
  CPD000466384 Niztididne 69 41 
  CPD000059047 Flucytosine 51 10 
  CPD000048684 Oxcarbazepine 73 7 
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CPD000466385 Troxipide 57 33 
  CPD000466341 Actarit 39 8 
  CPD000469183 Azelastine 54 9 
  CPD000466388 Tocainide 96 31 
  CPD000499525 Taxifolin 77 3 
  CPD000466387 Levofloxacin 86 29 
  CPD000469182 Cefatrizine 126 14 
  CPD000466364 Idebenone 92 17 
  CPD000466366 Levosulpiride 132 48 
  CPD000238142 Pemoline 142 51 
  CPD000466343 letrozole 131 68 
  CPD000469184 Meropenem 140 17 
  CPD000466339 Orlistat 139 41 
  CPD000469179 Ondansetran 111 15 
  CPD000059117 Levonorgestrel 244 92 
  CPD000469197 Cetraxate 189 18 
  CPD000149316 Alprazolam 161 73 
  CPD000058464 Lamotignine 189 34 
  CPD000059145 Crotamiton 185 19 
  CPD000472526 Amfebutamone 166 31 
  CPD000466340 Alfuzonsine 48 12 
  CPD000449309 Amisulpride 95 6 
  CPD000469292 Lofepramine 39 12 
  CPD000466362 Perospirone 69 20 
  CPD000059010 Docetaxel 76 1 
  CPD000387107 Honokiol 0 0 0 0 
CPD000469196 Tolterodine 70 9 
  CPD000466363 Carmofur 58 9 
  CPD000469181 Paroxetine 80 17 
  CPD000466337 Olmesartan 89 5 
  CPD000469593 Losartan 78 13 
  CPD000466338 Temozolomide 136 38 
  CPD000058528 Methyltestosterone 90 7 
  CPD000469195 Tosufloxacin 67 14 
  CPD000466361 Mecillinam 110 13 
  CPD000469177 Atomoxetine 92 36 
  CPD000466336 Artesunate 71 13 
  CPD000058959 Itraconazole 91 27 
  CPD000469193 Cefpodoxime 78 14 
  CPD000058803 Buflomedil 105 45 
  CPD000012114 Moclobemide 207 65 
  CPD000466330 Halometasone 167 40 
  CPD000466357 Triclabendazole 26 12 
  CPD000466331 Rofecoxib 138 23 
  CPD000471619 Bisoprolol 165 39 
  CPD000466334 Ezetimibe 183 53 
  CPD000469176 Tiagabine 268 42 
  CPD000466355 Idarubicin 0 0 15 27 
CPD000466360 Flubendazole 62 2 
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CPD000466356 Tacrolimus 72 11 
  CPD000469208 Valaciclovir 72 26 
  CPD000466382 Clarithromycin 43 7 
  CPD000466383 Aripiprazole 50 9 
  CPD000471622 Trimebutine 102 14 
  CPD000238198 Mestalone 81 17 
  CPD000466370 Nisoldipine 20 1 
  CPD000466371 Piceid 103 22 
  CPD000149359 Secnidazole 119 17 
  CPD000466369 Nifekalant 87 25 
  CPD000466372 Nateglinide 76 21 
  CPD000058691 Megestrol acetaat 93 11 
  CPD000466374 Ormetoprim 188 34 
  CPD000466377 Zileuton 89 28 
  CPD000058350 Stavudine 102 18 
  CPD000058918 Gabexate 98 44 
  CPD000469293 Oxiconazole 0 0 10 10 
CPD000469235 Kitasamycin 104 22 
  CPD000466375 Famciclovir 131 16 
  CPD000326828 Sotalol 109 35 
  CPD000466373 Rufloxacin 75 13 
  CPD000466389 Taxiflolin 160 87 
  CPD000469211 Alosetron 66 23 
  CPD000058423 Bupropion 98 6 
  CPD000471621 Irsogladine 125 10 
  CPD000466376 Acarbose 64 12 
  CPD000469294 Benproperine 30 3 
  CPD000466378 Fenprobamaat 82 1 
  CPD000058926 Adamantan 73 11 
  CPD000449280 Carvedilol 8 6 41 6 
CPD000466379 Lomifylline 75 13 
  CPD000466380 Pazufloxacin 50 12 
  CPD000466381 Miglitol 60 7 
  CPD000058373 Tranilast 60 4 
  CPD000466345 Olanzapine 79 26 
  CPD000449297 Nefazodone 27 6 
  CPD000469185 Moxifloxacin 59 9 
  CPD000469186 Nelfinavir 72 10 
  CPD000469187 Pravastatin 129 25 
  CPD000466344 Topotecan 97 24 
  CPD000466303 Levetiracetam 80 14 
  CPD000469142 Pramipexole 102 26 
  CPD000466323 Risperidone 114 17 
  CPD000469167 Pioglitazone 110 12 
  CPD000469147 Cilastatin 124 23 
  CPD000466348 Argatroban 155 53 
  CPD000466327 Valdecoxib 101 10 
  CPD000466346 Naftopidil 66 29 
  CPD000156231 Nobiletin 151 91 
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CPD000466304 Finasteride 82 9 
  CPD000469145 Zolpidem 104 9 
  CPD000048458 Viramune 98 15 
  CPD000466325 Topiramate 81 14 
  CPD000466350 Voriconazole 99 19 
  CPD000469190 Fenoldopam 65 1 
  CPD000471612 Rosiglitazone 71 6 
  CPD000469191 Escitalopram 96 15 
  CPD000058866 Zeranol 100 19 
  CPD000466354 Latanoprost 53 11 
  CPD000058576 Didanosine 114 23 
  CPD000466298 Sertraline 0 0 51 21 
CPD000466353 Calcipotriol 63 13 
  CPD000466308 Epirubicin 32 7 
  CPD000466329 Bicalutamide 99 10 
  CPD000469192 benidipine 123 24 
  CPD000466352 Amlexanox 59 12 
  CPD000469148 Cerivastatin 74 8 
  CPD000466309 Icariin 89 12 
  CPD000466310 Methylandrosternediol 64 6 
  CPD000466307 Triptolide 77 15 
  CPD000469170 Rosiglitazone 83 23 
  CPD000059106 Tegafur 93 12 
  CPD000466392 Oligomycin 62 3 
  CPD000469199 Benazepril 135 7 
  CPD000058877 Oxymetholone 0 0 88 47 
CPD000059060 Ipriflavone 101 10 
  CPD000058286 Oxaprozin 127 8 
  CPD000058510 Rolipram 119 14 
  CPD000469200 Mosapride 138 3 
  CPD000466391 Isoquercitrin 84 13 
  CPD000058450 Flumazenil 96 18 
  CPD000469164 Ozagrel 115 10 
  CPD000466394 Hyperoside 87 8 
  CPD000466322 Rifabutin 77 14 
  CPD000469141 Esmolol 116 19 
  CPD000466321 Tadalafil 89 10 
  CPD000058957 Modafinil 108 7 
  CPD000058570 Doxorubicin 12 1 
  CPD000469209 Moxonidine 94 8 
  CPD000058302 Nitrazepam 38 8 
  CPD000387024 Pefloxacin 147 18 
  CPD000469154 Venlafaxine 134 20 
  CPD000469592 Pantoprazole 125 27 
  CPD000469159 Fluticasone 89 5 
  CPD000469161 Indinavir 118 36 
  CPD000469160 Midazolam 121 6 
  CPD000466319 Lamivudine 91 17 
  CPD000469151 366-70-1 80 12 
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CPD000469280 Esomeprazole 133 6 
  CPD000059146 Sulfasalazine 158 22 
  CPD000466313 Torasemide 128 17 
  CPD000469156 Tropistrona HCl 139 11 
  CPD000326795 Ranolazine 148 13 
  CPD000058366 Nitrendipine 58 7 
  CPD000469290 Saquinavir 46 1 
  CPD000058970 Bifonazole 13 2 
  CPD000469158 Sumatriptan 165 27 
  CPD000466314 Exemestane 147 13 
  CPD000466367 Nitazoxanide 126 35 
  CPD000058398 Diazepam 69 16 
  CPD000471623 Quetiapine 119 16 
  CPD000112560 Rutin 125 16 
  CPD000466317 Penciclovir 83 17 
  CPD000466393 Calcitriol 208 44 
  CPD000469140 Diphenoxylate 140 12 
  CPD000449307 Felbamate 163 45 
  CPD000058855 Droperidol 51 10 
  CPD000035998 Pentoxifylline 71 6 
  CPD000058461 Ketorolac 69 18 
  CPD000466395 Ritonavir 65 4 
  CPD000469210 Vinorelbine tartrate 60 6 
  CPD000466335 Linezolid 43 3 
  CPD000469203 Lomerizine 45 4 
  CPD000466351 Efavirenz 0 1 5 8 
CPD000466306 Irbesartan 72 6 
  CPD000466305 Repaglinide 86 5 
  CPD000238204 Ethylestrenol 58 19 
  CPD000440694 Pterostilbene 29 12 
  CPD000469144 Roxatidine 110 22 
  CPD000471616 Dexbrompheniramine 79 9 
  CPD000469168 Anagrelide 85 5 
  CPD000471618 Tegaserod 101 21 
  CPD000058475 Milrinone 97 26 
  CPD000466315 Levocetirizine 136 16 
  CPD000326936 Citalopram 85 26 
  CPD000048468 Ticlopidine 92 13 
  CPD000469165 Sodium loxoprofen 3 1 42 29 
CPD000466316 Zafirlukast 98 9 
  CPD000469152 Terbinafine 111 12 
  CPD000466320 Isradipine 119 5 
  CPD000466318 Valsartan 94 46 
  CPD000449291 Piroxicam 43 6 
  CPD000469282 Glycopyrrolate 161 11 
  CPD000449286 Physostigmine 126 13 
  CPD000058465 Lobeline 113 6 
  CPD000058436 Doxylamine 90 24 
  CPD000449266 Milnacipran 73 21 
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CPD000449315 Fluoro pyrimidone 118 17 
  CPD000466271 Chlorpheniramine 65 22 
  CPD000466333 Dofetilide 46 17 
  CPD000471620 Formoterol 93 19 
  CPD000525252 Rizatriptan 94 7 
  CPD000466332 Rifapentine 127 31 
  CPD000469178 Loteprednol 91 9 
  CPD000466359 Enalaprilat 81 16 
  CPD000449292 Donepezil 113 15 
  CPD000238177 Nimetazepan 69 12 
  CPD000466365 Nicorandil 172 25 
  CPD000466326 Telmisartan 206 43 
  CPD000469143 Itopride 89 13 
  CPD000466324 Rifaximin 87 6 
  CPD000469188 Montelukast 71 27 
  CPD000058253 Didezoxycytidine 87 2 
  CPD000466276 Imidazol amine 78 6 
  CPD000466280 Pyridobenzodiazepin 99 8 
  CPD000466278 MK886 5 2 39 25 
CPD000466277 Etomidate 105 7 
  CPD000466281 Acetamide 73 10 
  CPD000466283 Altanserin 60 7 
  CPD000058420 Betaxolol 94 16 
  CPD000466311 Indirubine 114 15 
  CPD000466285 Azasetron 109 4 
  CPD000466287 GR 89696 134 15 
  CPD000058773 Delta-hydrocortisone 93 2 
  CPD000058392 Diazoxide 85 9 
  CPD000058612 Chloroadenosine 67 24 
  CPD000058726 Ornidazole 112 16 
  CPD000058572 Dimethyl phenylpiperzanine 97 12 
  CPD000058507 Pirenperone 84 7 
  CPD000059128 Mestramol 89 8 
  CPD000059100 Aminoethyl pyridine 159 52 
  CPD000059142 Benactyzine 65 21 
  CPD000059158 Dichloroacetic acid 121 9 
  CPD000059165 Bestatin 74 10 
  CPD000469213 Toremifene 0 0 9 7 
CPD000469214 Goserelin 73 4 
  CPD000469212 Secoisolarciciresinol 63 2 
  CPD000469217 Raltitrexed 75 16 
  CPD000469229 Doxapram 93 4 
  CPD000466294 Serotonin agonist 75 2 
  CPD000112281 Brucine 75 6 
  CPD000059115 Tryptoline 66 5 
  CPD000058411 Fluphenazine 6 3 33 9 
CPD000469233 Palonosetron 82 22 
  CPD000058746 Naproxen 82 10 
  CPD000058904 Mepivacaine 93 9 
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CPD000058310 Benzbromaron 13 3 
  CPD000058300 Nimodipine 74 10 
  CPD000058701 Rolitetracycline 121 11 
  CPD000058715 Epirizole 104 17 
  CPD000058273 Azauridine 76 12 
  CPD000466922 Reichsteins  100 21 
  CPD000059086 Pyridinemethanol 124 16 
  CPD000449283 Haloperidol 60 15 
  CPD000449279 Stiripentol 73 6 
  CPD000449303 Fluperlapine 91 23 
  CPD000058660 Oxyphenomium 110 30 
  CPD000112358 Homoveratrylamine 145 43 
  CPD000058194 Tinidalzole 188 14 
  CPD000058741 Xanthinol 129 14 
  CPD000059111 Synephrine 159 33 
  CPD000058206 Resveratrol 80 17 
  CPD000059093 Malrol 100 27 
  CPD000059077 Aminoimidazole 114 9 
  CPD000059011 Enrofloxacin 80 20 
  CPD000058603 Dehydrocholic acid 89 49 
  CPD000058250 Cefaclor 114 14 
  CPD000059044 Benzylimidazole 84 23 
  CPD000469136 Duloxetine 32 7 
  CPD000469155 Vardenafil 146 15 
  CPD000469137 Ropivacaine 130 36 
  CPD000466301 Anastrozole 155 44 
  CPD000058462 Ketotifen 196 38 
  CPD000058769 Medroxy-progesterone 139 36 
  CPD000466919 Pinacidil 187 38 
  CPD000058266 Nitro-indazole 84 6 
  CPD000112269 Methoxytryptamine 89 24 
  CPD000059045 Phenothiazine 114 18 
  CPD000058553 Cladribine 79 14 
  CPD000469138 Granisetron HCl 90 9 
  CPD000466293 Rimcazole 108 27 
  CPD000466292 Nafadoride 84 13 
  CPD000058856 Desoximetasone 101 10 
  CPD000471617 Dexchlorpheniramine 154 18 
  CPD000466288 Guanidine 91 16 
  CPD000466290 SMR000466290 113 24 
  CPD000466284 AM251 147 38 
  CPD000466289 HTMT 106 6 
  CPD000466286 Benzo phenanthridine 68 28 
  CPD000466291 Methanesulfonamide 72 21 
  CPD000466279 H2-indol-2-on  71 12 
  CPD000466920 Beclosmethasone 120 31 
  CPD000058847 Omeprazole 69 9 
  CPD000469228 Dolastron 87 18 
  CPD000449310 Zolmitriptan 98 16 
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CPD000469223 Tremaulacin 52 12 
  CPD000469227 Dactinomycin 33 8 
  CPD000449308 Tramadol 77 2 
  CPD000469226 Chlordiazeposide 106 24 
  CPD000469225 Cefixime 129 35 
  CPD000469224 Cefdinir 137 26 
  CPD000469232 Lofexidine 147 41 
  CPD000469221 Balsalazide 126 29 
  CPD000469220 Olopatadine 55 8 
  CPD000469287 Itavastatin 87 2 
  CPD000058334 Cortisone 101 26 
  CPD000058431 Cyproheptadine 72 14 
  CPD000469230 Homoharringonine 65 7 
  CPD000058318 Corticosterone 149 29 
  CPD000471625 Vecuronium 94 16 
  CPD000469219 Itibolone 119 31 
  CPD000058212 Niacinamide 120 11 
  CPD000059131 Nialamide 86 24 
  CPD000469153 Vindesine 84 22 
  CPD000058540 Vincristine 87 6 
  CPD000466342 Lacidipine 71 37 
  CPD000466347 Mirtazapine 33 14 
  CPD000469285 Ampiroxicam 54 8 
  CPD000466368 Glimepiride 67 25 
  CPD000469198 Amlodipine 81 39 
  CPD000469174 Rabeprazole 58 12 
  CPD000058704 Clofazimine 26 10 
  CPD000469166 Irinotecan 50 17 
  CPD000058469 Lansoprazole 69 17 
  CPD000149358 Desloratadine 70 19 
  CPD000058772 Premarine 53 14 
  CPD000058481 Mifepristaone 83 17 
  CPD000112002 Etoposide 181 30 
  CPD000238156 Sibutramine 115 28 
  CPD000469632 Clobenpropit 76 21 
  CPD000469231 Huperzine 102 28 
  CPD000472527 Sibutramine HCl 108 13 
  CPD000058410 Lorazepam 153 27 
  CPD000469633 Azaspiro-decane-dione 128 29 
  CPD000469631 Adenosine 167 16 
  CPD000058296 Amiodarone 6 9 68 6 
CPD000336944 Mevastatine 103 5 
  CPD000469175 Imatinib 150 26 
  CPD000468736 Melperone HCl 176 34 
  CPD000469594 Parecoxib 181 40 
  CPD000058504 Pergolide 185 14 
  CPD000471626 Atracurium 65 27 
  CPD000469218 Artemether 138 15 
  CPD000058445 Ebselen 180 117 
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CPD000468733 12066B 42 13 
  CPD000469222 Teletromycine 140 17 
  CPD000468732 CCPA 180 52 
  CPD000468734 Methanone 57 11 
  CPD000058878 Stanzolol 138 20 
  CPD000238180 Zaleplon 152 12 
  CPD000112594 Prostaglandin 98 25 
  CPD000058344 Testosteron 206 21 
  CPD000059075 Dehydroepiandrosterone 145 50 
  CPD000466297 Sdm25n 195 62 
  CPD000466299 Tiophene brome fluor 180 7 
  CPD000466300 Nonyloxytryptamine 0 0 37 15 
CPD000466295 Salmeterol 56 20 
  CPD000466296 SB 205607 145 59 
  CPD000326935 R-SCH 23390 89 14 
  CPD000058230 Doxepin 94 12 
  CPD000058382 Dipyridamole 81 8 
  CPD000059151 Propofol 105 16 
  CPD000058600 Ethacrynic acid 5 5 1 1 
CPD000058187 Flutamide 2 1 24 14 
CPD000058299 Fenofibrate 119 21 
  CPD000058202 Furosemide 100 9 
  CPD000038082 Fluorouracil 75 16 
  CPD000471860 Folic acid 86 23 
  CPD000653523 Hydrocortisone 74 6 
  CPD000653536 Cortell 90 25 
  CPD000058184 Ibuprofen 117 13 
  CPD000040181 Ketoprofen 113 23 
  CPD001906766 Minocycline 47 12 
  CPD000058733 Miconazole 9 10 33 22 
CPD000059134 Metyrapone 99 17 
  CPD001317860 Pyrogluatmic acid 100 22 
  CPD000058975 Nadolol 84 32 
  CPD000058999 Disipal 86 32 
  CPD000058192 Ofloxacin 98 16 
  CPD000059120 Pindolol 84 10 
  CPD000037139 Praziquantel 71 36 
  CPD000059104 Phenylbutyric acid 117 22 
  CPD000058326 Prednisolone 97 3 
  CPD000058379 Phenergan 67 21 
  CPD000058180 Perphenazine 9 3 29 8 
CPD000718761 Prednisolone 101 10 
  CPD000058506 Prilocaine 108 12 
  CPD001227202 Prednisone 61 24 
  CPD000059161 DL-penicillamine 80 23 
  CPD000058579 Piperacilline 107 12 
  CPD000857275 Quinidine 64 2 
  CPD000653467 Ranitidine 79 19 
  CPD001906767 Rifampicine 104 14 
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CPD000058245 Retinoic acid 111 14 
  CPD000471892 Spironolactone 90 32 
  CPD000035999 Trimethoprim 90 8 
  CPD000058219 Tyzine 83 21 
  CPD000059176 Thyroxine 95 2 
  CPD000058515 Trihexyphenidyl 137 38 
  CPD000058403 Ursodeoxycholic 107 25 
  CPD000059064 Dapsone 95 23 
  CPD001370746 Symmertrel 109 15 
  CPD000058849 Warfarin 113 8 
  CPD000058394 Acetazolamide 109 28 
  CPD000059083 Allopurinol 95 16 
  CPD001906768 Atropine 79 5 
  CPD000058264 Nalidixic acid 95 15 
  CPD001567029 Triiodothyronine 63 2 
  CPD000058284 Hydroflumethiazide 103 24 
  CPD000058368 Annoyltin 56 25 
  CPD000058613 Busulfan 80 23 
  CPD000058269 Chlorzoxazone 82 17 
  CPD000058429 Chlorothiazide 94 15 
  CPD001370748 Cimetidine 83 14 
  CPD000058433 Carisoprodol 80 35 
  CPD000058364 Chlorpropamide 130 18 
  CPD000058440 Bentyl 87 11 
  CPD000312779 Chloroxine 42 5 
  CPD000058723 Diflunisal 149 48 
  CPD001370749 Econazole 5 5 24 24 
CPD001370750 Ethionamide 173 62 
  CPD000058719 Methocarbamol 199 19 
  CPD000035778 Hydrochlorothiazide 181 40 
  CPD001370751 Vistaril 70 10 
  CPD000058356 Hexachlorophene 0 0 8 10 
CPD000059082 Isoniazid 280 75 
  CPD000058729 Duvadilan 249 9 
  CPD000058267 Isoproterenol 242 50 
  CPD000471847 Triclosan 0 0 2 3 
CPD000058188 Mefenamic acid 86 10 
  CPD000058832 Cantil 80 13 
  CPD000058471 Metoclopramide 132 9 
  CPD001370753 Methyldopa 96 44 
  CPD000058271 Nitrofurantoin 16 9 
  CPD000058486 nortriptyline 57 14 
  CPD000058292 Naphazoline 54 5 
  CPD000059024 Nicotinic 95 48 
  CPD000058817 Norflex 92 28 
  CPD001614498 Oxytetracycline 83 34 
  CPD000718771 Procaine 87 14 
  CPD000058714 Pyrimethamine 111 8 
  CPD000058661 Pro-banthine 95 7 
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CPD000058280 Probenecid 66 3 
  CPD001906769 Pyridine 2 aldoxime 98 14 
  CPD000058501 Primidone 82 6 
  CPD000058275 Propylthiouracil 79 6 
  CPD000036662 Pyrazinamide 95 20 
  CPD000059079 Probesyl 80 12 
  CPD000037657 Sulfisoaxole 75 15 
  CPD000058223 Sulfamethoxazole 115 24 
  CPD000058173 Sulfacetamide 90 20 
  CPD000058991 Sulfinpyrzone 153 21 
  CPD000326718 Sulindac 168 16 
  CPD001906770 Tetracycline 114 27 
  CPD000058537 Theophylline 127 30 
  CPD000058363 Tolbutamide 106 7 
  CPD000059118 Triamteren 70 14 
  CPD000059081 Intropin 89 2 
  CPD000058416 Amoxapine 91 6 
  CPD000471872 Adenine 95 13 
  CPD000036768 Atenolol 104 19 
  CPD001491671 Tamoxifen 0 0 67 10 
CPD000058418 Bumetanide 93 9 
  CPD000058745 Clobetasol 136 10 
  CPD000058254 Chlorpromazine 17 6 
  CPD001491644 Cefazoline sodium 131 23 
  CPD000059061 Captopril 126 2 
  CPD000058372 Chlorambucil 98 15 
  CPD000058809 Cefoxitin 116 27 
  CPD000058321 Danazol 93 10 
  CPD000058375 Diltiazem 133 11 
  CPD001906774 Digoxin 154 16 
  CPD000058346 17- beta estradiol 95 29 
  CPD000058672 Edroponium 103 16 
  CPD000058329 Fluocinolone acetonide 117 23 
  CPD000042823 Flurbiprofen 141 35 
  CPD000058455 Glipizide 119 11 
  CPD000058393 Gemfibrozil 84 29 
  CPD000058229 Glyburide 171 28 
  CPD000058328 Hydrocortisone 163 41 
  CPD000058829 Indapamide 140 19 
  CPD001906775 Ipratropium bromide 109 19 
  CPD000058388 Imipramine 111 13 
  CPD000058463 Labetalol 116 21 
  CPD000058466 Loperamide 12 7 
  CPD000058833 Pro amatine 113 36 
  CPD000653524 Medroxyprogesterone acetate 120 13 
  CPD001906776 19-norethindrone acetate 77 3 
  CPD000499579 19-norethindrone 96 23 
  CPD000059074 Nicotine 102 13 
  CPD001456372 Cardene 90 9 
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CPD000058835 Nabmetone 165 14 
  CPD000058490 Oxybutynin 119 36 
  CPD000058605 Mestinon 132 61 
  CPD001453705 Rythmol 133 31 
  CPD001491654 Pfizerpen 87 15 
  CPD000499581 Valproic acid 76 7 
  CPD000058821 Procyclidine 75 18 
  CPD000875264 Proxymetacaine 60 12 
  CPD000058766 Naloxone 50 8 
  CPD001906777 Spectinomycin 83 21 
  CPD000058523 Tropicamide 62 14 
  CPD000058290 Tolazamide 49 9 
  CPD000058335 Triamcinolone acetonide 74 3 
  CPD001456519 S-timolol 63 7 
  CPD000058170 Thiabendazole 63 15 
  CPD000058380 Thioridazine 0 0 35 16 
CPD000058181 Altretamine 74 7 
  CPD001491672 Phylloquinone 75 10 
  CPD001491659 Eryped 84 4 
  CPD000058422 Dibenzyline 24 8 
  CPD000058693 Medrysone 132 27 
  CPD000058524 Thalidomide 69 11 
  CPD000857229 Aminolevulinec 37 1 
  CPD001496929 Arbinoxamine 108 12 
  CPD001496930 Demeclocycline 55 12 
  CPD001496932 Westcort 81 18 
  CPD000449328 Selegiline 100 16 
  CPD000058840 6-2-ethoxy-1-naphthamido 86 23 
  CPD000875314 Primaquine 42 11 
  CPD001496934 Micropenin 117 10 
  CPD001550033 Doxycycline 43 9 
  CPD001233361 Beclomethasone 79 9 
  CPD000058721 Cromolyn 82 16 
  CPD000149600 Priscoline 88 5 
  CPD000544948 Mercaptopurine 95 12 
  CPD000427366 Azathioprine 67 12 
  CPD000036735 Albendazole 97 10 
  CPD000718755 Griseofulvin 101 3 
  CPD000059006 Lincomycine 107 8 
  CPD001496938 Methazolamide 111 18 
  CPD001496939 Terbutaline 96 32 
  CPD000471888 Mypirocin 76 2 
  CPD000058331 Fluocinonide 113 4 
  CPD000875233 Mefloquine HCl 21 4 
  CPD001496941 Floxuridine 78 4 
  CPD001563707 Mitoxantrone 55 8 
  CPD001906784 Enalapril maleate 84 13 
  CPD000058337 Budesonide 81 15 
  CPD000466386 Ramipril 73 6 
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CPD000718757 Depo medrol 85 15 
  CPD000058383 Norepinephrine 61 7 
  CPD001491664 Amcinonide 43 7 
  CPD001317855 Clomid 0 0 13 1 
CPD001819784 Phentolamine mono HCl 66 13 
  CPD000058874 Fludarabine 73 14 
  CPD000109709 Testosterone 80 19 
  CPD000471891 Isotretinoin 68 4 
  CPD000058376 Methimazole 66 2 
  CPD000596519 Zonisamide 95 21 
  CPD000058355 Brimondidine 64 4 
  CPD000036734 Mebendazole 66 8 
  CPD000058736 Meclizine 107 14 
  CPD000058451 Flecainide 0 0 
  CPD000146393 Dilantin 60 13 
  CPD000059182 Miochol 56 5 
  CPD000326766 Dantrolene sodium 26 2 
  CPD001227192 Dexamethasone 75 20 
  CPD000394012 Cogentin 66 11 
  CPD000058324 Ganciclovir 63 13 
  CPD000059219 Mesna 82 17 
  CPD000058785 Meclomen 119 5 
  CPD000471882 Fluconazole 146 18 
  CPD001453712 Metaproterenol 177 46 
  CPD000071170 Methoxsalen 133 41 
  CPD000058224 Chloramphenicol 116 11 
  CPD000499584 Tizanididne 191 4 
  CPD001453706 Paroxetine 31 14 
  CPD000550486 Mirtazapine 213 9 
  CPD000010931 Etomidate 161 15 
  CPD000499578 Moban 147 18 
  CPD001453708 Fluvastatin 140 37 
  CPD000058680 Urecholine 140 17 
  CPD001496804 Cefuroxime 146 18 
  CPD000718805 Cytoxan 153 15 
  CPD000550478 Eszopiclone 66 7 
  CPD000058802 Bendrofluazide 116 9 
  CPD000058508 Raloxifen 52 37 
  CPD000058351 Zidovudine 61 11 
  CPD000058365 Clozapine 61 11 
  CPD001317850 Amicillin 69 31 
  CPD000058800 Acebutol 57 15 
  CPD000058707 Amoxicilline 43 7 
  CPD000857209 Epinephrine 61 27 
  CPD000857239 Azacytidine 62 23 
  CPD000058186 Buspar 42 8 
  CPD000436311 Rimantadine 54 9 
  CPD000059121 Podofilox 88 47 
  CPD000058313 D-cycloserine 64 8 
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CPD000059124 Cortisone 81 6 
  CPD000058295 Clomipramine 47 14 
  CPD001227191 Carbamazepine 58 36 
  CPD000875213 Memantine 30 5 
  CPD000036827 Desipramine 23 6 
  CPD000326711 Mexiletine 60 22 
  CPD000058438 Disopyramide 55 9 
  CPD000673569 Stavudine 88 47 
  CPD000097306 Doxazosin 36 19 
  CPD000058963 Minoxidil 46 22 
  CPD000059167 Propranolol 95 23 
  CPD001496943 Ribavirin 106 43 
  CPD000058309 Terazosin 158 25 
  CPD000058635 Chlorthalidone 141 46 
  CPD000058330 Methylprednisolone 136 60 
  CPD001496977 Phenelzine 213 137 
  CPD000058767 Naltrexone 162 15 
  CPD000469282 Glycopyrrolate 145 20 
  CPD000046147 Ethambutol 160 20 
  CPD001453715 Cetirizine 128 17 
  CPD000539527 Dicloxacillin 151 45 
  CPD000718800 Meloxicam 143 32 
  CPD001906781 Daunorubicin 0 0 18 16 
CPD001906779 Rifapentine 152 49 
  CPD000274084 Penicillin 98 5 
  CPD000043336 Gatifloxacin 83 7 
  CPD000550475 Clopidogrel 102 7 
  CPD001551784 Cefotaxime 79 5 
  CPD000466319 Lamivudine 90 7 
  CPD001307702 Ondansetron 97 10 
  CPD000339803 Betamethasone 89 11 
  CPD000550473 Celecoxib 102 4 
  CPD000058778 Aminomethylbenzenesulf 93 0 
  CPD001906782 Thiothixene 75 2 
  CPD000465669 Citalopram 89 14 
  CPD000471864 Azithromycin 116 7 
  CPD000673570 Lovastatin 73 9 
  CPD000326785 Aminoglutetimide 103 7 
  CPD000058452 Fluoxetine 11 5 
  CPD001233272 Flunisolide 106 20 
  CPD000058225 Acyclovir 93 10 
  CPD000058443 Etodolac 71 9 
  CPD000718785 Simvastatin 95 12 
  CPD001227203 Rifabutin 88 12 
  CPD001496951 Felodipine 76 19 
  CPD000499582 Quinapril 96 15 
  CPD000499573 Acitretin 50 13 
  CPD000718798 Fexofenadine 83 9 
  CPD001563899 Fluoromethadolone 108 30 
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CPD000466298 Sertraline 8 3 51 21 
CPD001566944 Carbidopa 111 15 
   
	  
	  
Figure S2. Activity of tobramycin (TOB) and thioridazine (TZ) or no treatment at different plasma gradients on 
the growth inhibition of S. aureus Mu50. Absorbance (abs.) is measured at 590 nm. 
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ABSTRACT 
 
Burkholderia cenocepacia is an opportunistic pathogen responsible for life-threatening 
infections in cystic fibrosis patients. B. cenocepacia is extremely resistant towards antibiotics 
and therapy is complicated by its ability to form biofilms. 
 
We investigated the efficacy of an alternative antimicrobial strategy for B. cenocepacia lung 
infections using in vitro and in vivo models. A screening of the NIH Clinical Collection 1&2 
was performed against biofilms of B. cenocepacia formed in 96-well microtiter plates in the 
presence of tobramycin to identify repurposing candidates with potentiator activity. The 
efficacy of selected hits was evaluated in a three-dimensional (3D) organotypic human lung 
epithelial cell culture model. The in vivo effect was evaluated in the invertebrate Galleria 
mellonella and in a murine B. cenocepacia lung infection model.  
 
The screening resulted in 60 hits that potentiated the activity of tobramycin against B. 
cenocepacia biofilms, including four imidazoles of which econazole and miconazole were 
selected for further investigation. However, a potentiator effect was not observed in the 3D 
organotypic human lung epithelial cell culture model. Combination treatment was also not 
able to increase survival of infected G. mellonella. Also in mice, there was no added value for 
the combination treatment.  
 
Although potentiators of tobramycin with activity against biofilms of B. cenocepacia were 
identified in a repurposing screen, the in vitro activity could not be confirmed nor in a more 
sophisticated in vitro model, neither in vivo. This stresses the importance of validating hits 
resulting from in vitro studies in physiologically relevant model systems. 
 
INTRODUCTION 
 
Species belonging to the Burkholderia cepacia complex (Bcc) are opportunistic pathogens 
mainly known for causing chronic lung infections in cystic fibrosis (CF) patients and in 
patients with chronic granulomatous disease [240, 241]. Burkholderia cenocepacia belongs to 
the Bcc and accounts for approximately 45% of Bcc infections in CF patients in the United 
States [240, 241]. The complex interaction between B. cenocepacia and the CF lung is 
reflected by the various clinical outcomes and disease severity, from transient colonization to 
necrotizing pneumonia and sepsis resulting in early death. In addition, respiratory infections 
caused by B. cenocepacia are associated with lower survival following lung transplantation 
[242, 243]. Antimicrobial therapy against these infections frequently fails due to B. 
cenocepacia’s resistance to many antibiotics and the induction of biofilm-specific tolerance 
mechanisms [203, 244, 245].  
 
Compounds that improve the activity of antibiotics have been called helper compounds [185], 
potentiators [246], adjuvants [247], or resistance breakers [13]. The aim of the present study 
was to identify such compounds that reverse tolerance and/or resistance towards tobramycin 
by increasing the susceptibility of B. cenocepacia biofilms. To this end, we screened a 
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repurposing library containing compounds that passed human safety assessments and for 
which the toxicity and metabolic properties are already known [189]. Activity was evaluated 
in several in vitro and in vivo assays.  
 
MATERIAL AND METHODS 
 
Strains and culture conditions 
B. cenocepacia LMG 16656 was maintained on tryptic soy agar plates (TSA, Lab M, 
Lancashire, UK). Overnight suspensions were obtained by inoculating Mueller Hinton broth 
(MH, Lab M) with several colonies and incubation with shaking for 18 h. A green fluorescent 
protein (GFP) producing B. cenocepacia K56-2 mutant was maintained on LB agar (Lab M) 
supplemented with 800 µg/mL trimethoprim (Ludeco, Brussels, Belgium) [248]. Overnight 
suspensions were made in LB broth supplemented with 800 µg/mL trimethoprim and 
inoculated for 23-24 h in a shaker (250 rpm). All cultures were kept aerobically at 37°C. 
 
Library compounds and antimicrobial agents 
The NIH Clinical Collection 1&2 (NIHCC 1&2, Evotec, San Francisco, CA) contain 727 
compounds dissolved in 100% dimethyl sulfoxide (DMSO) at a concentration of 10 mM. 
Miconazole nitrate was obtained from Certa NV (Eigenbrakel, Belgium), meropenem from 
Astrazeneca (Zoetermeer, The Netherlands), econazole nitrate, ketoconazole, ciprofloxacin, 
and gentamicin sulfate from Sigma (Bornem, Belgium), oxiconazole nitrate from Santa Cruz 
Biotechnology (Heidelberg, Germany), and tobramycin from TCI chemicals (Tokyo, Japan). 
Azoles were dissolved in 100% DMSO (Sigma) and subsequently diluted in MilliQ water 
(Millipore, Billerica, MA) for MIC determination, in physiological saline (PS, 0.9% w/v 
NaCl) for the checkerboard assays, the tests with biofilms formed in 96-well MTPs, and the 
G. mellonella assay, or in GTSF-2 medium for the 3D organotypic human cell culture model 
[249]. Antibiotic stocks were made in MQ water or PS. All antibiotic solutions were filter 
sterilized (0.22 µm, Whatman, Dassel, Germany) and immediately used. 
 
Library screen and identification of hits 
B. cenocepacia LMG 16656 biofilms were formed in round-bottomed 96-well MTPs as 
described by Van den Driessche et al. [220] and subsequently treated with one µl library 
compound (final concentration: 100 µM), 49 µL PS and 50 µL of a 1024 µg/mL tobramycin 
solution (final concentration: 512 µg/mL). One µL of compound solution was added to 99 µL 
PS for the experiments carried out in absence of tobramycin. An untreated control, a control 
for tobramycin treatment alone and a blank were included on every plate. After 24 h, biofilms 
were rinsed with 100 µL PS and the effect of the treatment was evaluated using CellTiter-
Blue staining (CTB, Promega, Leiden, The Netherlands). Fluorescence was measured using a 
multilabel MTP-reader (Envision, Perkin Elmer LAS, Waltham, MA) as described by Peeters 
et al. [200]. The blank corrected fluorescence signals generated by B. cenocepacia biofilms 
treated with the combination of component and tobramycin were compared to the 
fluorescence signals generated by biofilms that were treated with tobramycin alone. Hits were 
defined as compounds that caused a decrease in fluorescence signal of ≥ 90% in combination 
with tobramycin compared to the fluorescence signal generated by biofilms treated with 
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tobramycin alone. Hit compounds were also tested in absence of tobramycin and the 
fluorescence generated was compared to that from the untreated control. 
 
Determination of the in vitro activity of econazole and miconazole against B. cenocepacia  
To determine the MICs of miconazole and econazole, overnight B. cenocepacia LMG 16656 
cell suspensions were adjusted to OD595 of 0.05 and diluted 1:50 in double concentrated MH. 
Subsequently, 100 µL cell suspension was added to flat-bottomed 96-well MTP (SPL 
Lifescience, Korea) containing 100 µL of 1/2 serial diluted imidazole solutions (concentration 
range 0-400 µM). OD590 was measured using a multilabel MTP reader (Envision) after 24 h. 
MICs were determined in triplicate on different days. 
 
Biofilms were formed as described above and treated with 50 µL 200 µM econazole or 
miconazole (final concentration: 100 µM) and 50 µL 1024 µg/mL tobramycin (final 
concentration: 512 µg/mL). After 24 h, supernatants were removed and wells were rinsed. 
Cells were collected from the wells by 2 cycles of shaking (5 min, 700 rpm, Titramax 1000) 
and sonicating (5 min, Branson 3570E-MT, Branson Ultrasonic Corporation, Banbury, CT). 
The content of 5 wells was pooled in tubes containing 9 mL PS and the number of CFU per 
biofilm (CFU/BF) was determined by plating serial 10-fold dilutions on TSA plates. In 
addition, the potentiating activity of lower concentrations of econazole and miconazole (1 and 
10 µM), as well as the combination of 100 µM econazole with meropenem (320 and 3200 
µg/mL), ciprofloxacin (250 µg/mL) and gentamicin (512 and 2560 µg/mL) was evaluated in 
the same model system. Experiment were performed in triplicate on different days. 
 
For checkerboard assays biofilms were treated with tobramycin (128 - 8192 µg/mL) and 
econazole (25 - 200 µM) or miconazole (25 - 200 µM). Potential synergistic activity of these 
treatments was assessed by calculation of the fractional inhibitory concentration index (FICI) 
based on metabolic activity determination using CTB. In detail, FICI was calculated as 
FICI=(CTOB+IMI/CTOB)+(CIMI+TOB/CIMI), where CTOB+IMI is the concentration of tobramycin in 
the presence of the imidazole at which the fluorescence generated is equal to the fluorescence 
of the blank control, CTOB is the concentration of tobramycin that causes a fluorescence equal 
to the fluorescence of the blank control, CIMI+TOB is the concentration of the imidazole that 
causes in the presence of tobramycin a fluorescence equal to that of the blank control and CIMI 
is the concentration of the imidazole that causes a fluorescence signal equal to the 
fluorescence signal of the blank control. Interactions were scored as synergistic when FICI ≤ 
0.5 [250]. 
 
Evaluation of the effect of econazole or miconazole and tobramycin in a 3D organotypic 
human cell culture model 
A 3D human lung epithelial cell culture model was generated by growing A549 cells (ATCC 
CCL-185) on porous microcarrier beads in a low fluid shear bioreactor, as previously 
described [251, 252]. A549 cells were maintained in GTSF-2 medium supplemented with 2.5 
mg/L insulin transferrin selenite (ITS, Sigma-Aldrich), 1.5 g/L sodium bicarbonate, and 10% 
heat-inactivated FBS (Life Technologies). All cultures were grown at 37°C under 5% CO2 
conditions.  
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Infection studies were performed using 3D cultures grown for 11 to 14 days, and at the time 
of infection cell culture medium without FBS and supplemented with 0.2% rhamnose was 
used. 3D cell cultures containing 2.5 x 105 cells in 250 µL per well were transferred to 48-well 
plates (SPL Life Sciences). An overnight culture of a GFP-producing B. cenocepacia K56-2 
mutant was resuspended in cell culture medium and added to the 3D cells at a multiplicity of 
infection of ~15:1.  
 
Treatments (156 µg/mL tobramycin and/or 10 µM econazole or miconazole) were added to 
the cell culture medium at the start of the infection. Plates were incubated at 37 °C under 5% 
CO2 conditions for 1 h, rinsed with Hanks’ Balanced Salt Solution (Life Technologies) where 
after fresh cell culture medium containing the treatment reagents was supplied. After 16 h 
additional incubation, the number of B. cenocepacia that associated with the 3D cells was 
determined. To this end, the content of each well was transferred to new wells to avoid 
inclusion of bacteria attached to the plastic surface. Cultures were rinsed twice with HBSS 
followed by the addition of 0.1% Triton X-100, vigorous mixing and plating. The experiments 
were performed in the absence and presence of 3D cells, under otherwise identical conditions, 
to assess the effect of tobramycin and/or imidazoles on the inhibition of bacterial association 
with an abiotic or biotic surface, respectively. Controls with no antimicrobials and uninfected 
3D cell cultures were included in every assay. Assessment of the overall 3D cell culture 
model integrity and visualization of GFP-producing bacteria was performed using an EVOS 
FL Auto Imaging System (Life Technologies) at a magnification of 300x.  
 
In addition, the 3D lung epithelial cell viability was evaluated based on a lactate 
dehydrogenase (LDH) assay. The LDH activity assay kit (Sigma) was used to measure the 
release of cytosolic LDH by 3D lung epithelial cells following exposure to B. cenocepacia 
K56-2. Medium from 3D aggregates infected with B. cenocepacia for 17 h was centrifuged 
for 15 minutes at 3700 rpm, where after the supernatants was used for LDH quantification 
following the manufacturer’s instructions. A standard curve using NADH was included. As a 
positive control, 2.5 x 105 3D lung epithelial cells were lysed with 0.1% Triton-X100 in 250 
µL (the same volume as for the test conditions). The data are presented as a percentage of 
LDH release from the positive control.  
 
Evaluation of the potentiating effect in a Galleria mellonella infection assay 
In vivo activity of tobramycin and econazole or miconazole was evaluated in the G. 
mellonella infection assay, as described by Brackman et al. [221]. G. mellonella larvae 
(Hengelsport de Poorter, Ghent, Belgium) were kept at 4°C in the dark on wooden flakes 
prior to use and divided in groups with similar weight distribution (300-450 mg, 450-550 mg 
or 550-650 mg). Equal amounts of larvae were taken from each group to compose new groups 
containing at least 12 larvae for the infected groups and 6 for the uninfected groups. 
Overnight cultures of B. cenocepacia LMG 16656 were centrifuged, resuspended in PS and 
adjusted to 107 CFU/mL. Larvae were injected with 10 µL cell suspension in the last left 
proleg and 10 µL of the treatment solution (512 µg/mL tobramycin, 50 µM econazole, 50 µM 
miconazole, or combinations) in the last right proleg using a syringe (BD ultrafine insulin 
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syringes, Becton Dickinson, Erembodegem, Belgium). Larvae were incubated at 37°C and 
survival was scored after 24, 48 and 72 h. Larvae were considered dead when no movement 
was observed in response to touch. To determine whether the treatment caused a reduction in 
the number of CFU/larvae 24 h post infection (p.i.), larvae were homogenized (Polytron, 
Kinematica, Eschbach, Germany), serially diluted and plated on Burkholderia cepacia 
selective agar (Thermo Scientific, Erembodegem, Belgium). 
 
Development of a formulation for inhalation containing tobramycin and miconazole 
In contrast to tobramycin which is highly soluble in water, miconazole is very slighty soluble 
in water [253]. Therefore, it was decided to formulate the combination tobramycin-
miconazole as a suspension for nebulization. In order to decrease the particle size of the 
suspended miconazole particles (i.e. down to desired particle size for deposit in the lungs), the 
wet bead milling technique was applied. The formulation was prepared by weighing 330 mg 
tobramycin and 15.4 mg or 61.6 mg miconazole into a 20 mL vial, followed by the addition of 
1 mL Tween 80 solution (1 mg/mL) (Fagron, Waregem, Belgium), 4 mL PS, and 10 g 
zirconium oxide beads (diameter 0.5 mm, Netzsch Feinmahltechnik, Selb, Germany) as 
milling pearls. Subsequently, the vials were placed on a roller-mill (Peira, Beerse, Belgium) 
and grinding was performed at 150 rpm for 72 h. After milling, the microsuspension was 
separated from the grinding pearls by pipetting. The particle size distribution of miconazole 
was measured in triplicate by laser diffraction (Mastersizer S long bench, Malvern 
Instruments, Worcestershire, UK). The wet dispersion technique was applied using the 300RF 
lens (Malvern Instruments, Worcestershire, UK). The powders were dispersed in a solution of 
0.2% Tween 80 in Miglyol 812 and subsequently vortexed and sonicated in order to eliminate 
agglomerates. In addition, biofilms formed in 96-well MTPs were treated with the 
formulation in a dilution of 1 in 129 (corresponding to 512 µg/mL tobramycin and 200 µM 
miconazole) to confirm the antibacterial activity. Experiments were performed six times 
independently and the effect was quantified by plate counts. 
 
Mouse lung infection model 
Animals were treated in accordance to the guidelines provided by the University of Antwerp 
and the European Directive for Laboratory Animal Care (Directive 2010/63/EU of the 
European Parliament). The laboratory Animal Ethics Committee of the University of Antwerp 
authorized and approved all animal experimentation in this study (file 2014-81). Female 
inbred BALB/c ByJRj mice of 8-9 weeks old (Janvier Labs, Le Genest-Saint-Isle, France) 
were kept under standard pathogen-free conditions with a constant temperature of 20-25°C, 
an average humidity of 50-60%, a 12 h dark-light cycle and food and drinking water ad 
libitum. Mice were rendered transiently leukopenic with cyclophosphamide (Endoxan, 
Baxter) at 150 mg/kg body weight (bw) given intraperitoneally 4 days prior to infection and 
50 mg/kg bw administered both 2 days before infection and on the day of infection. To 
prepare the inoculum for intratracheal infection, a bacterial cryostock was thawed, diluted in 
LB broth (105 CFU/mL) and incubated for 24 h in a shaken incubator (25 rpm) at 37°C in a 14 
mL vent cap sterile tube. Cells were harvested by centrifugation after 24 h and diluted in PBS 
to 2 x 107 CFU/mL. Before intratracheal challenge with B. cenocepacia, mice were 
anesthetized with isoflurane (Halocarbon, Norcross, GA). Next anesthetized mice were 
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inoculated intratracheally with B. cenocepacia (106 CFU/mouse) in 50 µL of PBS. Thereafter, 
infected mice were treated intranasally with 40 µl of the formulations described above, i.e. 
vehicle (0.02% Tween 80 dissolved in PS), tobramycin (66 mg/mL, corresponding to 120 
mg/kg bw), miconazole (3.08 mg or 12.32 mg/mL corresponding to 5.6 and 22.4 mg/kg bw 
miconazole, respectively), and the combination, at 1 h, 24 h and 48 h p.i.. Mice were observed 
daily for functional behavior (fur quality, posture, state of activity and bw) and pneumonia 
symptoms (respiratory frequency).  B. cenocepacia infected mice were sacrificed at day 3 p.i. 
by cervical dislocation. Lung, spleen and liver were excised, weighed and homogenized in 5 
mL PBS and were used for the enumeration of CFU on LB agar or Burkholderia cepacia 
selective agar. 
 
Statistics 
Data are expressed as the mean ± standard error of the mean (SEM). SPSS version 23 
software was used and data were analyzed using the Kruskal-Wallis test. P-values < 0.05 were 
considered statistically significant. 
 
RESULTS 
 
Library screen against B. cenocepacia biofilms in combination with tobramycin 
Screening the NIHCC 1&2 against biofilms of B. cenocepacia formed in 96-well MTPs in the 
presence of tobramycin allowed us to identify 60 hits (8.2%). In the presence of tobramycin 
these hit compounds caused a decrease of ≥ 90% in fluorescence signal after CTB staining 
compared to treatment with tobramycin alone (Table S1). Hits were classified in four groups 
according to their therapeutic indication: anti-infective agents (n = 11), antipsychotics and 
antidepressants (n = 23), antineoplastic and/or hormonal drugs (n = 6), and a miscellaneous 
group (n = 20) (Table S2). Subsequently, B. cenocepacia biofilms were treated with the hit 
compounds alone; 19 compounds (i.e. miconazole, oxiconazole, ketoconazole, perphenazine, 
droperidol, thiothixene, clozapine, perospirone, tamoxifen, ethylestreol, montelukast, AM404, 
atomoxetine, nitrendipine, donepezil, procyclidine, tolterodine, and propranolol) did not cause 
a significant decrease in fluorescence. In contrast, 41 compounds caused a significant 
reduction in fluorescence compared to the untreated control suggesting their potentiating 
activity is at least partially due to an intrinsic activity against B. cenocepacia biofilms (Table 
S2).  
 
Antifungal imidazoles are potentiators in vitro 
Four antifungal imidazoles, i.e. econazole, miconazole, oxiconazole, and ketoconazole were 
identified as hits in the screening. Treatment of biofilms with econazole alone reduced the 
fluorescence significantly compared to the untreated control. Miconazole, oxiconazole, and 
ketoconazole did not cause a significant reduction in fluorescence compared to untreated 
control (Table S2).  
 
Subsequently, B. cenocepacia biofilms were treated with 100 µM econazole or miconazole in 
combination with 512 µg/mL tobramycin and the antimicrobial effect was quantified by plate 
counts. Treatment with econazole or miconazole alone did not cause a reduction in the 
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number of CFU/BF. However, in combination with tobramycin, a significant reduction in the 
number of CFU/BF was observed, compared to treatment with tobramycin alone (Figure 1). 
Lower concentrations of econazole and miconazole were tested for potentiating activity 
towards tobramycin; there was no potentiator activity for 1 µM, while 10 µM econazole or 
miconazole were equally effective as 100 µM (Figure 1). The potentiator activity of econazole 
was subsequently investigated in combination with other antibiotics; 100 µM econazole 
caused a statistically significant reduction in CFU/BF in combination with 2560 µg/mL 
gentamicin, but not with 512 µg/mL gentamicin. Econazole did not potentiate the activity of 
meropenem or ciprofloxacin (Figure 1). 
 
 
Figure 1. Number of CFU per biofilm after treating mature biofilms of B. cenocepacia LMG 16656 for 24 h with 
100 µL PS (untreated control, CTRL), 1, 10, 100 µM econazole (ECO) or 1, 10, 100 µM miconazole (MICO), in 
combination with 512 µg/mL tobramycin (TOB), 512 and 2560 µg/mL gentamicin (GEN), 320 and 3200 µg/mL 
meropenem (MEM), or 250 µg/mL ciprofloxacin (CIP). Asterisks (*) indicate a significantly different number in 
log CFU/BF compared to untreated control, while double asterisks (**) indicate a significantly different number 
in log CFU/BF compared to treatment with the respective antibiotic alone (P-value < 0.05). (data shown are 
average; n ≥ 3;  error bars indicate SEM) 
  
The MIC for econazole and miconazole against B. cenocepacia exceeded 200 µM. 
Subsequently, checkerboard assays were performed against biofilms of B. cenocepacia and 
showed that in the presence of the imidazoles, the concentration of tobramycin necessary to 
completely eradicate biofilms decreased substantially. As the imidazoles alone did not 
eradicate biofilms in the concentrations tested, and as higher concentrations could not be 
tested due to solubility issues, exact FICIs could not be calculated.  
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Evaluation of the activity of the combination treatment in a 3D organotypic cell culture 
model 
B. cenocepacia K56-2 infected 3D lung epithelial cells without significantly affecting the 3D 
model integrity (Figure 2) and host cell viability (Figure S3) up till 17 h post infection. 
Specifically, based on the LDH release assay less than 10% cell death of infected cultures was 
observed, which was similar to that observed in the non-infected controls (Figure S3). 
 
Figure 2. Left image showing an uninfected control where the microcarrier bead scaffolds are covered with A549 
human lung epithelial cells, right image shows the 3D lung epithelial cells 17 h p.i., green dots (white arrows) 
indicate intracellular growth of B. cenocepacia K56-2, while the large green structure (blue arrow) suggests that 
biofilm-like structures are formed. Magnification is 300x. Scale bar is 400 µm. 
 
B. cenocepacia associated with the 3D lung epithelial cells both as dense clusters associated 
with single host cells and as structures that were spread out over multiple epithelial cells 
(Figure 2). Single bacteria associating with the 3D lung epithelial cells were also observed. 
3D lung epithelial cells were exposed to 10, 50 and 100 µM of the imidazoles in the absence 
of B. cenocepacia for 17 h (Figure S4). The epithelial cells completely detached from their 
microcarrier bead scaffolds when exposed to 50 or 100 µM econazole or miconazole; this was 
not observed when cells were exposed to 10 µM of the imidazoles (Figure S4) and the latter 
concentration was chosen for further experiments. High concentrations of tobramycin (1000 
µg/mL) did not affect the 3D lung model integrity (Figure S4). Adding 10 µM econazole or 
miconazole led to an additional reduction in B. cenocepacia biofilm formation in MTP in 
combination with 156 µg/mL tobramycin (Figure 3 and Figure S5), and this concentration 
was used to assess the number of viable and culturable bacteria associated with 3D cells. 
When the combination treatment was tested in this model, no potentiating effect of 
miconazole and econazole was observed, while the activity of tobramycin was similar as in 
the MTP (Figure 3).  
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Figure 3. Effect of treatment with 10 µM econazole (ECO), 10 µM miconazole (MICO), 156 µg/mL tobramycin 
(TOB) or the combination on inhibition of biofilm formation of B. cenocepacia K56-2 with a plastic surface 
(left, number of biofilm cells per well) or the effect on the treatment on the number of bacterial cells associated 
with human 3D lung epithelial cells (right, number of host associated cells per well). Asterisks (*) indicate a 
significantly different number in CFU/well compared to no treatment, while double asterisks (**) indicate a 
significantly different number in CFU/well compared to treatment with tobramycin (P-value < 0.05). (data 
shown are average; n ≥ 3;  error bars indicate SEM) 
 
G. mellonella survival assay 
G. mellonella larvae were injected with B. cenocepacia and treated with 10 µL vehicle (PS), 
512 µg/mL tobramycin, 50 µM miconazole, 50 µM econazole, tobramycin combined with 
miconazole, or tobramycin combined with econazole. No differences were observed between 
the different treatments 24 h p.i., which indicated that the treatment is not toxic at the 
concentrations applied. However, more than 50% of the larvae had died in the infected groups 
48 h p.i., regardless of the treatment which indicated that the treatment cannot protect the 
larvae against B. cenocepacia infection (Figure 4). These observations were confirmed by the 
fact that no differences in CFU/larvae were observed among the different groups 24 h p.i. 
(Figure S6).  
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Figure 4. Percentage survival of G. mellonella in uninfected control groups (NI) and infected groups (I) 24, 48, 
and 72 h after administration of the different treatments (tobramycin (TOB), econazole (ECO), miconazole 
(MICO) or the combinations) and/or infection. (Data shown are average, n = 6, error bars indicate SEM) 
 
Evaluation of the combination tobramycin and miconazole in a mouse lung infection 
model 
The combination of tobramycin and miconazole was evaluated in a B. cenocepacia mouse 
lung infection model. To this purpose, a formulation for inhalation was developed in which 
the particle size was lower than 5 µm (i.e. d10 = 0.23 µm, d50 = 0.41 µm, and d90 = 3.68 µm),  
which is suitable for drug deposition in the lungs [254]. The formulation was found to be 
stable over 5 days (i.e. no shift in d50-value) which covered the duration of the in vivo study. 
A similar tobramycin concentration (66 mg/mL) as the TOBI inhaler (Novartis, 60 mg/mL) 
was chosen for the treatment of B. cenocepacia infected mice, which is 129 times the 
concentration used in the MTP assay. The concentration of miconazole in the formulation was 
based on the ratio tobramycin/miconazole in the MTP experiments and the activity of the 
diluted formulation was confirmed against biofilms formed in 96-well MTPs (Figure S7). 
Treatment of infected mice with tobramycin resulted in prevention of dissemination to liver 
and spleen, and a reduction in lung burden of approx. 1 log (Figure 5). Mice treated with 22.4 
mg/kg bodyweight miconazole suffered from side effects and were characterized by a 
hunchback posture, weak breathing and an overall bad fur condition. Also dissemination of 
bacteria to liver and spleen was observed in every miconazole treated mouse whereas only 
approx. half of the vehicle-treated mice (5/11) had dissemination of bacteria to liver and 
spleen (Figure 5). Therefore, a lower dose of miconazole (5.6 mg/kg bodyweight) was chosen 
for the evaluation of the combination therapy in mice. As shown in Figure 5, no significant 
difference in lung burden could be observed between mice treated with tobramycin and 
tobramycin combined with miconazole. Also mice treated with this lower dose of miconazole 
alone suffered from the same toxic effects as 22.4 mg/kg bodyweight miconazole.  
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Figure 5. Colony counts in lung (a), spleen (b), and liver (c) in mice treated with: (i) vehicle, (ii) 22.4 mg/kg 
bodyweight miconazole (MICO), (iii) 5.6 mg/kg bodyweight miconazole, (iv) 120 mg/kg bodyweight 
tobramycin (TOB) and (v) 120 mg/kg bodyweight tobramycin combined with 5.6 mg/kg bodyweight miconazole 
(TOB + MICO). Error bars indicate SEM. 3 independent repeats of mice treated with vehicle (n ≤ 3), 2 
independent repeats of mice treated with miconazole 22.4 mg/kg (n ≤ 3), 1 independent repeat of mice treated 
with miconazole 5.6 mg/kg (n = 2) and 1 independent repeat of mice treated with tobramycin + miconazole (n = 
6). 
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DISCUSSION 
 
Library screening identifies antifungal imidazoles as antibacterial potentiators 
Screening two repurposing libraries against B. cenocepacia biofilms in the presence of 
tobramycin resulted in the identification of 60 hit compounds. Four antifungal imidazoles, i.e. 
econazole, miconazole, oxiconazole, and ketoconazole were among the hits identified. Other 
azoles present in the library were less or not active, e.g. the triazoles fluconazole, 
itraconazole, or voriconazole. This is in accordance with results from a structure-activity 
relationship study on several oxiconazole derivatives in which compounds with an imidazole 
moiety were shown to be more potent antibacterials against Klebsiella pneumoniae, 
Escherichia coli and Staphylococcus aureus compared to triazoles [255].  
 
The MIC of econazole and miconazole against B. cenocepacia exceeded 200 µM, indicating 
that they potentiate tobramycin at concentrations that do not inhibit growth of planktonic cells 
when administered alone. This is in accordance with a study in which no growth inhibitory 
activity was observed for miconazole against planktonic cells of Pseudomonas aeruginosa 
and E. coli, while the combination of miconazole with polymyxin B resulted in a strong 
synergistic interaction [256].  
 
The activity of imidazoles towards Gram-positive bacteria has been described before [190, 
257-259]. Sud and Feingold investigated the bactericidal effect of miconazole and concluded 
that interference with the membrane of Gram-positive bacteria results in leakage of K+ [190]. 
In addition, imidazoles bind S. aureus flavohemoglobin, a protein with NO dioxygenase 
activity, causing nitrosative and oxidative stress [224]. Miconazole also binds 
flavohemoglobin of E. coli, and in vitro data showed that the combination of a NO-donor, 
miconazole and polymyxin B nonapeptide were effective to treat four ESBL-producing E. coli 
isolates [260].  
 
Activity of the combination in relevant model systems  
Activity of tobramycin in combination with econazole or miconazole was tested in an in vitro 
3D organotypic human cell culture model. 3D organotypic cell culture models are valuable 
research tools that mimic key aspects of the parental tissue and reduce the gap between in 
vitro cell culture models and physiological tissue [261, 262]. A 3D A549 lung epithelial cell 
culture model has previously been developed and validated, and was used previously to study 
the colonization of P. aeruginosa and Francisella tularensis. These studies demonstrated that 
the 3D lung epithelial cells generate more in vivo-like phenotypes compared to conventional 
monolayers [252, 263]. B. cenocepacia has been shown to both infect intracellular and form 
biofilms in the lungs of CF patients [203, 264, 265]. However, the biofilm formation capacity 
of Burkholderia species in CF lungs is still under debate [266]. Infection of the 3D lung 
epithelial model with B. cenocepacia K56-2 reflected aspects of the in vivo infection profile, 
as phenotypic characteristics that were indicative of both intracellular growth and biofilm 
formation were observed. 
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Tobramycin showed an increased inhibition on biofilm formation in MTP in the presence of 
econazole or miconazole, so the imidazoles tested both potentiate the biofilm-inhibiting and 
biofilm-eradicating activity of tobramycin, as described above. However, no potentiating 
effect could be observed in the 3D lung epithelial cell model (Figure 3).  
 
The effect of the combination treatment was also evaluated in G. mellonella, which is a 
suitable model to test Bcc virulence [267]. G. mellonella was used before to estimate the 
activity of treatments towards B. cenocepacia infections, including novel agents with 
potentiator activity [221, 268]. Neither treatment with tobramycin, miconazole, econazole, nor 
the combination could protect the larvae against B. cenocepacia infection (Figure 4). 
 
Finally, the combination of tobramycin and miconazole was evaluated in a B. cenocepacia 
mouse lung infection model. As 22.4 mg/kg bodyweight miconazole was toxic, a lower dose 
of miconazole (5.6 mg/kg bodyweight) was chosen for the evaluation of the combination 
therapy in mice. This dose is far below LD50 values for mice reported in literature, which 
range from 80 mg/kg for intravenous administration, to 220 mg/kg for intraperitoneal 
administration, and even up to 519 mg/kg upon oral administration [268]. However, also this 
lower dose appeared to be toxic for the mice used in the present study and no significant 
difference in lung burden could be observed between mice treated with tobramycin, and those 
treated with tobramycin and miconazole.  
 
Different activity in a conventional in vitro biofilm model system and other model 
systems of host-pathogen interactions 
Based on in vitro data the promising combination of tobramycin with econazole or 
miconazole was evaluated in other model systems which all indicated that the combination 
did not improve the outcome upon infection with B. cenocepacia infection. Discrepancies in 
antimicrobial activity between in vitro and in vivo situations are often observed [269]. This 
may be because basic in vitro models for susceptibility testing lack host factors (e.g. cellular 
and humoral immunity of the host, the pathogen’s level of expression of virulence 
determinants and protein binding). Also, pharmacokinetic parameters as penetration into the 
site of infection are not taken into account. In the present study azoles lost their potentiating 
activity when they were investigated in models including host factors and it is thus likely that 
these host factors play a role in their inactivation. Protein binding of miconazole (reported to 
be 90%) might contribute to a substantial decrease in biologically active free fraction and loss 
of activity in the three models [270]. Also, a differential transcriptomic and phenotypic profile 
in the presence of host cells might resulting in a reduced susceptibility to the combination 
treatment.  
 
The screening described in the present study was performed in one of the most frequently 
used models for the evaluation of novel biofilm inhibitory/eradication compounds, i.e. the 
static MTP biofilm model system [64]. Although this system has multiple advantages, it lacks 
many of the micro-environmental factors that are encountered during the natural course of 
infection of B. cenocepacia, including host components. Therefore, more advanced in vitro 
and in vivo model systems should be considered that are more reflective of the host 
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environment and thus better predict the efficacy of the combination therapy. Hence, it seems 
appropriate for future screenings of antimicrobial compounds that conventional in vitro model 
systems are complemented with model systems that incorporate key host factors in an early 
stage. 
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SUPPLEMENTARY DATA 
 
Table S1. The NIH Clinical Collection 1&2 were screened at a concentration of 100 µM in the presence of 512 
µg/ml tobramycin for potentiators against biofilms of B. cenocepacia LMG 16656. Hits were subsequently tested 
in absence of tobramycin. Effect was evaluated using CTB staining. The values shown in the left column 
represent the mean residual metabolic activity of the compound in the presence of tobramycin compared to 
treatment with tobramycin alone, and the standard deviation (SD). The values in the right column represent the 
mean residual metabolic activity of the compound compared to untreated control, and the standard deviation.  
 
PUBCHEM 
CODE 
COMPOUND NAME 
 
MEAN 
(%) 
SD 
 
MEAN 
(%) 
SD 
 
CPD000449281 Nalbuphine 30 14 
  CPD000449275 Raclopride 50 24 
  CPD000449271 Zacopride 58 40 
  CPD000449276 SKF 83566 D1 R agonist 29 33 
  CPD000449316 3'-deoxydenosine 106 77 
  CPD000449274 AM 404 N-arachidonoylaminofenol 7 9 99 10 
CPD000059053 Pilocarpine 114 29 
  CPD000058291 Rifedipine 55 29 
  CPD000042823 Flurbiprofen 121 58 
  CPD000059136 Deferiprone 106 15 
  CPD000058470 Loxapine 2 5 43 6 
CPD000326694 D-3-MEO-N-methylmorphinan 39 24 
  CPD000449282 Duloxetine 4 6 20 2 
CPD000449320 Glycine 217 97 
  CPD000449318 Benzene acetic acid 53 12 
  CPD000058345 S-progesterone 27 12 
  CPD000058961 Famotine 73 22 
  CPD000449299 5-HTR-3 agonist 55 20 
  CPD000466270 Pancuronium 52 13 
  CPD000058175 Metronidazole 61 29 
  CPD000449327 Benzenaeacetic acid 67 25 
  CPD000449323 Benzeneacetonitrile 23 4 
  CPD000449328 Selegiline HCl 57 8 
  CPD000449294 Zucapsaicin 21 9 
  CPD000058513 Salbutamol 69 19 
  CPD000057879 Vesamicol 44 18 
  CPD000469289 Picrotin 77 28 
  CPD000449268 Terazosin 64 17 
  CPD000449319 Diphenylcyclopropenone 26 20 
  CPD000449326 Thiazolidinecarboxylic acid 75 40 
  CPD000466274 Mesoridazine 23 5 
  CPD000449313 Pyridazinone difluoromethoxy 58 40 
  CPD000466275 Phenothiazine 17 10 
  CPD000449322 Cyclopentaquinolin 48 10 
  CPD000058306 Clotrimazole 25 3 
  CPD000058255 Loratadine 12 10 
  CPD000058500 Phenelzine 71 44 
  CPD000449311 Riluzole 49 15 
  CPD000449312 Naltrindole 22 10 
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CPD000449277 Nornicotine 98 21 
  CPD000449269 Bifemelane 6 2 23 9 
CPD000449284 CGS antagonist  64 30 
  CPD000449287 Cinanserin 17 8 
  CPD000449272 Cisapride 75 56 
  CPD000449273 Indatrline 12 11 
  CPD000058520 Trazodone 37 15 
  CPD000449301 Prazosin 75 55 
  CPD000058525 Urapidil 123 43 
  CPD000449278 Cotinine 70 26 
  CPD000058313 Cycloserine 92 73 
  CPD000466268 Fluvoxamine 13 12 
  CPD000449270 Doxepin 11 4 
  CPD000059133 Trifluoperazine 3 4 20 7 
CPD000058908 Hydroxy methylmorphinan 95 32 
  CPD000449329 Ornithine 108 25 
  CPD000148117 Maprotiline 12 11 
  CPD000466272 Pizotifen 7 5 51 9 
CPD000059126 Beta-estradiol 30 13 
  CPD000059046 Diacetyl diaminohexane 85 7 
  CPD000058353 Diphengydramine 41 8 
  CPD000449267 Galanthamine 100 26 
  CPD000449296 Ifenprodil 20 14 
  CPD000059171 Tetraethylthiuram 20 8 
  CPD000449302 Piribedil 59 23 
  CPD000058460 Ketoconazole 6 6 73 9 
CPD000058623 Tripelennamine 34 5 
  CPD000449325 Pyrazinecarboxamide 90 29 
  CPD000059105 Amino tetrahydroacridine 47 41 
  CPD000058319 Ethynylestradiol 14 4 
  CPD000449317 Pyrimidinone arabinofu 102 25 
  CPD000449324 L glutaminic acid 63 15 
  CPD000449305 1-(3-trifluoromethylphenyl)piperazine  26 17 
  CPD000449298 Pramipexole 103 34 
  CPD000058189 Lidocaine 121 87 
  CPD000449290 Indometacine 197 62 
  CPD000058555 Tomelukast 71 34 
  CPD000466269 Paroxetine maleate 5 6 23 4 
CPD000449288 Epigallocatechin 189 42 
  CPD000145728 Amino hydroxy benzoic 120 53 
  CPD000449321 Oxiranecarboxylic acid 84 31 
  CPD000338536 Cephalexine 51 13 
  CPD000466390 Pidotimod 75 10 
  CPD000466386 Ramipril 108 13 
  CPD000469284 Fenpiverinium 66 20 
  CPD000058610 Nortestosterone 40 1 
  CPD000466384 Niztididne 67 14 
  CPD000059047 Flucytosine 81 13 
  CPD000048684 Oxcarbazepine 67 39 
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CPD000466385 Troxipide 60 4 
  CPD000466341 Actarit 85 28 
  CPD000469183 Azelastine 6 7 36 3 
CPD000466388 Tocainide 98 19 
  CPD000499525 Taxifoli 62 12 
  CPD000466387 Levofloxacin 89 8 
  CPD000469182 Cefatrizine 82 17 
  CPD000466364 Idebenone 31 14 
  CPD000466366 Levosulpiride 81 38 
  CPD000238142 Pemoline 92 22 
  CPD000466343 Letrozole 89 18 
  CPD000469184 Meropenem 75 20 
  CPD000466339 Orlistat 88 29 
  CPD000469179 Ondansetran 58 17 
  CPD000059117 Levonorgestrel 98 14 
  CPD000469197 Cetraxate 96 8 
  CPD000149316 Alprazolam 81 6 
  CPD000058464 Lamotignine 102 26 
  CPD000059145 Crotamiton 73 27 
  CPD000472526 Amfebutamone 89 21 
  CPD000466340 Alfuzonsine 49 10 
  CPD000449309 Amisulpride 56 11 
  CPD000469292 Lofepramine 11 11 
  CPD000466362 Perospirone 7 4 49 10 
CPD000059010 Docetaxel 25 18 
  CPD000387107 Honokiol 5 4 8 3 
CPD000469196 Tolterodine 8 6 62 8 
CPD000466363 Carmofur 62 12 
  CPD000469181 N-methyl paroxetine 2 2 31 20 
CPD000466337 Olmesartan 84 47 
  CPD000469593 Potassium losartan 66 24 
  CPD000466338 Temozolomide 108 54 
  CPD000058528 Methyltestosterone 55 43 
  CPD000469195 Tosufloxacin 75 40 
  CPD000466361 Mecillinam 62 12 
  CPD000469177 Atomoxetine 5 6 47 7 
CPD000466336 Artesunate 52 25 
  CPD000058959 Itraconazole 66 11 
  CPD000469193 Cefpodoxime 68 13 
  CPD000058803 Buflomedil 56 17 
  CPD000012114 Clore morpholin ehyl 71 16 
  CPD000466330 Halometasone 51 24 
  CPD000466357 Triclabendazole 43 15 
  CPD000466331 Rofecoxib 27 5 
  CPD000471619 Bisoprolol 69 10 
  CPD000466334 Ezetimibe 43 18 
  CPD000469176 Tiagabine 38 12 
  CPD000466355 Idarubicin 11 8 
  CPD000466360 Flubendazole 52 17 
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CPD000466356 Tacrolimus 34 15 
  CPD000469208 Valaciclovir 76 19 
  CPD000466382 Clarithromycin 38 21 
  CPD000466383 Aripiprazole 45 16 
  CPD000471622 Trimebutine 44 10 
  CPD000238198 Mestalone 47 4 
  CPD000466370 Nisoldipine 62 19 
  CPD000466371 Piceid 73 38 
  CPD000149359 Methyl nitro imidazole 74 22 
  CPD000466369 Nifekalant 88 14 
  CPD000466372 Nateglinide 96 19 
  CPD000058691 Megestrol acetaat 41 16 
  CPD000466374 Ormetoprim 110 31 
  CPD000466377 Zileuton 51 11 
  CPD000058350 Stavudine 74 44 
  CPD000058918 Gabexate 68 21 
  CPD000469293 Oxiconazole 4 4 65 16 
CPD000469235 Kitasamycin 42 13 
  CPD000466375 Famciclovir 76 18 
  CPD000326828 Sotalol 66 12 
  CPD000466373 Rufloxacin 74 17 
  CPD000466389 Taxiflolin 90 21 
  CPD000469211 Alosetron 86 21 
  CPD000469159 Fluticasone 59 25 
  CPD000469161 Indinavir 68 31 
  CPD000469160 Midazolam 38 21 
  CPD000466319 Lamivudine 77 17 
  CPD000469151 366-70-1 117 31 
  CPD000469280 Esomeprazole 34 18 
  CPD000059146 Sulfasalazine 64 15 
  CPD000466313 Torasemide 70 18 
  CPD000469156 Tropistrona HCl 37 15 
  CPD000326795 Ranolazine 62 24 
  CPD000058423 Bupropion 83 33 
  CPD000471621 Irsogladine 53 27 
  CPD000466376 Acarbose 79 13 
  CPD000469294 Benproperine 2 4 25 8 
CPD000466378 Fenprobamaat 71 27 
  CPD000058926 Adamantan 28 31 
  CPD000449280 Carvedilol 11 12 
  CPD000466379 Lomifylline 64 23 
  CPD000466380 Pazufloxacin 69 20 
  CPD000466381 Miglitol 76 44 
  CPD000058373 Tranilast 59 35 
  CPD000466345 Olanzapine 16 19 
  CPD000449297 Nefazodone HCl 10 14 47 22 
CPD000469185 Moxifloxacin 49 28 
  CPD000469186 Nelfinavir 52 18 
  CPD000469187 Pravastatin 143 52 
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CPD000466344 Topotecan 79 36 
  CPD000466303 Levetiracetam 79 21 
  CPD000469142 Pramipexole 63 23 
  CPD000466323 Risperidone 22 10 
  CPD000469167 Pioglitazone 73 31 
  CPD000469147 Cilastatin 66 24 
  CPD000466348 Argatroban 74 35 
  CPD000466327 Valdecoxib 59 19 
  CPD000466346 Naftopidil 5 6 24 5 
CPD000156231 Nobiletin 29 24 
  CPD000466304 Finasteride 76 34 
  CPD000469145 Zolpidem 81 29 
  CPD000048458 Viramune 117 66 
  CPD000466325 Topiramate 123 41 
  CPD000466350 Voriconazole 94 29 
  CPD000469190 Fenoldopam 94 39 
  CPD000471612 Rosiglitazone 51 17 
  CPD000469191 Escitalopram 22 14 
  CPD000058866 Zeranol 58 20 
  CPD000466354 Latanoprost 17 13 
  CPD000058576 Didanosine 90 18 
  CPD000466298 Sertraline 5 7 2 4 
CPD000466353 Calcipotriol 38 10 
  CPD000466308 Epirubicin 35 7 
  CPD000466329 Bicalutamide 41 21 
  CPD000469192 Benidipine 56 9 
  CPD000466352 Amlexanox 79 13 
  CPD000469148 Cerivastatin 109 28 
  CPD000466309 Icariin 101 19 
  CPD000466310 Methylandrosternediol 109 16 
  CPD000466307 Triptolide 103 20 
  CPD000469170 Rosiglitazone 88 19 
  CPD000059106 Tegafur 79 13 
  CPD000466392 Oligomycin 15 7 
  CPD000469199 Benazepril 93 16 
  CPD000058877 Oxymetholone 41 15 
  CPD000059060 Ipriflavone 75 16 
  CPD000058286 Oxaprozin 74 16 
  CPD000058510 Rolipram 92 31 
  CPD000469200 Mosapride 75 28 
  CPD000466391 Isoquercitrin 93 25 
  CPD000058450 Flumazenil 107 10 
  CPD000469164 Ozagrel 127 32 
  CPD000466394 Hyperoside 123 26 
  CPD000466322 Rifabutin 27 20 
  CPD000469141 Esmolol 72 21 
  CPD000466321 Tadalafil 22 14 
  CPD000058957 Modafinil 31 20 
  CPD000058570 Doxorubicin 18 16 
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CPD000469209 Moxonidine 74 58 
  CPD000058302 Nitrazepam 48 40 
  CPD000387024 Pefloxacin 105 88 
  CPD000469154 Venlafaxine 77 44 
  CPD000469592 Pantoprazole 49 50 
  CPD000058366 Nitrendipine 8 4 73 10 
CPD000469290 Saquinavir 11 7 
  CPD000058970 Bifonazole 12 10 
  CPD000469158 Sumatriptan 47 16 
  CPD000466314 Exemestane 31 5 
  CPD000466367 Nitazoxanide 6 4 16 13 
CPD000058398 Diazepam 25 15 
  CPD000471623 Quetiapine 25 13 
  CPD000112560 Rutin 63 18 
  CPD000466317 Penciclovir 60 11 
  CPD000466393 Calcitriol 18 11 
  CPD000469140 Diphenoxylate 76 39 
  CPD000449307 Felbamate 73 26 
  CPD000058855 Droperidol 9 7 62 10 
CPD000035998 Pentoxifylline 79 17 
  CPD000058461 Ketorolac 45 21 
  CPD000466395 Ritonavir 32 7 
  CPD000469210 Vinorelbine tartrate 5 3 22 9 
CPD000466335 Linezolid 56 41 
  CPD000469203 Lomerizine 38 11 
  CPD000466351 Efavirenz 2 2 20 8 
CPD000466306 Irbesartan 55 34 
  CPD000466305 Repaglinide 64 14 
  CPD000238204 Ethylestrenol 6 7 46 9 
CPD000440694 Pterostilbene 5 9 30 10 
CPD000469144 Roxatidine 88 37 
  CPD000471616 Dexbrompheniramine 37 62 
  CPD000469168 Anagrelide 47 32 
  CPD000471618 Tegaserod 4 5 10 4 
CPD000058475 Milrinone 78 21 
  CPD000466315 Levocetirizine 83 16 
  CPD000326936 Citalopram 27 11 
  CPD000048468 Ticlopidine 18 9 
  CPD000469165 Sodium loxoprofen 92 18 
  CPD000466316 Zafirlukast 23 13 
  CPD000469152 Terbinafine 45 26 
  CPD000466320 Isradipine 23 18 
  CPD000466318 Valsartan 91 17 
  CPD000449291 Piroxicam 76 23 
  CPD000469282 Glycopyrrolate 94 19 
  CPD000449286 Physostigmine 62 20 
  CPD000058465 Lobeline 40 30 
  CPD000058436 Doxylamine 52 10 
  CPD000449266 Milnacipran 75 26 
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CPD000449315 Fluoro pyrimidone 80 24 
  CPD000466271 Chlorpheniramine 24 10 
  CPD000466333 Dofetilide 110 38 
  CPD000471620 Formoterol 71 9 
  CPD000525252 Rizatriptan 95 20 
  CPD000466332 Rifapentine 10 6 35 8 
CPD000469178 Loteprednol 97 21 
  CPD000466359 Enalaprilat 107 15 
  CPD000449292 Donepezil 5 4 57 5 
CPD000238177 Nimetazepan 79 15 
  CPD000466365 Nicorandil 156 39 
  CPD000466326 Telmisartan 61 7 
  CPD000469143 Itopride 50 21 
  CPD000466324 Rifaximin 13 15 
  CPD000469188 Montelukast 8 5 85 21 
CPD000058253 Didezoxycytidine 45 8 
  CPD000466276 Imidazol amine 51 27 
  CPD000466280 Pyridobenzodiazepin 45 40 
  CPD000466278 Indole propanoic acid 12 7 
  CPD000466277 Imidazol carboxylic 37 11 
  CPD000466281 Acetamide 66 49 
  CPD000466283 Altanserin 42 10 
  CPD000058420 Betaxolol 67 31 
  CPD000466311 Indirubine 78 32 
  CPD000466285 Azasetron 52 9 
  CPD000466287 Gr 89696 54 15 
  CPD000058773 Delta hydrocortisone 83 13 
  CPD000058392 Diazoxide 65 14 
  CPD000058612 Chloroadenosine 80 25 
  CPD000058726 Ornidazole 91 21 
  CPD000058572 Dimethyl phenylpiperzai 108 26 
  CPD000058507 Pienperone 29 8 
  CPD000059128 Mestramol 68 26 
  CPD000059100 Aminoethyl pyridine 87 27 
  CPD000059142 Benactyzine 125 14 
  CPD000059158 Dichloroacetic acid 97 18 
  CPD000059165 Bestatin 75 16 
  CPD000469213 Toreminfene 19 1 
  CPD000469214 Goserelin 38 13 
  CPD000469212 Secoisolarciciresinol 66 11 
  CPD000469217 Raltitrexed 90 25 
  CPD000469229 Doxapram 79 25 
  CPD000466294 Serotinen agonist 48 4 
  CPD000112281 Brucine 68 8 
  CPD000059115 Tryptoline 37 8 
  CPD000058411 Fluphenazine 5 4 26 8 
CPD000469233 Palonosetron 18 5 
  CPD000058746 Naproxen 96 20 
  CPD000058904 Mepivacaine 105 14 
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CPD000058310 Dibromohydroxybenz 29 31 
  CPD000058300 Nimodipine 21 5 
  CPD000058701 Rolitetracycline 60 8 
  CPD000058715 Epirizole 63 9 
  CPD000058273 Azauridine 72 8 
  CPD000466922 Reichsteins  53 17 
  CPD000059086 Pyridinemethanol 93 12 
  CPD000449283 Haloperidol 6 1 20 3 
CPD000449279 Stiripentol 62 14 
  CPD000449303 Fluperlapine 41 10 
  CPD000058660 Oxyphenomium 57 10 
  CPD000112358 Homoveratrylamine 90 10 
  CPD000058194 Tinidalzole 104 27 
  CPD000058741 Xanthinol 121 32 
  CPD000059111 Synephrine 116 36 
  CPD000058206 Resveratrol 56 10 
  CPD000059093 Malrol 71 10 
  CPD000059077 Aminoimidazole 52 6 
  CPD000059011 Enrofloxacin 61 12 
  CPD000058603 Dehydrocholic acid 72 23 
  CPD000058250 Cefaclor 88 14 
  CPD000059044 Benzylimidazole 90 20 
  CPD000469136 Duloxetine hcl 6 2 10 4 
CPD000469155 Vardenafil 90 15 
  CPD000469137 Ropivacaine 84 14 
  CPD000466301 Anastrozole 97 15 
  CPD000058462 Ketotifen 70 8 
  CPD000058769 Medroxy progesterone 94 14 
  CPD000466919 Pinacidil 124 10 
  CPD000058266 Nitro indazole 66 17 
  CPD000112269 Methoxytryptamine 67 17 
  CPD000059045 Phenothiazine 18 4 
  CPD000058553 Cladribine 81 11 
  CPD000469138 Granisetron HCl 45 8 
  CPD000466293 Rimcazole 13 10 
  CPD000466292 Nafadoride 11 6 
  CPD000058856 Desoximetasone 62 18 
  CPD000471617 Dexchlorpheniramine 58 13 
  CPD000466288 Guanidine 104 17 
  CPD000466290 Cpd000466290 18 7 
  CPD000466284 Cpd000466284 93 25 
  CPD000466289 HTMT 98 35 
  CPD000466286 Benzo phenanthridine 53 27 
  CPD000466291 Methanesulfonamide 66 15 
  CPD000466279 2H-indol-2-one 66 9 
  CPD000466920 Beclosmethasone 64 17 
  CPD000058847 Omeprazole 56 17 
  CPD000469228 Dolastron 49 16 
  CPD000449310 Zolmitriptan 68 23 
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CPD000469223 Tremaulacin 72 33 
  CPD000469227 Dactinomycine 42 12 
  CPD000449308 Tramadol 69 24 
  CPD000469226 Chlordiazeposide 66 25 
  CPD000469225 Cefixime 101 20 
  CPD000469224 Cefdinir 95 22 
  CPD000469232 Lofexidine 67 24 
  CPD000469221 Balsalazide 84 10 
  CPD000469220 Olopatadine 27 20 
  CPD000469287 Itavastatin 57 31 
  CPD000058334 Cortisone 61 35 
  CPD000058431 Cyproheptadine 28 27 
  CPD000469230 Homoharringonine 46 10 
  CPD000058318 Corticosterone 65 39 
  CPD000471625 Vecuronium 44 28 
  CPD000469219 Itibolone 58 37 
  CPD000058212 Niacinamide 102 46 
  CPD000059131 Nialamide 100 46 
  CPD000469153 Vindesine 45 9 
  CPD000058540 Vincristine 68 21 
  CPD000466342 Lacidipine 90 18 
  CPD000466347 Mirtazapine 58 10 
  CPD000469285 Ampiroxicam 78 4 
  CPD000466368 Glimepiride 85 23 
  CPD000469198 Amlodipine 12 2 
  CPD000469174 Rabeprazole 51 13 
  CPD000058704 Clofazimine 87 14 
  CPD000469166 Irinotecan 76 17 
  CPD000058469 Lansoprazole 71 13 
  CPD000149358 Chloro piperidin ylideen 24 9 
  CPD000058772 Premarine 96 30 
  CPD000058481 Mifepristaone 111 23 
  CPD000112002 Etoposide 79 6 
  CPD000238156 Sibutramine 81 16 
  CPD000469632 Clobenpropit 64 15 
  CPD000469231 Huperzine 81 9 
  CPD000472527 Sibutraminde 79 16 
  CPD000058410 Lorazepam 71 25 
  CPD000469633 Azaspiro decane dione 72 12 
  CPD000469631 Adenosine 82 13 
  CPD000058296 Amiodarone 84 11 
  CPD000336944 Mevastatine 80 8 
  CPD000469175 Imatinib 45 10 
  CPD000468736 Methylperon 65 12 
  CPD000469594 Parecoxib 82 7 
  CPD000058504 Pergolide 106 8 
  CPD000471626 Atracurium 70 15 
  CPD000469218 Artemether 95 15 
  CPD000058445 Ebselen 64 18 
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CPD000468733 12066b 14 10 
  CPD000469222 Teletromycine 72 10 
  CPD000468732 CCPA 97 24 
  CPD000468734 Methanone 83 22 
  CPD000058878 Stanzolol 99 14 
  CPD000238180 Zaleplon 73 9 
  CPD000112594 Prostaglandin 87 6 
  CPD000058344 Testosteron 78 18 
  CPD000059075 Dehydroepiandrosterone 79 6 
  CPD000466297 Sdm25n 34 5 
  CPD000466299 Dup 697 112 17 
  CPD000466300 Nonyloxytryptamine 14 6 
  CPD000466295 Salmeterol 37 6 
  CPD000466296 Sb 67 14 
  CPD000326935 R sch 23390 71 25 
  CPD000058230 Doxepin 2 1 39 7 
CPD000058382 Dipyridamole 36 12 
  CPD000059151 Propofol 38 5 
  CPD000058600 Ethacrynic acid 20 13 
  CPD000058187 Flutamide 6 2 36 6 
CPD000058299 Fenofibrate 50 35 
  CPD000058202 Furosemide 33 9 
  CPD000038082 Fluorouracil 33 14 
  CPD000471860 Folic acid 50 16 
  CPD000653523 Hydrocortisone 42 12 
  CPD000653536 Cortell 45 5 
  CPD000058184 Ibuprofen 55 20 
  CPD000040181 Ketoprofen 52 13 
  CPD001906766 Minocycline 32 3 
  CPD000058733 Miconazole 1 1 49 11 
CPD000059134 Metyrapone 50 16 
  CPD001317860 Pyrogluatmic acid 82 35 
  CPD000058975 Nadolol 68 25 
  CPD000058999 Disipal 17 15 
  CPD000058192 Ofloxacin 87 47 
  CPD000059120 Pindolol 60 27 
  CPD000037139 Praziquantel 40 21 
  CPD000059104 Phenylbutyric acid 87 57 
  CPD000058326 Prednisolone 61 19 
  CPD000058379 Promethazine 4 8 30 10 
CPD000058180 Perphenazine 3 3 46 8 
CPD000718761 Prednisolone 58 20 
  CPD000058506 Prilocaine 104 19 
  CPD001227202 Prednisone 65 27 
  CPD000059161 Dl penicillamine 88 28 
  CPD000058579 Piperacilline 76 25 
  CPD000857275 Quinidine 28 5 
  CPD000653467 Ranitidine 47 19 
  CPD001906767 Rifampicine 17 3 
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CPD000058245 Trans retinoic 23 11 
  CPD000471892 Spironolactone 34 13 
  CPD000035999 Trimethoprim 90 25 
  CPD000058219 Tyzine 91 13 
  CPD000059176 Thyroxine 56 13 
  CPD000058515 Trihexyphenidyl 20 9 
  CPD000058403 Ursodeoxycholic 97 23 
  CPD000059064 Dapsone 105 26 
  CPD001370746 Symmertrel 58 15 
  CPD000058849 Warfarin 74 7 
  CPD000058394 Acetazolamide 78 21 
  CPD000059083 Allopurinol 67 11 
  CPD001906768 Atropine 76 17 
  CPD000058264 Nalicixic acid 57 21 
  CPD001567029 Triiodothyronine 21 6 
  CPD000058284 Hydroflumethiazide 79 18 
  CPD000058368 Amitryptiline 0 0 22 4 
CPD000058613 Busulfan 71 22 
  CPD000058269 Chlorzoxazone 84 19 
  CPD000058429 Chlorothiazide 91 27 
  CPD001370748 Cimetidine 107 30 
  CPD000058433 Carisoprodol 103 42 
  CPD000058364 Chlorpropamide 104 24 
  CPD000058440 Bentyl 24 14 
  CPD000312779 Chloroxine 5 6 44 11 
CPD000058723 Diflunisal 63 15 
  CPD001370749 Econazole 1 1 21 5 
CPD001370750 Ethionamide 39 24 
  CPD000058719 Methocarbamol 68 22 
  CPD000035778 Hydrochlorothiazide 70 22 
  CPD001370751 Vistaril 25 3 
  CPD000058356 Hexachlorophene 0 1 5 6 
CPD000059082 Isoniazid 73 26 
  CPD000058729 Duvadilan 111 47 
  CPD000058267 Isoproterenol 89 30 
  CPD000471847 Triclosan 3 3 1 1 
CPD000058188 Mefenamic acid 60 32 
  CPD000058832 Cantil 72 13 
  CPD000058471 Metoclopramide 57 23 
  CPD001370753 Methyldopa 55 22 
  CPD000058271 Nitrofurantoin 52 24 
  CPD000058486 Nortriptyline 2 3 21 3 
CPD000058292 Naphazoline 28 6 
  CPD000059024 Nicotinic 50 20 
  CPD000058817 Norflex 16 10 
  CPD001614498 Oxytetracycline 39 13 
  CPD000718771 Procaine 97 38 
  CPD000058714 Pyrimethamine 54 20 
  CPD000058661 Pro banthine 39 11 
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CPD000058280 Probenecid 100 96 
  CPD001906769 Pyridine 2 aldoxime 117 39 
  CPD000058501 Primidone 59 38 
  CPD000058275 Propylthiouracil 48 11 
  CPD000036662 Pyrazinamide 72 20 
  CPD000059079 Probesyl 81 54 
  CPD000037657 Sulfisoaxole 76 48 
  CPD000058223 Sulfamethoxaole 113 61 
  CPD000058173 Sulfacetamide 153 78 
  CPD000058991 Sulfinpyrzone 118 45 
  CPD000326718 Sulindac 121 52 
  CPD001906770 Tetracycline 53 32 
  CPD000058537 Theophylline 97 62 
  CPD000058363 Tolbutamide 58 12 
  CPD000059118 Triamteren 44 11 
  CPD000059081 Intropin 65 31 
  CPD000058416 Amoxapine 5 6 34 5 
CPD000471872 Adenine 65 14 
  CPD000036768 Atenolol 68 34 
  CPD001491671 Tamoxifen 4 9 69 10 
CPD000058418 Bumetanide 57 17 
  CPD000058745 Clobetasol 44 9 
  CPD000058254 Chlorpromazine 2 4 22 10 
CPD001491644 Cefazoline sodium 75 18 
  CPD000059061 Captopril 141 41 
  CPD000058372 Chlorambucil 136 39 
  CPD000058809 Cefoxitin 76 43 
  CPD000058321 Danazol 96 32 
  CPD000058375 Diltiazem 52 12 
  CPD001906774 Digoxin 170 37 
  CPD000058346 17- beta estradiol 54 27 
  CPD000058672 Edroponium 86 15 
  CPD000058329 Fluocinolone acetonide 67 14 
  CPD000042823 Flurbiprofen 101 17 
  CPD000058455 Glipizide 111 28 
  CPD000058393 Gemfibrozil 127 45 
  CPD000058229 Glyburide 99 21 
  CPD000058328 Hydrocortisone 146 43 
  CPD000058829 Indapamide 178 47 
  CPD001906775 Ipratropium bromide 135 54 
  CPD000058388 Imipramine 4 6 36 7 
CPD000058463 Labetalol 117 32 
  CPD000058466 Loperamide 2 4 36 6 
CPD000058833 Pro amatine 103 34 
  CPD000653524 Medroxyprogesterone acetate 18 12 
  CPD001906776 19-norethindrone acetate 24 12 
  CPD000499579 19-norethindrone 76 19 
  CPD000059074 Nicotine 99 27 
  CPD001456372 Cardene 27 11 
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CPD000058835 Nabmetone 99 3 
  CPD000058490 Oxybutynin 8 9 44 9 
CPD000058605 Mestinon 99 16 
  CPD001453705 Rythmol 12 4 
  CPD001491654 Pfizerpen 68 26 
  CPD000499581 Valproice acid 75 34 
  CPD000058821 Procyclidine 6 7 48 20 
CPD000875264 Proxymetacaine 43 17 
  CPD000058766 Naloxone 66 34 
  CPD001906777 Spectinomycin 52 18 
  CPD000058523 Tropicamide 65 26 
  CPD000058290 Tolazamide 94 58 
  CPD000058335 Triamcinolone acetonide 49 12 
  CPD001456519 S-timolol 67 17 
  CPD000058170 Thiabendazole 63 18 
  CPD000058380 Thioridazine 0 1 18 3 
CPD000058181 Altretamine 60 21 
  CPD001491672 Phylloquinone 84 15 
  CPD001491659 Eryped 204 131 
  CPD000058422 Dibenzyline 12 11 
  CPD000058693 Medrysone 38 26 
  CPD000058524 Thalidomide 80 67 
  CPD000857229 Aminolevulinec 74 44 
  CPD001496929 Carbinoxamine 51 45 
  CPD001496930 Demeclocycline 57 29 
  CPD001496932 Westcort 54 28 
  CPD000449328 Selegiline 62 23 
  CPD000058840 Nafcillin sodium 56 20 
  CPD000875314 Primaquine 7 5 29 2 
CPD001496934 Micropenin 94 15 
  CPD001550033 Doxycycline 43 20 
  CPD001233361 Beclomethasone 50 13 
  CPD000058721 Cromolyn 94 11 
  CPD000149600 Priscoline 43 16 
  CPD000544948 Mercaptopurine 90 18 
  CPD000427366 Azathioprine 98 40 
  CPD000036735 Albendazole 88 25 
  CPD000718755 Griseofulvin 69 26 
  CPD000059006 Lincomycine 88 39 
  CPD001496938 Methazolamide 107 43 
  CPD001496939 Terbutaline 83 44 
  CPD000471888 Mypirocin 122 70 
  CPD000058331 Fluocinonide 64 10 
  CPD000875233 Mefloquine hcl 4 4 11 8 
CPD001496941 Floxuridine 79 14 
  CPD001563707 Mitoxantrone 8 5 31 4 
CPD001906784 Enalapril maleate 100 30 
  CPD000058337 Budesonide 23 5 
  CPD000466386 Ramipril 77 25 
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CPD000718757 Depo medrol 63 29 
  CPD000058383 Norepinephrine 92 22 
  CPD001491664 Amcinonide 57 19 
  CPD001317855 Clomid 13 12 
  CPD001819784 Phentolamine HCl 53 9 
  CPD000058874 Fludarabine 90 37 
  CPD000109709 Testosterone 133 61 
  CPD000471891 Isotretinoin 38 10 
  CPD000058376 Methimazole 58 15 
  CPD000596519 Zonisamide 67 15 
  CPD000058355 Brimondidine 187 350 
  CPD000036734 Mebendazole 52 16 
  CPD000058736 Meclizine 29 13 
  CPD000146393 Dilantin 55 22 
  CPD000059182 Miochol 75 14 
  CPD000326766 Dantrolene sodium 54 15 
  CPD001227192 Dexamethasone 68 24 
  CPD000394012 Benztropine mesylate 5 3 40 15 
CPD000058324 Ganciclovir 71 28 
  CPD000059219 Mesna 94 25 
  CPD000058785 Meclomen 53 9 
  CPD000471882 Fluconazole 82 11 
  CPD001453712 Metaproterenol 88 15 
  CPD000071170 Methoxsalen 83 36 
  CPD000058224 Chloramphenicol 96 32 
  CPD000499584 Tizanididne 75 16 
  CPD001453706 Paroxetine hcl 6 8 10 7 
CPD000550486 Mirtazapine 42 28 
  CPD000010931 Etomidate 71 20 
  CPD000499578 Moban 49 20 
  CPD001453708 Fluvastatin 43 17 
  CPD000058680 Urecholine 109 20 
  CPD001496804 Cefuroxime 76 19 
  CPD000718805 Cytoxan 125 13 
  CPD000550478 Eszopiclone 209 365 
  CPD000058802 Bendrofluazide 43 19 
  CPD000058508 Raloxifen 13 4 
  CPD000058351 Zidovudine 49 13 
  CPD000058365 Clozapine 6 5 56 15 
CPD001317850 Amicillin 62 7 
  CPD000058800 Acebutol 59 20 
  CPD000058707 Amoxicilline 46 17 
  CPD000857209 Epinephrine 50 16 
  CPD000857239 Azacytidine 51 10 
  CPD000058186 Buspar 122 250 
  CPD000436311 Rimantadine 29 10 
  CPD000059121 Podofilox 60 14 
  CPD000058313 D cycloserine 92 30 
  CPD000059124 Cortisone 50 10 
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CPD000058295 Clomipramine 5 4 22 6 
CPD001227191 Carbamazepine 76 15 
  CPD000875213 Memantine 35 10 
  CPD000036827 Desipramine 6 4 28 7 
CPD000326711 Mexiletine 62 19 
  CPD000058438 Disopyramide 65 14 
  CPD000673569 Stavudine 63 10 
  CPD000097306 Doxazosin 21 14 
  CPD000058963 Minoxidil 73 6 
  CPD000059167 Propranolol 10 6 68 6 
CPD001496943 Ribavirin 38 7 
  CPD000058309 Terazosin 72 25 
  CPD000058635 Chlorthalidone 54 38 
  CPD000058330 Methylprednisolone 46 21 
  CPD001496977 Phenelzine 67 13 
  CPD000058767 Naltrexone 51 31 
  CPD000469282 Glycopyrrolate 42 3 
  CPD000046147 Ethambutol 109 28 
  CPD001453715 Cetirizine 66 30 
  CPD000539527 Dicloxacillin 67 13 
  CPD000718800 Meloxicam 125 15 
  CPD001906781 Daunorubicin 8 5 32 10 
CPD001906779 Rifapentine 37 15 
  CPD000274084 Penicillin 73 31 
  CPD000043336 Gatifloxacin 94 38 
  CPD000550475 Clopidogrel 56 20 
  CPD001551784 Cefotaxime 109 71 
  CPD000466319 Lamivudine 113 45 
  CPD001307702 Ondansetron 66 12 
  CPD000339803 Betamethasone 83 30 
  CPD000550473 Celecoxib 95 54 
  CPD000058778 Aminomethylbenzenesulf 90 19 
  CPD001906782 Thiothixene 5 6 75 18 
CPD000465669 Citalopram 44 15 
  CPD000471864 Azithromycin 63 24 
  CPD000673570 Lovastatin 85 28 
  CPD000326785 Aminoglutetimide 129 59 
  CPD000058452 Fluoxetine 1 1 17 9 
CPD001233272 Flunisolide 73 18 
  CPD000058225 Acyclovir 61 21 
  CPD000058443 Etodolac 48 8 
  CPD000718785 Simvastatin 70 13 
  CPD001227203 Rifabutin 16 8 
  CPD001496951 Felodipine 15 7 
  CPD000499582 Quinapril 69 13 
  CPD000499573 Acitretin 18 3 
  CPD000718798 Fexofenadine 64 17 
  CPD001563899 Fluoromethadolone 89 18 
  CPD000466298 Sertraline 1 2 17 5 
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CPD001566944 Carbidopa 81 55 
   
Table S2. Overview of the hits identified after screening the NIH Clinical Collection 1&2 against biofilms of B. 
cenocepacia. Hits are classified according to their therapeutic indication. Compounds were tested at a 
concentration of 100 µM in the presence or absence of tobramycin (512 µg/ml). The values shown in the left 
column represent the mean residual metabolic activity of the compound in the presence of tobramycin compared 
to treatment with  tobramycin alone, and the standard deviation (SD). The values in the right column represent 
the mean residual metabolic activity of the compound compared to untreated contol, and the standard deviation. 
X means that the compounds did not cause a significant difference in fluorescence signal compared to the signal 
of untreated biofilms. SNRI: serotonin-norephinephrine reuptake inhibtor, SSRI: serotonin reputake inhibitor, 
TCA: tricyclic antidepressant, LTRA: leukotriene receptor antagonist.	  
	  
# PUBCHEM COMPOUND DESCRIPTION (function or structure) 
MEAN 
(%) SD 
MEAN 
(%) SD   
Anti-infective agents               
1 CPD000058356 Hexachlorophene Desinfectant 0 1 5 6  
2 CPD000471847 Triclosan Desinfectant 3 3 1 1  
3 CPD000058733 Miconazole nitrate Antifungal drug 1 1 48 11 x 
4 CPD001370749 Econazole nitrate Antifungal drug 1 1 21 5  
5 CPD000469293 Oxiconazole nitrate Antifungal drug 4 4 65 16 x 
6 CPD000058460 Ketoconazole Antifungal drug 6 6 73 9 x 
7 CPD000466351 Efavirenz Antiviral drug 2 2 20 8  
8 CPD000466367 Nitazoxanide Anti-protozoal drug 6 4 16 13  
9 CPD000875314 Primaquine phosphate Anti-protozoal drug 7 5 29 2  
10 CPD000875233 Mefloquine HCl Anti-protozoal drug 4 4 11 8  
11 CPD000312779 Chloroxine Anti-microbial drug 5 6 44 11  
Antipsychotics and antidepressants             
12 CPD000058411 Fluphenazine HCl Phenothiazine  5 4 26 8  
13 CPD000058180 Perphenazine Phenothiazine 3 3 46 8 x 
14 CPD000058380 Thioridazine HCl Phenothiazine 0 1 18 3  
15 CPD000059133 Trifluoperazine HCl Phenothiazine 3 4 20 7  
16 CPD000058254 Chlorpromazine HCl Phenothiazine 2 4 22 10  
17 CPD000058855 Droperidol Butyrophenone 9 7 62 10 x 
18 CPD000449283 Haloperidol HCl Butyrophenone 6 1 20 3  
19 CPD001906782 Thiothixene Thioxanthene 5 6 75 18 x 
20 CPD000058470 Loxapine succinate Dibenzoxazepine 2 5 43 6  
21 CPD000058365 Clozapine Dibenzoxazepine 6 5 56 15 x 
22 CPD000466362 Perospirone HCl Azopirones 7 4 49 10 x 
23 CPD000449282 Duloxetine SNRI 4 6 20 2  
 CPD000469136 Duloxetine HCL SNRI 6 2 10 4  
24 CPD000466298 Sertraline HCl SSRI 3 5 10 9  
25 CPD000469181 N-methylparoxetine SSRI 2 2 31 20  
 CPD001453706 Paroxetine HCl SSRI 6 8 10 7  
 CPD000466269 Paroxetine maleate SSRI 5 6 23 4  
26 CPD000058452 Fluoxetine HCl TCA 1 1 17 9  
27 CPD000058295 Clomipramine HCl TCA 5 4 22 6  
28 CPD000058388 Imipramine HCl TCA 4 6 36 7  
29 CPD000036827 Desipramine HCl TCA 6 4 28 7  
30 CPD000058486 Nortriptyline HCl TCA 2 3 21 3  
31 CPD000058368 Amitriptyline HCl TCA 0 0 22 4  
32 CPD000058416 Amoxapine TCA 5 6 34 5  
33 CPD000058230 Doxepin HCl TCA 2 1 39 7  
34 CPD000449297 Nefazodone HCl other 10 14 47 22  
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Anticancer therapy and/or hormonal therapy             
35 CPD001906781 Daunorubicin Anthracycline 8 5 32 10  
36 CPD000469210 Vinorelbine Antimitotic 5 3 22 9  
37 CPD001563707 Mitoxantrone Topoisomerase inhibitor 8 5 31 4  
38 CPD001491671 Tamoxifen SERM 4 9 69 10 x 
39 CPD000238204 Ethylestrenol Anabol steroid 6 7 46 9 x 
40 CPD000058187 Flutamide Antiandrogene 6 2 36 6  
Miscellaneous group               
41 CPD000469188 Montelukast sodium LTRA 8 5 85 21 x 
42 CPD000058379 Promethazine HCl Histamine antagonist 4 8 30 10  
43 CPD000469183 Azelastine HCl Histamine antagonist 6 7 36 3  
44 CPD000449274 AM404 Metabolite paracetamol 7 9 99 10 x 
45 CPD000466272 Pizotifen meleate Serotonine antagonist 7 5 51 9 x 
46 CPD000387107 Honokiol Neolignal biphenol 5 4 8 3  
47 CPD000469177 Atomoxetine HCl SNRI 5 6 8 3 x 
48 CPD000469294 Benproperine Cough agent 2 4 25 8  
49 CPD000058366 Nitrendipine Ca channel blocker 8 4 73 10 x 
50 CPD000440694 Pterostilbene Stilbenoid 5 9 30 10  
51 CPD000471618 Tegaserod maleate 5-HT 4 agonist 4 5 10 4  
52 CPD000449269 Bifemelane HCl Choligeric drug 6 2 23 9  
53 CPD000449292 Donepezil HCl Acetylcholinesterase inhibitor 5 4 57 5 x 
54 CPD000058466 Loperamide HCl Opioid receptor agonist  2 4 36 7  
55 CPD000058490 Oxybutynin chloride Anticholinergic 8 9 44 9  
56 CPD000058821 Procyclidine HCl Anticholinergic 6 7 48 20 x 
57 CPD000394012 Benztropine mesylate Anticholinergic, benzatropine 5 3 40 15  
58 CPD000469196 Tolterodine tartrate Antimuscarinic 8 6 62 8 x 
59 CPD000466346 Naftodipil α1-adrenergic R antagonist 5 6 24 5  
60 CPD000059167 Propranolol HCl Beta blocker 10 6 68 6 x 
	  
 
Figure S3. Lactate dehydrogenase (LDH) release assay of 3D A549 lung epithelial cells that were non-infected 
and infected with B. cenocepacia K56-2 for 17h. LDH release is presented as a percentage of a positive control 
(3D lung epithelial cells lysed with Triton-X100). Data shown are average, error bars indicate standard 
deviation. 
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Figure S4. Exposure of 3D A549 lung epithelial cells for 17h to 10, 50, 100 µM econazole (B, E, G); 10, 50, 100 
µM miconazole (C, F, H) or 1000 µg/mL tobramycin (D). A control condition where no antimicrobial agents 
were added is also included (A). High concentrations of the imidazoles resulted in detachment of host cells from 
microcarrier beads. Magnification is 300x. Scale bar is 400 µm. 
 
 
 
Figure S5. Preliminary data indicating that 10 µM econazole (E) or miconazole (M) in combination with ≥ 156 
µg/mL tobramycin causes an additional reduction in B. cenocepacia biofilm formation in MTP compared to 
treatment with tobramycin alone, n=1, error bars indicate standard error of the mean on the technical replicates. 
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Figure S6. G. mellonella was infected with B. cenocepacia LMG 16656 and treated with tobramycin (TOB), 
econazole (ECO), or the combination. CFU/larvae was determined 24 h p.i. and treatment. Lavae were 
homogenized and plated on selective Burkholderia medium. Data shown are average, n≥3, error bars indicate 
standard error of the mean. 
 
Figure S7. In order to evaluate the antimicrobial activity of a formulation for inhalation prior to use in the mouse 
lung infection model, biofilms of B. cenocepacia LMG 16656 were formed in 96-well MTPs and subsequently 
treated with the diluted (129x) formulation. This diluted formulation corresponds to vehicle (tween80 dissolved 
in PS), 512 µg/mL tobramycin (TOB), 200 µM miconazole (MICO) or the combination of tobramycin and 
miconazole. The asterisk indicates a significantly different number in log CFU/BF compared to treatment with 
tobramycin alone (P value < 0.05). Data shown are average, n≥3, error bars indicate standard error of the mean. 
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1. The continuous need for new antibacterial drugs 
 
Antibiotics are critical for our health as we need them to treat and prevent the spread of 
infectious diseases [9, 16, 271]. However, the use of antibiotics results in a selective pressure 
towards resistant bacteria [16]. Between 1930 and 1980, AMR was tackled by the 
introduction of new classes of antibiotics, but this is where the shoe pinches now. Although 
new antibiotic classes active against Gram-positive pathogens were introduced more recently, 
the last time a new class of antibiotics active against Gram-negative bacteria has been 
introduced to the market was in the 1960’s [13, 144] and new antibiotics active against both 
Gram-positive and Gram-negative bacteria are urgently needed.  
 
The screening of NP in empirical whole-cell screens resulted in the discovery of many 
important antibacterial classes in the fifties and sixties of the 20th century [135]. The 
antibiotics developed in this ‘golden era’ and their derivatives are still indispensable today 
[135]. Nevertheless, this once so successful approach was abandoned as the NP source failed 
to provide new antibiotics [154]. All hope was put on new techniques introduced in the 
nineties, i.e. genomics, HTS, SBDD, and combinatorial chemistry [153]. Huge libraries were 
screened in target-based assays, but not a single lead compound was developed into a 
marketed antibacterial compound so far [132, 135]. There are multiple reasons for this failure, 
for instance, screening against isolated targets instead of whole cells [160], and screening 
libraries that did not cover a broad chemical space [135, 144]. More recent screenings met 
these flaws and implemented the techniques in whole-cell assays [160]. For instance, whole 
cells of B. cenocepacia K56-2 were screened with the Canadian Chemical Biology Network 
Compound Collection. This collection covers an ample chemical space as it is built up out of 
several different libraries: 16,000 synthetic small molecules from the Custom Library, 9989 
synthetic small molecules from the DIVERSet Library, 1120 off-patent small molecules from 
the Prestwick Chemical Library, 361 NP from the BIOMOL Natural Products Library, 1214 
NP from the Spectrum Collection and 690 synthesized lactams, lactones and piperidines from 
the Dennis Hal Compounds library, in total 30,259 compounds [272]. 
 
2. Drug repurposing and repurposing libraries 
 
However, the development of new antibacterial drugs is extremely time-consuming, 
expensive and risky [189]. Moreover, the return on investment is relatively low for 
antibacterial therapies [147]. The use of existing drugs for the treatment of diseases for which 
they were not initially developed, is called drug repurposing [177]. Because toxicity and 
metabolic profiles of these drugs are very well characterized by clinical use, the costs and 
risks to develop and market these drugs is reduced [177]. Repurposing libraries are built out 
of approved drugs or drugs tested in clinical trials and are commercially available to enable 
HTS for the identification of repurposing candidates for a selected target/disease [182]. The 
screening of libraries containing drugs approved for non-bacteriological indications offers an 
alternative approach in antibiotic drug discovery [184]. Screening of these libraries resulted in 
Chapter IV: Broader international context, relevance, and future perspectives  
	  
	  
118 
the identification of several interesting repurposing candidates with confirmed in vivo effect 
to treat bacterial infections [183, 189, 198].  
 
In this dissertation, the NIHCC 1&2 repurposing libraries were used, which consist out of 727 
compounds that were tested in clinical trials and passed human safety assessment. Most of the 
compounds are approved and off-patent drugs currently in use [273]. The compounds are 
dissolved in dimethyl sulfoxide (DMSO) and distributed in 96-well MTPs [273]. However, is 
screening 727 compounds enough to represent the entire space of existing drugs? FDA 
registered over 100,000 drug products [178]. However, this huge number is misleading as 
several drug products are different formulations, brand names, salts or esters, from only one 
‘molecular entity’. Thus, this number can be reduced to 3936 approved molecular entities and 
4935 not approved molecular entities but used experimentally in humans worldwide, thus 
8969 drugs in total [178]. When drugs unsuitable for laboratory-based HTS are removed (e.g. 
molecules insoluble in DMSO or unstable molecules), 7631 ‘small molecule’ drugs remain 
[178]. So, the NIHCC 1&2 represents approx. 10% of all compounds that can be tested for 
repurposing purposes. The number of drugs in the NIHCC 1&2 is equal to the Screen-Well 
FDA-approved drug library V2 [274], and only slightly lower than the Prestwick Chemical 
Library which contains 1280 drugs (85% FDA approved) [182, 272], and the John Hopkins 
Clinical Compound Collection which contains 1600 compounds [275]. The NPC Screening 
Resource (NIH Chemical Genomics Center Pharmaceutical Collection) is one of the most 
comprehensive libraries, with 2400 approved drugs [182, 276]. The different therapeutic 
groups present in the NIHCC 1 are shown in Figure 1. Although a substantial number of 
drugs are anti-infective drugs and drugs used to treat diseases related to the central nervous 
system (CNS), the library covers all main therapeutic groups and thus possesses a high 
pharmacological heterogeneity.   
 
 
Figure 1. Pie chart representing the amount of drugs in each therapeutic group as contained in the NIHCC 1 
[273]. 
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In addition to the diversity of the library, also the quality is crucial in order to obtain reliable 
results upon screening, and we did encounter problems regarding the quality of the NIHCC 
1&2. For example, a hit compound in the screening against P. aeruginosa biofilms was 
annotated with the code CPD000058451 in the documents provided by Evotec. This code 
corresponds to flecainide acetate in the Pubchem database. However, flecainide acetate, 
purchased from Sigma, had no activity towards P. aeruginosa biofilms in combination with 
tobramycin. Analysis of the mass spectrum revealed that the compound provided in the 
library was not flecainide but chlorhexidine. This stresses the importance of confirming hits 
with independently obtained pure compounds [277]. Luckily, this is quite easy to do for 
compounds present in repurposing libraries, as all tested compounds are well characterized 
and readily available for further research. The suppliers of the NIHCC 1&2 noted other 
quality problems as well and recognized they should have controlled all the vender supplied 
material before including the products in their library. The NIHCC 1&2 we purchased in 2013 
is not available anymore but substituted by the NIH Clinical Collection which contains now 
719 compounds in which incorrect compounds were replaced with the correct compounds and 
about 26 compounds were dropped for various reasons (personal communication). 
 
3. The screening approach and the need for anti-biofilm 
therapies 
 
Beside the selection of the library, the model in which the library screen is performed is 
equally important. Ideally, the model resembles the host-environment closely, and allows 
HTS. The screening against purified enzyme targets allows HTS but hits identified often 
failed to overcome the impermeability of bacterial cells [144]. Whole-cell screening is thus a 
more valuable approach and several repurposing screenings for new antibacterial therapies 
have been performed in whole-cell growth-based assays [183, 189, 278]. Generally, these 
screenings are performed against planktonic bacterial cells under optimal growth conditions in 
nutrient rich cell culture medium (e.g. Mueller Hinton or Luria Bertani broth).  
 
For instance, Younis et al. screened the NIHCC 1&2 in a whole-cell assay against planktonic 
cells of various pathogens (Enterococcus faecium ATCC 700221, S. aureus USA300, 
Klebsiella pneumoniae ATCC BAA-1705, Acinetobacter baumannii ATCC BAA-1605, P. 
aeruginosa ATCC 15442, Enterobacter cloacae ATCC BAA-1143) [189], and Torres et al. 
screened the Prestwick Library against planktonic S. aureus TCH1516 [278]. Also Jacobs et 
al. screened the Prestwick Chemical Library for antimicrobial agents active against planktonic 
E. coli 8295 and the ESKAPE pathogens (E. faecium 824-05, S. aureus USA300, K. 
pneumoniae cKP1, A. baumannii 98-37-09, P. aeruginosa PAO1, and E. cloacae PMD1001) 
growing in Mueller Hinton broth [279]. In contrast to the screening performed by Younis et 
al. [189] or Torres et al. [278], in which the effect of the treatment was evaluated by 
measuring bacterial growth inhibition, Jacobs et al. developed an adenylate kinase assay 
which identified compounds that disrupt cellular integrity [279]. 
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However, bacteria growing in nutrient rich laboratory media do not resemble the in vivo 
situation and it is thus important to screen existing libraries in alternative conditions [214, 
280]. For example, Miller et al. performed a screening with the LOPAC library against M. 
smegmatis both in nutrient rich medium (Luria Bertani broth) and in carbon and nitrogen-
limited medium and identified different hits in both conditions [214].  
 
Also, bacteria can be non-growing and protected in biofilms in vivo. Biofilms contain micro-
organisms organized in an EPM, acting as a reservoir that is responsible for persisting 
infections and showing increased resistance and tolerance towards antibiotic treatment [70]. 
Since they are estimated to be responsible for 80% of infections, it is important that new drugs 
are also effective against bacteria residing in biofilms [70].  
 
Torres et al. selected 9 hit compounds from the initial screen against planktonic cells and 
tested their activity against biofilms of S. aureus [278]. Only three hit compounds were 
active: niclosamide, carmofur, and auranofin caused a reduction in CFU/BF of 1-2 log 
compared to untreated controls after 20 h [278]. Also Jacobs et al. evaluated the activity 
against biofilms of one hit compound identified in their primary screening against planktonic 
cells: the antihistamine drug terfenadine showed antimicrobial activity against planktonic S. 
aureus and its activity at 10xMIC was evaluated against biofilms formed by S. aureus 
UAMS1. This treatment resulted in a 2.7-fold increase in adenylate kinase release, 
corresponding to a 1.1-log reduction in biofilm cell viability [279].  
 
Colquhoun and colleagues performed a screening of the complete Selleck library (853 
approved drugs) against A. baumannii 98-37-09 growing in conventional laboratory medium 
(Mueller Hinton broth), but also in human serum, lung surfactant, and against biofilms [215]. 
They identified 90 compounds (73 antibiotics and 17 non-antibiotic drugs) with antimicrobial 
activity in at least one screening condition. Of the antibiotics identified, only four (rifampin, 
rifaximin, ciprofloxacin, and tetracycline) exhibited antibacterial activity in all conditions 
tested. From the 17 non-antibiotic drugs, four compounds (epirubicin, idarubicin, nebivolol 
and pyrimethamine) were identified as hits in the screening performed in MH, but they were 
not active in the other test conditions. Zink pyrithione was active both against cells in MH and 
against biofilms, while two other compounds, ciclopirox and ribavirin, were active in MH and 
lung surfactant. Doxorubicin was active against serum grown cells only, while eight drugs 
were active solely in the lung surfactant screen. The differences in screening conditions result 
in differences in bacterial physiology and this affects the organism’s susceptibility: the screen 
resulted in the identification of several compounds showing activity in one or more of the 
alternative test conditions without activity against A. baumannii grown in conventional 
medium [215]. These compounds would thus have been missed if the screening was 
performed solely in conventional growth medium, although they may be promising anti-
Acinetobacter drugs [215].  
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4. Combination therapy to treat biofilm infections 
 
Looking for repurposing compounds active against established biofilms in monotherapy 
might result in very low hit rates as exemplified by the screening by Colquhoun (one hit) 
[215] and Torres (three hits) [278]. The eradication of mature biofilms using antibiotic 
monotherapy is very difficult and requires high concentrations and long treatments, which is 
often clinically impossible due to toxicity [111, 281]. The combination of drugs with different 
modes of action might improve the success of anti-biofilm therapies [90, 201, 282].  
 
4.1. Combination of antibiotics to treat biofilm infections 
Several combinations of antibiotics were shown to better kill biofilms than antibiotic 
monotherapy as illustrated by the following examples. Neither moxifloxacin nor daptomycin 
were able to kill S. aureus biofilms in vitro, while the combination of moxifloxacin or 
daptomycin with clarithromycin resulted in a significant reduction of biofilm survival [281]. 
Similarly, combining linezolid and daptomycin resulted in greater effect compared to 
treatment with the respective antibiotics alone [281]. The combinations rifampicin and 
vancomycin, and rifampicin and linezolid were superior to vancomycin or linezolid 
monotherapy in a rat model of foreign-body osteomyelitis [281]. An in vitro evaluation of the 
activity of eight antibiotics against P. aeruginosa biofilms revealed synergistic activity only 
between tobramycin and clarithromycin, while no anti-biofilm activity was observed for the 
single antibiotics [283]. This synergy between tobramycin and clarithromycin was not 
observed in planktonic cultures, and this might be explained by the fact that clarithromycin 
enhances the penetration of tobramycin by inhibiting the alginate synthesis, among others 
[283]. Another study investigated the combination of tobramycin with colistin and found that 
the combination was superior to monotherapy in killing biofilms of P. aeruginosa in vitro 
[90]. In a rat lung infection model, treatment with the combination resulted in reduced 
mortality rates and lower CFUs recovered from the lungs compared to monotherapy [90].  
 
Clinically, combinations of antibiotics are used as well in an attempt to eradicate or control 
biofilms, for example in the treatment of prosthetic joint infections caused by S. aureus 
biofilms [281] or lung infections in CF patients caused by P. aeruginosa biofilms [90, 284]. 
The treatment in which nebulized tobramycin or colistin is combined with oral ciprofloxacin 
is successful to eradicate P. aeruginosa when the colonization is recent [284]. However, 
combination treatment fails to eradicate P. aeruginosa in chronically infected CF patients 
[284]. Also in the case of S. aureus biofilm infections, surgical removal of the nidus of 
infection is sometimes the only way to resolve the infection [202]. It is clear that conventional 
antimicrobial therapy, even when using combinations, often fails to eradicate infections 
caused by biofilms and that novel alternative strategies are urgently needed [285, 286].  
 
4.2. Helper compounds to improve antibacterial activity  
A strategy to restore or increase the antibacterial activity of antibiotics is the use of helper 
compounds [185], also called potentiators [246], adjuvants [247], or ‘antibiotic resistance 
breakers’ [13]. Reversal of antibiotic resistance by the helper compound can extend the 
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antimicrobial arsenal and increase the lifespan of existing antibiotics [187]. These helper 
compounds have no antimicrobial effect when administered alone, but they increase the 
activity of antibiotics in combination therapy [14].  
 
One very well-known example of this strategy is the successful combination of β-lactam 
antibiotics with β-lactamase inhibitors [13, 14]. The addition of clavulanic acid to amoxicillin 
allowed the continuous use of amoxicillin against pathogens that are amoxicillin resistant due 
to activity of certain β-lactamases. Without this combination, the use of amoxicillin would be 
limited, while Augmentin (the marketed combination) was the best-selling antibiotic in 2001 
[14].  
 
Nevertheless, the number of successfully used combinations is limited as there has not been a 
broad exploitation of this concept in the past [13]. However, the identification of helper 
compounds is currently an important topic of research [247]. For instance, numerous 
researchers have been investigating compounds for their ability to block the QS system [287]. 
QS regulates several important bacterial virulence factors (e.g. rhamnolipids and proteases) 
and QS inhibitors might attenuate bacterial virulence resulting in a facilitated eradication by 
the host immune system [287]. In addition, QS inhibitors increase the susceptibility of 
bacterial biofilms towards antibiotics [287]. QS inhibitors have been identified in natural 
sources, e.g. iberin (horseradish), ajoene (garlic [287]), or hamamelitannin (witch hazel) [288, 
289], but also synthetic compounds, like furanones [287], or off-patent non-antibiotic drugs, 
like the anthelmintic drug niclosamide [180] are described as QS inhibitors. Another example 
of a strategy that seems promising for restoring the activity of existing antibiotics is the use of 
helper compounds that inhibit efflux pumps [290]. Also here, existing drugs (i.e. reserpine, 
phenothiazines, calcium channel antagonists, SSRIs, and proton pump inhibitors) have been 
identified as efflux pump inhibitors [290]. Unfortunately, their use as helper compounds is 
often limited by the fact that they require concentrations too high to be clinically useful [290]. 
 
A so far under-investigated source of potentiators are drugs in use for non-bacteriological 
indications. For example, Ejim et al. screened 1057 previously approved drugs to identify 
potentiators of minocycline against planktonic P. aeruginosa PAO1, E. coli BW25113 and S. 
aureus ATCC 29213 [198]. This screening resulted in the identification of several hits, among 
them loperamide. Treatment with loperamide alone had no effect against P. aeruginosa, but 
combination with minocycline resulted in a synergistic interaction and similar effects were 
observed in other Gram-negative pathogens [198]. The in vivo efficacy was confirmed in a 
mouse model of infectious colitis caused by Salmonella enterica Typhimurium [198]. 
Treatment with loperamide or minocycline alone had no impact on the infection, while the 
combination caused a significant decrease in bacterial load in the cecum [198]. Loperamide is 
thus an attractive candidate to develop for clinical use in a combination therapy as it increases 
the susceptibility of microbes to an existing antimicrobial agent and thus enhancing the 
antibacterial activity 
 
Chapter IV: Broader international context, relevance, and future perspectives  
	  
	  
123 
4.3. Helper compounds to improve anti-biofilm activity 
The strategy of combining antibiotics with compounds that increase the susceptibility of 
biofilms has been investigated as well and several combinations with improved anti-biofilm 
activity have been described [95, 111]. For instance, DNase and alginate lyase enhance the 
penetration of aminoglycosides through P. aeruginosa biofilms resulting in a decreased 
biofilm growth and lower bacterial counts in CF sputum [286]. Similarly, the activity of 
antibiotics towards E. coli biofilms was improved in combination with a lipopeptide 
biosurfactant originating from Bacillus licheniformis [286]. Besides improving the penetration 
of antibiotics, also compounds that induce biofilm dispersion, inhibit efflux pumps or 
interfere with the QS system, might contribute to a better anti-biofilm activity of antibiotics 
[111, 286, 291]. For instance, garlic-treated P. aeruginosa biofilms were more susceptible 
towards tobramycin than control biofilms. This was also confirmed in a mouse pulmonary 
infection model, although a clinical trial in 26 CF patients failed to demonstrate a significant 
difference between patients receiving the garlic extract and placebo-treated patients [95, 109]. 
De Cremer et al. screened 1600 off-patent drugs for potentiator activity towards miconazole 
against biofilms of Candida albicans SC 5314. This resulted in the identifications of 8 hit 
compounds (hexachlorophene, pyrvinium pamoate, artesunate, broxyquinoline, 
dihydroartemisinin, gentian violet, bithionate disodium, and nitroxoline) [292]. Although 
several screenings of repurposing libraries against bacterial biofilms have been performed 
[215, 278], none of them screened against bacterial biofilms in the presence of an antibiotic 
for potentiators, like De Cremer et al. did against fungal biofilms. In this dissertation, we 
performed such a screening for the first time.  
 
5. Screening a repurposing library for combination 
therapy against bacterial biofilms  
 
The screenings in this dissertation were performed against three important pathogens: S. 
aureus, P. aeruginosa, and B. cenocepacia. The screening against B. cenocepacia and P. 
aeruginosa was performed in the presence of the antibiotic tobramycin. Tobramycin is 
commonly used to treat P. aeruginosa infections in CF patients, but it fails to eradicate P. 
aeruginosa in chronically infected patients (MIC P. aeruginosa PAO1: 1 µg/ml [293], 
concentration used: 2 µg/ml) [283]. B. cenocepacia is intrinsically resistant towards 
tobramycin (MIC B. cenocepacia LMG 16656: 256 µg/ml [294], concentration used: 512 
µg/ml). The screening against S. aureus biofilms was performed in combination with 
vancomycin, the drug of choice to treat MRSA infections. S. aureus Mu50 is intermediate 
resistant towards vancomycin (MIC: 8 µg/ml [295], concentration used 40 µg/ml). The 
concentration at which library compounds were used was 100 µM. 
 
Biofilms were formed in 96-well MTPs and treated after 24 h with the antibiotics and/or the 
library compounds (dissolved in physiological saline with 1% DMSO). The effect of the 
treatments after 24 h was evaluated with CTB staining. CTB is reduced by metabolically 
active cells into a fluorescent reaction product. Quantification of the fluorescence generated 
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gives an indication of the number of metabolically active cells present in the biofilm. This 
indirect quantification method is less labor intensive and time consuming than direct 
quantification by using plate counts [220]. For B. cenocepacia and S. aureus, the method as 
described by Peeters et al. was used [200]. In this method, CTB is diluted in physiological 
saline, added to the wells containing the treated biofilms, and the fluorescence signal 
generated is measured after 30 minutes incubation for S. aureus, and 1 h for B. cenocepacia. 
However, for P. aeruginosa, the fluorescence signals generated with this protocol were too 
low and variable. We optimized the protocol in order to overcome this problem and to allow 
us to use CTB for measurement of activity against P. aeruginosa biofilms as well. CTB was 
diluted in Mueller Hinton broth and the increase in fluorescence signal was followed over 
time till a threshold fluorescence signal of 100,000 was reached. The time necessary to reach 
this threshold correlates with the number of biofilm cells initially present [220].  
 
Hits in our screening were compounds that, in the case of S. aureus and B. cenocepacia, 
caused a decrease of at least 90% in fluorescence compared to the fluorescence generated by 
biofilms that were treated with antibiotic alone. For P. aeruginosa, compounds were 
considered as hits if the amount of CFU/biofilm was lower than 103 after combination 
treatment. The hit rate resulting from the screenings performed for this dissertation was 8.2%, 
1.7%, and 3.4% for potentiators of tobramycin or vancomycin against biofilms of B. 
cenocepacia, P. aeruginosa, and S. aureus, respectively. Although there are no data available 
for other screenings with a similar set up, we can compare this hit rate with that of other 
repurposing screens. A screening performed with the same library against planktonic S. 
aureus USA300 resulted in a hit rate of 3.3% (concentration used: 16 µM) [189], another 
repurposing screening in the presence of ½ MIC minocycline against planktonic S. aureus 
ATCC 29213, P. aeruginosa PAO1, and E. coli BW25113 resulted in hits rates of 15%, 4.5%, 
and 13% (concentration used: 10 µM) [198]. A screen of the Prestwick Chemical Library 
against planktonic S. aureus TCH1516 identified 104 compounds (hit rate: 8.1%, 
concentration used: 10 µM). A screen using the same library for compounds (tested at 20 µM) 
that inhibit biofilm formation of C. albicans SC5314 resulted in a hit rate of 3.25% [218]. 
Thus, the hit rate in our screening was comparable with these in other repurposing screenings. 
It should however be noted that we used higher concentrations compared to these other 
screenings, which might help explain the high hit rate in our screenings.  
 
The hit compounds we identified could be divided in several groups based on their therapeutic 
indication: anti-infective agents, anti-psychotics and antidepressants, anticancer drugs and/or 
hormone related drugs, and a miscellaneous group.  
 
5.1. Anti-infective agents 
The NIHCC 1&2 library contained 47 antibiotics belonging to different classes. Almost all 
hits identified in the screening against P. aeruginosa were antibiotics: seven fluoroquinolones, 
rifampicin, and doxycycline. This result contrasted to the results from the screening against S. 
aureus and B. cenocepacia, where not a single antibiotic was a hit for S. aureus, and only 
chloroxine was a hit for B. cenocepacia. For instance, in the screening against S. aureus 
biofilms, linezolid (100 µM, corresponding to 34 µg/ml) was not identified as a hit compound 
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in combination with vancomycin, as it only caused a reduction of 50% in CTB signal. 
However, S. aureus Mu50 is a linezolid susceptible strain, as the MIC is only 2 µg/ml [296]. 
This illustrates the high resistance encountered in mature biofilms towards conventional 
antibiotics in contrast to planktonic cells and supports our strategy to look for potentiators 
among drugs with non-bacteriological indications.  
 
Representatives of other antimicrobial drugs (antiseptics, antiviral, anthelmintic and 
antifungal drugs) present in the library were also identified as hits. Among them, four 
antifungal imidazole drugs, i.e. miconazole, ketoconazole, econazole and oxiconazole, 
showed a strong potentiating effect towards tobramycin against B. cenocepacia biofilms. 
Other azoles tested were not identified as hits. The antifungal imidazoles did not potentiate 
the activity of tobramycin against biofilms of P. aeruginosa. Against biofilms of S. aureus, 
ketoconazole was not effective, while the three other imidazoles mentioned above were 
identified as hit compounds. The activity observed against S. aureus probably originates in the 
intrinsic antibiotic activity of the antifungal imidazoles towards Gram-positive bacteria. The 
bactericidal effect of miconazole towards S. aureus is described by Sud and Feingold in which 
interference with the membrane results in leakage of K+ [190]. In addition, imidazoles bind S. 
aureus flavohemoglobin, a protein with NO dioxygenase activity, causing nitrosative and 
oxidative stress [224, 258]. Miconazole also binds flavohemoglobin of E. coli, and in vitro 
data showed that the combination of a NO-donor, miconazole and polymyxine B nonapeptide 
(to increase the intracellular miconazole concentration) were effective to treat four ESBL-
producing E. coli isolates [260]. However, to our knowledge, potentiating activity of 
antifungal imidazoles towards tobramycin against biofilms of B. cenocepacia had never been 
reported before.  
 
5.2. Antipsychotics and antidepressants 
The NIHCC 1&2 contains a large amount of drugs related to the central nervous system 
(Figure 1), and many of these drugs were amongst the hits identified in the screening against 
B. cenocepacia and S. aureus, but not against P. aeruginosa. Four phenothiazine 
antipsychotics and the antidepressant sertraline, a selective serotonin reuptake inhibitor 
(SSRI), were hits for S. aureus. These compounds were not identified as hit in the screening 
against planktonic S. aureus with the same library performed by Younis et al. [189], probably 
because they screened with lower concentrations (16 µM in contrast to 100 µM). A third of all 
hits identified against B. cenocepacia biofilms were antipsychotics and antidepressants, 
among them five antipsychotic phenothiazines. Although these drugs are not used to treat 
bacterial infections, their antimicrobial activity has been described extensively in literature 
[196, 225, 226, 297, 298]. Phenothiazines are known efflux pump inhibitors [32] and synergy 
with several antibiotics, especially β-lactams, has been observed in vitro [227, 297, 299, 300] 
and in vivo in C. elegans [231]. However, results obtained in mice are conflicting [228, 230] 
and no studies were found that describe any activity towards bacterial biofilms.  
 
Chapter IV: Broader international context, relevance, and future perspectives  
	  
	  
126 
5.3. Anticancer and hormonal therapy 
Several antineoplastic and hormonal drugs showed intrinsic activity towards established 
biofilms, or potentiator activity towards tobramycin or vancomycin against biofilms of B. 
cenocepacia, P. aeruginosa, and S. aureus. We did not pursue research on any of these hit 
compounds as, in our opinion, the compounds are too toxic to be repurposing candidates. 
However, other researchers did explore the potential of anticancer drugs identified in their 
screen with promising results. Younis et al. identified the anticancer drug 5-fluoro-2’-
deoxyuridine as a hit against planktonic MRSA [189]. Activity of the compound was 
confirmed in a septicemic MRSA mice infection model with concentrations of 5-fluoro-2’-
deoxyuridine much lower compared to concentrations therapeutically used for cancer 
treatment, and thus with reduced toxicity [189].  
 
5.4. Miscellaneous group 
Beside the antibiotics, the antiseptic hexachlorophene, and the anticancer drug bicalutamide, 
only one other drug was identified as a hit against biofilms of P. aeruginosa: L-pyroglutamic 
acid 7-amido-4-methylcoumarin. This compound is a strong potentiator of tobramycin, as the 
biofilms treated with this combination were not able to reach the threshold fluorescence signal 
of 100,000. The compound has also intrinsic activity towards P. aeruginosa biofilms. In 
contrast, the compound was not a hit in the screening against B. cenocepacia and S. aureus.  
 
Treatment with the antihistaminics azelastine and promethazine, in combination with 
tobramycin, decreased the fluorescence signal generated by B. cenocepacia biofilms 
significantly compared to treatment with tobramycin alone. Promethazine has a tricyclic 
structure and belongs to the phenothiazine family, so the mode of action might be in line with 
that from the antipsychotic phenothiazines. Azelastine was not identified as a hit in the screen 
against S. aureus and has thus no potentiating activity towards vancomycin against S. aureus 
biofilms. In contrast, azelastine has been described to potentiate β-lactams, macrolides, 
fluoroquinolones, aminoglycosides and tetracyclines against several planktonic S. aureus 
strains in vitro [197].  
 
Loperamide was identified as a hit in the screening against S. aureus, but not against B. 
cenocepacia and P. aeruginosa. Interestingly, loperamide was previously identified to 
potentiate the activity of minocycline against planktonic P. aeruginosa [198].  
 
Other hit compounds identified in our screenings have been described for antibacterial 
properties in literature: honokiol [235, 301] which was a hit for S. aureus and B. cenocepacia, 
MK-886 and 5-nonyloxytryptamine [189] which were hits for S. aureus, and tegaserod [198], 
propranolol [302], and pterostilbene [303] which were hits in B. cenocepacia. Four hits for S. 
aureus, and 13 for B. cenocepacia have, to our knowledge, never been reported for having an 
antibacterial effect.  
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6. Validation of selected hits in vitro 
 
We selected the antifungal imidazoles miconazole and econazole as promising repurposing 
candidates for B. cenocepacia. We rationalized that, if potent activity was observed in 
relevant in vivo models, the step to bring them to the market to treat another antimicrobial 
disease would be smaller, in comparison to drugs belonging to other therapeutic groups.  
 
The phenothiazine antipsychotics trifluoperazine, fluphenazine, perphenazine and thioridazine 
were selected for further tests in S. aureus. Potent in vitro activity of phenothiazines was 
observed in several studies [32, 195, 227, 297, 304], but in vivo data were not consistent [228, 
230, 231]. We selected these phenothiazine compounds because the activity towards biofilms 
had never been investigated in previous studies.  
 
No further tests were performed with P. aeruginosa because the only hit that was not an 
antibiotic, antiseptic or anti-cancer drug, L-pyroglutamic acid 7-amido-4-methylcoumarin, 
turned out not to be an approved drug. Probably, the compound passed safety assessments in a 
clinical trial, but it was not clear to the provider Evotec why the compound was included in 
the library (personal communication).  
 
The selected compounds were purchased and biofilms were treated with them to confirm the 
results from the screening by another quantification method, i.e. plate counts. Different 
concentrations were tested in combination with several antibiotics to identify other potentially 
promising combinations. The antifungal imidazoles miconazole and econazole did not have 
intrinsic activity against B. cenocepacia biofilms, however, they caused an additional 
decrease in CFU/BF in combination with tobramycin compared to treatment with tobramycin 
alone. This effect was not observed with ciprofloxacin or meropenem. Treatment with 100 
µM trifluoperazine or perphenazine did not affect formed S. aureus biofilms, while treatment 
with 50 and 100 µM thioridazine or 100 µM fluphenazine caused a significant decrease in 
CFU/BF compared to no treatment. Treatment with thioridazine caused no potentiating 
activity towards vancomycin, so the effect seen in the screening was due to the intrinsic 
activity of thioridazine alone. However, there was a potentiating activity towards tobramycin, 
flucloxacillin and linezolid as these combinations caused a significant reduction in CFU/BF 
compared to treatment with antibiotics alone. Thus, overall we were able to confirm the 
results observed in the screening against biofilms and were able to validate the hits in vitro. 
 
7. Validation of selected hits in other model systems  
 
The biofilms used to screen for potentiators of antibiotics were formed on the bottom of 96-
well MTPs, which is a closed biofilm model system that is often used [93]. However, this 
basic biofilm model differs a lot from the in vivo host environment [93]. It is thus necessary to 
confirm the potentiating activity of the selected hits in other, more relevant models as well. 
We evaluated the effect of miconazole and econazole with tobramycin in a three-dimensional 
(3D) organotypic human lung epithelial cell culture model, which is a more sophisticated in 
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vitro model that better mimics the in vivo situation [261]. We also used two in vivo models, 
i.e. the invertebrate Galleria mellonella infection assay and a mouse acute lung infection 
model. In addition, the potentiating activity of thioridazine towards tobramycin, flucloxacillin, 
and linezolid was evaluated in an in vitro model for chronic wound infections. However, in 
contrast to the activity observed in the general MTP model, the potentiating activity of our 
selected hit compounds could not be confirmed in any of these more sophisticated infection 
models. The reason for this failure is not clear, but probably host factors play an important 
role in deactivation of the compounds or in decreasing the susceptibility of the bacteria.  
 
8. Recommendations for future screenings 
 
8.1. Determination of the concentration to be used in the screening 
The screenings in this dissertation were performed with 100 µM of each library compound. 
This concentration is higher than concentrations used in other screenings described in 
literature (i.e. 16 µM [189], 10 µM [198, 278], 20 µM [218] and 50 µM [279]). One hundred 
µM is relatively high and surpasses the clinically achievable levels for several drugs. For most 
drugs, the therapeutic plasma concentration (Cp) is well below 100 µM [305] and 
concentrations above the Cp might be toxic. For example, the Cp for miconazole is approx. 
2.4 µM, which is well below the concentration used in our screening. Not surprisingly, we 
observed loss of integrity of the 3D organotypic human lung epithelial cells at 100 and 50 µM 
miconazole and econazole, indicating that the compounds are toxic at these concentrations. 
Similarly, severe toxicity was observed upon administration of miconazole to mice. Also in 
the case of thioridazine, 100 µM is well above the therapeutic Cp, which is between 0.02 and 
0.54 µM. Indeed, drugs in use for non-bacteriological indications with antibacterial effect 
often possess this effect only at concentrations too high to use clinically without toxicity 
problems [189]. For this reason, it is reasonable to screen in lower concentrations. However, 
screening at higher concentrations like we did has advantages as well. It is likely to identify 
more hits with a potential in topical formulations or for catheter lock therapy. Secondly, 
analogues of these hits might be evaluated for activity at lower concentrations. Also, a second 
screen with the hits identified can be performed at lower concentrations and further tests 
continued only with those hits (if any) active at sub-micromolar concentrations.  
 
8.2. Selection of the model system for screening  
We have evaluated the effect of the antifungal imidazoles and the antipsychotic 
phenothiazines in more relevant model systems. Unfortunately, we could not confirm 
antibacterial activity in these model systems. The failure of identifying hits with activity in 
more relevant models might be explained by the fact that we performed the screening in vitro, 
against biofilms formed on plastic in closed systems without the presence of host factors that 
bacteria usually encounter in vivo. Indeed, problems with host-free antimicrobial discovery 
efforts have been reported before, because both pathogens and tested compounds might 
behave differently in vitro and in a host [306]. Although the compound’s adsorption, 
distribution, metabolism, elimination, and toxicity are known for the compounds in our 
repurposing libraries, these factors are not taken into account in in vitro screenings [306]. In 
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order to meet some of these potential shortcomings, it might be valuable to perform future 
screenings in other model systems (Figure 2) that do include host factors and still enable HTS, 
e.g. in C. elegans [307-309] or in the presence of mammalian cells [184]. 
 
Figure 2. Different screening tools in drug discovery ordered according to their efficiency to perform HTS in one 
way and their relevance to humans in the other way [310].  
 
For instance, Andersson et al. screened 780 FDA-approved drugs (Screen-Well-FDA-
approved drug library V2) in an in vitro assay to asses RAW 264.7 murine macrophage 
viability following infection with Y. pestis CO92 [184]. Of the 94 non-antibiotic hits that 
prevented macrophage cytotoxicity during infections, 17 were tested in a murine model of 
pneumonic plague and trifluorperazine, doxapram, and amoxepine increased animal survival 
[184].  
 
In addition, several screenings using C. elegans as a platform for antibacterial drug discovery 
have recently been described [311-313]. C. elegans is a free-living nematode and HTS is 
feasible because C. elegans is relatively inexpensive to maintain, it is small (1 mm), has a 
rapid generation time, and there are no ethical issues with its use [311, 314]. In contrast to 
traditional in vitro screenings, antimicrobial drug screening in C. elegans enables the 
evaluation of toxicity of the test compound to the host and in vivo efficacy simultaneously 
[309, 311, 312]. C. elegans can be infected and killed by a wide range of important human 
pathogens, like P. aeruginosa, S. enterica, B. cenocepacia, E. faecalis, or S. aureus [221, 
309].  
 
Rajamuthiah et al. evaluated the activity of 640 FDA-approved drugs (Biomol 4 Library) in 
an automated C. elegans-MRSA infection assay [311]. This screen resulted in the 
identification of the anthelmintic drug closantel which prolonged the survival of C. elegans 
upon infection with S. aureus MW2 BAA-1707 [311]. Moy et al. screened approx. 37.000 
small molecules and NP in an automated C. elegans assay infected with E. faecalis MMH594 
[312]. Twenty-eight compounds without known antimicrobial activity increased survival of C. 
elegans [312]. Six of these compounds are thought to be virulence inhibitors or host immune 
enhancers as no significant inhibition of microbial growth in vitro was observed [312]. 
Indeed, in contrast to traditional in vitro screenings, whole animal screenings allow the 
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identification of compounds that target bacterial virulence or enhance immune defenses, 
mechanisms that are only manifested when the host/pathogen relationship is intact [311, 312]. 
However, although C. elegans is a powerful tool in drug discovery, it has some shortcomings 
as well and confirmation of activity in mammals remains essential [314, 315]. Because C. 
elegans, and other model invertebrates like Drosophila melanogaster, lack important parts of 
the human immune system (e.g. leukocytes, complement pathway, and adaptive immunity) 
[306], the use of vertebrate models like Danio rerio (zebrafish) is currently under 
investigation. D. rerio is more similar to humans and screens with zebrafish embryos and 
larvae can be conducted in microtiter plates [315]. Nevertheless, the equipment cost is higher 
compared to the costs to maintain C. elegans and D. melanogaster [315]. Recently, an 
optimized method to allow HTS in zebrafish against S. epidermidis and Mycobacterium 
marinum [316] has been published, although such screenings have not yet been reported.  
	  
8.3. Compound prioritization process 
Based on our experiences, some changes to the entire workflow would seem appropriate for 
future studies. While major changes to the primary screening do not seem necessary, the 
introduction of a second screening step could be valuable. In this second screening, lower 
concentrations of hit compounds could be tested, allowing a better selection of the most 
potent compounds to be included in further studies. Also, a secondary screening could have 
been performed with a broad selection of hits in more relevant in vitro infection models 
before starting in vivo studies. The antifungal imidazoles lost their potentiator effect in the 3D 
organotypic human lung epithelial cell culture model, and this was confirmed in two different 
in vivo models. It seems thus that the 3D model might be a valuable predictor for the in vivo 
activity. Thus, a secondary screen for the evaluation of the activity of a broad selection of hits 
in this model would possibly have allowed to eliminate hits that lost their potentiator activity 
in vivo.  
 
8.4. Valorization   
Since we were not able to confirm in vivo activity of the selected hit compounds, no 
immediate valorization resulted from this screening project. Nevertheless, several hits 
identified in our screening remain to be evaluated in more detail. However, even if further 
evaluation of our hit compounds would reveal potentiator activity in in vivo models, we are 
far from bringing these drugs to the market in the fight against resistant pathogens. Several 
issues will have to be addressed first, for instance, formulations for the combination therapy 
will have to be developed, drug-drug interactions will have to be evaluated, and the best drug 
ratios and dosing regimens will have to be determined for the combination therapies.  
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9. The future of drug repurposing for antibacterial 
treatments 
 
Is drug repurposing a good idea to find new antibacterial therapies? For sure it is a good idea 
to investigate the activity of known drugs for their antibacterial activity. There are positive 
results observed for several repurposing candidates in mice infection models [184, 189, 198]. 
Even if these compounds will never make it to the market, they can reveal interesting 
information. For instance, the drugs can be used as lead compound for development of 
analogues with increased activity at lower concentrations or the targets they work on can be 
identified and other compounds that bind more selectively to them might be developed or 
screened for. Of course, in this scenario, the assets of reduced risk, time and costs no longer 
apply. It should be clear that the search for antibacterial drugs is long and many obstacles are 
on the way, and this is not different in a repurposing approach. All things considered, all 
possible approaches to find new antibacterial agents are important, and one of them is drug 
repositioning. 
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Biofilms are communities of bacterial cells embedded in an extracellular matrix and attached 
to a surface. Treatment of biofilm-related infections is challenging because the cells within 
the biofilm are more resistant and tolerant towards antibiotic treatment compared to 
planktonic cells. In addition, the biofilm matrix protects the cells from host immune defenses, 
contributing to the persistence of biofilm-related infections. Biofilms are a growing problem 
in health care settings, but currently there are no anti-biofilm treatments available. The aim of 
this dissertation was to find compounds that enhance the activity of existing antibiotics 
against biofilms of three important bacterial pathogens: S. aureus, P. aeruginosa and B. 
cenocepacia.  
 
Compounds that enhance or restore the activity of antibiotics are called helper compounds or 
potentiators. In order to find these potentiators, we screened a library containing 727 off-
patent drugs in the presence of tobramycin or vancomycin against biofilms of P. aeruginosa, 
B. cenocepacia, or S. aureus. The use of drugs to treat diseases different than the initial 
indication they were developed for, is called drug repurposing. Drug repurposing has several 
advantages over de novo drug development, including reduced development time and cost. 
Multiple drugs used for non-bacteriological indications are known to possess antibacterial 
activity or to synergize with antibiotics. Several screenings have been performed with off-
patent drug libraries to evaluate (i) the antibacterial activity in monotherapy against 
planktonic cells, (ii) the antibacterial effect in monotherapy against biofilms, or (iii) the 
potentiator activity towards antibiotics against planktonic cells. However, a comprehensive 
screening with off-patent drug libraries to evaluate the potentiator activity towards antibiotics 
against bacterial biofilms has never been performed before.  
 
Before we initiated the screening project, we adjusted the existing protocol of the CTB-based 
viability staining. The non-fluorescent dye CTB is reduced by metabolically active cells to 
resorufin which is fluorescent. The amount of fluorescence generated is related to the number 
of viable cells present. In the original protocol, CTB is diluted in physiological saline, added 
to the biofilms, and the fluorescence generated is measured after 30 min to 2 h incubation. In 
our optimized protocol, we diluted CTB in fresh growth medium. Subsequently, after adding 
it to the biofilms, the increase in CTB-based fluorescence was followed over time and we 
determined the time needed to reach a specific value of fluorescence as well as the time to 
reach the maximum fluorescence. These time points correlate with the number of viable cells 
that were initially present. Using these alternative read-outs, we were able to extend the linear 
range from 106–108 to 103–108 CFU per biofilm, meaning that lower numbers of viable cells 
can be measured and the effect of anti-biofilm treatments can be quantified more accurately.  
 
Subsequently, we performed the screening against mature biofilms of P. aeruginosa, B. 
cenocepacia, or S. aureus. The biofilms were treated with 100 µM of the library compound in 
combination with 2 µg/ml tobramycin, 512 µg/ml tobramycin, or 40 µg/ml vancomycin, for 
P. aeruginosa, B. cenocepacia, or S. aureus respectively. After 24 h, the effect of the 
treatment was quantified using the optimized CTB protocol against the biofilms of P. 
aeruginosa, and the original CTB protocol against B. cenocepacia and S. aureus. The 
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screening resulted in the identification of 60 hits for B. cenocepacia, 25 hits for S. aureus and 
12 hits for P. aeruginosa.  
 
The antifungal imidazoles miconazole and econazole were among the hits identified against 
B. cenocepacia. We confirmed their potentiating effect towards tobramycin by plate counts: 
treatment with 10 - 100 µM miconazole or econazole did not cause a decrease in 
CFU/biofilm, however, in combination with tobramycin, the azoles caused a statistically 
significant decrease of 1.5 log  CFU/biofilm compared to treatment with tobramycin alone. 
Nevertheless, this in vitro biofilm model system does not resemble the in vivo conditions. For 
this reason, we evaluated the effect of the combination in other in vitro and in vivo model 
systems as well. We used the three-D organotypic human cell culture model, Galleria 
mellonella, and a mouse lung infection model. Unfortunately, the potentiating effect of the 
imidazoles towards tobramycin could not be confirmed in any of these models.  
 
The antipsychotic phenothiazines thioridazine, fluphenazine, perphenazine, and 
trifluoperazine were identified as hits against S. aureus. In contrast to fluphenazine, 
perphenazine, and trifluoperazine, thioridazine showed anti-biofilm activity in monotherapy: 
treatment with 100 - 50 µM thioridazine caused a significant reduction in CFU/biofilm 
compared to untreated biofilms. The potentiating effect of 100 µM thioridazine was evaluated 
against a broad panel of antibiotics. The combination of thioridazine with tobramycin, 
flucloxacillin, and linezolid resulted in an additional reduction in CFU/biofilm compared to 
treatment with the antibiotic alone. We used a chronic wound biofilm model to confirm the 
effect in a more relevant situation. However, despite the use of high concentration, biofilms 
formed in this model were not affected by treatment with thioridazine, the antibiotics, or the 
combination treatment.  
 
To summarize, the screening of a repurposing library in combination with antibiotics against 
bacterial biofilms resulted in the identification of several potentiators. We could confirm the 
activity of several selected hits against biofilms formed in 96-well MTPs by plate counts. 
Nevertheless, the selected hits lost their potentiator activity when evaluated in more 
sophisticated models containing host factors.  
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Biofilms zijn opgebouwd uit bacteriën omgeven door een zelfgeproduceerde extracellulaire 
matrix. Zij vormen zich zowel op biotische als op abiotische oppervlakken. De behandeling 
van biofilm-gerelateerde infecties is een uitdaging. Cellen die zich in de biofilm bevinden 
vertonen immers een verhoogde resistentie en tolerantie in vergelijking met planktonische 
(vrij levende) cellen. Bovendien beschermt de matrix de bacteriën in de biofilm tegen het 
immuunsysteem van de gastheer, wat ook bijdraagt aan de persistentie van biofilm-
gerelateerde infecties. Biofilms zijn een groeiend probleem, maar een specifieke behandeling 
tegen infecties ten gevolge van biofilms bestaat vooralsnog niet. De identificatie van 
componenten die de activiteit van bestaande antibiotica verhogen tegen biofilms was het doel 
van deze scriptie. Biofilms gevormd door drie belangrijke pathogenen, nl. S. aureus, P. 
aeruginosa en B. cenocepacia werden onderzocht.  
 
Componenten die de activiteit van antibiotica verhogen worden ook wel ‘potentiators’ 
genoemd. Om deze potentiators te identificeren werd een bibliotheek van 727 componenten 
gecreend, waarvan de meerderheid off patent-geneesmiddelen zijn. Deze screening tegen P. 
aeruginosa en B. cenocepacia werd uitgevoerd in de aanwezigheid van het antibioticum 
tobramycine. In het geval van de screening tegen S. aureus was dit vancomycine. Het gebruik 
van geneesmiddelen voor de behandeling van andere ziekten dan deze waartegen de 
geneesmiddelen ontwikkeld werden, wordt benoemd met de term ‘drug repurposing’. Drug 
repurposing heeft verschillende voordelen in vergelijking met de novo ontwikkeling van 
geneesmiddelen, bijvoorbeeld een verlaagde ontwikkelingskost en een verkorte 
ontwikkelingstijd. Van verschillende geneesmiddelen die gebruikt worden om ziekten van 
niet-bacteriële oorsprong te behandelen, is geweten dat ze ook anti-bacteriële activiteit 
bezitten of de activiteit van antibiotica versterken. Meerdere screenings werden reeds 
uitgevoerd met bibliotheken bestaande uit geneesmiddelen gebruikt in allerhande indicaties. 
Deze screenings evalueerden ofwel (i) de antibacteriële activiteit van deze geneesmiddelen in 
monotherapie tegen planktonische cellen, ofwel (ii) de antibacteriële activiteit in 
monotherapie tegen biofilms, ofwel (iii) de potentiator activiteit tegenover antibiotica tegen 
planktonische cellen. Echter, een uitgebreide screening met deze bibliotheken om potentiators 
te identificeren met activiteit specifiek tegen bacteriële biofilms werd nog niet eerder 
uitgevoerd. 
 
Vooraleer de screening werd aangevat, werd een bestaande quantificatiemethode 
geoptimaliseerd om het anti-biofilm effect van de behandelingen beter te evalueren. Deze 
quantificatiemethode is gebaseerd op een leefbaarheidskleuring, gebruik makend van 
CellTiter-Blue (CTB). CTB is een niet-fluorescente kleurstof die door metabool actieve cellen 
gereduceerd wordt, waardoor de fluorescente stof resorufin ontstaat. De hoeveelheid 
fluorescentie die gevormd wordt, hangt af van het aantal levende en metabool actieve cellen 
dat aanwezig is. In het originele protocol wordt CTB verdund in fysiologisch water, 
toegevoegd aan de biofilm. Vervolgens wordt de fluorescentie gemeten die ontstaat tijdens 
een 30 minuten tot 2 uur durende incubatie. In het aangepaste protocol wordt CTB verdund in 
vers groei medium. Daarna wordt het toegevoegd aan de biofilms en wordt de toename in 
CTB-gebaseerde fluorescentie gemeten gedurende een 18-tal uur. Vervolgens wordt de tijd 
bepaald die nodig was om een specifieke fluorescentie waarde (i.e. 100 000) of om de 
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maximum fluorescentiewaarde te bereiken. De tijd om deze waarden te bereiken is gerelateerd 
aan het aantal levende cellen dat initieel aanwezig was. Het lineair gebied van dit alternatief 
protocol is veel breder dan dat van het originele protocol (van 106–108 tot 103–108 kolonie-
vormende-eenheden per biofilm (KVE/BF)). Hierdoor kunnen lagere hoeveelheden leefbare 
cellen gemeten worden en kan het anti-biofilm effect van de behandelingen accurater 
geëvalueerd worden.  
 
Vervolgens werd de screening uitgevoerd tegen mature biofilms gevormd door P. aeruginosa, 
B. cenocepacia, en S. aureus. Deze biofilms werden behandeld met een component uit de 
bibliotheek in een concentratie van 100 µM, in combinatie met 2 µg/ml tobramycine in het 
geval van P. aeruginosa, van 512 µg/ml tobramycine in het geval van B. cenocepacia, of van 
40 µg/ml vancomycine in het geval van S. aureus. Na 24 uur werd vervolgens het effect van 
de behandeling bepaald door middel van CTB kleuring. In het geval van P. aeruginosa 
biofilms werd het geoptimaliseerde protocol gebruikt, terwijl het originele protocol gebruikt 
werd voor de kwantificatie van het behandelingseffect tegen biofilms van B. cenocepacia en 
S. aureus. Uiteindelijk werden 60 hits geïdentificeerd in de screening tegen B. cenocepacia, 
25 hits in de screening tegen biofilms van S. aureus en 12 hits in de screening tegen P. 
aeruginosa. 
 
De imidazoles miconazole en econazole, die als antifungale geneesmiddelen gebruikt worden, 
werden geïdentificeerd als hit in de screening tegen B. cenocepacia. Dat deze imidazoles 
effectief de activiteit van tobramycine versterkten kon bevestigd worden met een andere 
kwantificatietechniek, namelijk uitplaten. De behandeling met 10 -100 µM miconazole of 
econazole leidde niet tot een daling in KVE/BF. In combinatie met tobramcyine 
veroorzaakten de imidazoles evenwel een statistisch significante daling van 1,5 log KVE/BF 
in vergelijking met de behandeling met tobramycine alleen. Echter, het in vitro biofilm model 
waarin de biofilms werden gevormd, bootst niet de omstandigheden na die in vivo 
aangetroffen worden. Daarom werd het effect van de combinatie tobramycine-imidazoles ook 
geëvalueerd in andere in vitro en in vivo modelsystemen. Hiervoor werd een 3D 
organotypisch humaan celcultuur model gebruikt, alsook larven van de grote wasmot Galleria 
mellonella en muizen waarin een longinfectie werd geïnduceerd. Helaas kon het potentiërend 
effect van de imidazoles in deze modellen niet aangetoond worden.  
 
De fenothiazine antipsychotica thioridazine, fluphenazine, perphenazine en trifluoperazine 
werden als hits geïdentificeerd in de screening tegen S. aureus. In tegenstelling tot 
fluphenazine, perphenazine en trifluoperazine vertoonde thioridazine anti-biofilm activiteit op 
zichzelf: behandeling met 100 en 50 µM thioridazine resulteerde in een significante daling in 
KVE/BF in vergelijking met het aantal KVE/BF in onbehandelde biofilms. Het potentiërend 
effect van 100 µM thioridazine werd vervolgens geëvalueerd in combinatie met verscheidene 
antibiotica. Toevoegen van thioridazine aan een behandeling met tobramycine, flucloxacilline 
of linezolid zorgde voor een extra afdoding in vergelijking met behandeling met de 
respectievelijke antibiotica alleen. Ook hier werd vervolgens de activiteit van de combinaties 
getest in een model dat een beter idee geeft van activiteit in een relevante klinische situatie. 
Hiervoor werd gebruik gemaakt van een biofilm model dat een chronische wonde simuleert. 
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Ondanks het feit dat hoge concentraties gebruikt werden, waren de in dit model gevormde 
biofilms niet gevoelig aan de behandeling met de componenten alleen of in combinatie.  
Samengevat resulteerde de screening van een herpositionering bibliotheek in aanwezigheid 
van antibiotica in de identificatie van verschillende potentiators. De activiteit van enkele 
geselecteerde hits tegen biofilms gevormd in 96-well MTPs konden bevestigd worden door 
middel van uitplatingen. In meer gesofisticeerde modellen verloren deze geselecteerde 
componenten echter hun potentiator activiteit. 
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